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Abstract 
Most proteins in nature are chemically modified after they are made to control how, when and 
where they function. One type of chemical modification is the cleavage of disulphide bonds 
that link pairs of cysteine residues in the polypeptide chain. These cleavable bonds are known 
as allosteric disulphides. From an analysis of labile disulphide bonds in all protein structures 
from the Protein Data Bank (PDB), my colleagues and I identified a potential allosteric 
disulphide in the serine/threonine protein kinase B/Akt; linking cysteine residues 60 and 77 in 
the N-terminus pleckstrin homology (PH) domain. Akt plays a central role in glucose 
metabolism, cell survival and angiogenesis and is often hyper-activated in cancer cells. Akt is 
activated at the plasma membrane via binding to phosphatidylinositol-3,4,5-trisphosphate (PIP3) 
through its PH domain. Dissociation of Akt from the plasma membrane leads to PH domain-
mediated autoinhibition of the kinase by a mechanism that is currently unknown. I hypothesised 
that the PH domain Cys60–Cys77 disulphide is an allosteric bond that regulates autoinhibition 
and inactivation of the kinase. To elucidate the role of the Cys60–Cys77 disulphide bond in Akt 
function, wild-type and reduced (Cys60 and/or Cys77 substituted with Ser) PH domain or full-
length Akt mutants were analysed for PIP3 plasma membrane binding, Akt phosphorylation and 
Akt downstream substrate activation, transformation of fibroblasts, and angiogenesis, survival 
and development of zebrafish. Ablation of the Cys60–Cys77 disulphide bond did not appreciably 
affect binding of recombinant PH domain to PIP3, but markedly impaired insulin-stimulated 
binding of full-length Akt to the plasma membrane of adipocytes. Ablation of the Cys60–Cys77 
disulphide bond had mixed effects on insulin-stimulated phosphorylation of Akt in fibroblasts. 
The Cys60Ser mutant was phosphorylated to the same extent as the wild-type, while the Cys77Ser 
mutant was poorly phosphorylated. Wild-type but not disulphide mutant Akt induced 
transformation of fibroblasts, indicating an oncogenic role for oxidised but not reduced Akt. 
Expression of disulphide mutant Akt in zebrafish increased the induction of angiogenesis and 
xiii 
 
development of embryos but did not affect zebrafish survival. My findings imply that the Cys60–
Cys77 disulphide bond in the PH domain of Akt is an allosteric disulphide involved in 
autoinhibition and functioning of the kinase. 
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1. Introduction 
1.1 Tumour Metabolism 
For the last few decades, there has been a focus on identifying hallmarks of cancer; such as cell 
proliferative signalling, resistance to cell death, and tissue invasion and metastases (Hanahan 
& Weinberg, 2000). Multiple attempts have been made on developing therapeutic approaches 
to target genetic abnormalities in cancer cells (Holland, 2000), however, these abnormal cells 
ultimately evade signalling pathways that these therapies target. An increasing amount of 
research has suggested that deregulation of cellular energetics is involved in the pathogenesis 
of cancer (Hanahan & Weinberg, 2011; Neary & Pastorino, 2013; Ramsay et al., 2011; 
Warburg et al., 1927; Weinberg & Chandel, 2015; Wolf et al., 2011; Zhao et al., 2013). Cancer 
cells excessively consume nutrients in their environment to meet increased demands of cell 
growth. An increased uptake of glucose and high glycolysis rate are channelled toward the 
biosynthesis of deoxyribonucleic acid (DNA), lipids and proteins to support new cancer cell 
division (Ward & Thompson, 2012). 
 
Cancer cells express an aberrant metabolic phenotype known as the ‘Warburg effect’. In 
aerobic conditions, quiescent cells generate 36 adenosine 5'-triphosphate (ATP) molecules per 
glucose molecule from both glycolysis and mitochondrial oxidative phosphorylation. In 
proliferating tumour cells, however, energy production shifts from oxidative phosphorylation 
to glycolysis – generating two ATP molecules per glucose even in the presence of oxygen. This 
phenomenon was named ‘aerobic glycolysis’ by Otto Warburg and is characterised by 
increased lactic acid production (Warburg, 1956a, 1956b). Surrounding cancer cells utilise this 
lactic acid as an energy source to promote cell growth (Hanahan & Weinberg, 2011), and thus 
autonomously maintain their aberrant metabolic phenotype. Glycolysis is much less efficient 
than oxidative phosphorylation in yielding ATP, however, cancer cells adapt by increasing 
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their glucose uptake; thus increasing the rate of glycolysis (Ganapathy-Kanniappan & 
Geschwind, 2013). Increased aerobic glycolysis and glucose uptake has previously been shown 
to be directly activated by the human oncogene, Akt (Elstrom et al., 2004). Akt-induced tumour 
metabolism dominates cancer cell proliferation and survival, suggesting constitutively active 
Akt is sufficient in inducing the shift to aerobic glycolysis, and rendering cancer cells 
dependent on aerobic glycolysis for survival (Elstrom et al., 2004). Therapeutics can, in 
principle, be developed to selectively target cancer cell metabolism without being toxic to 
normal cells. 
 
 Cell signalling in tumour metabolism 
Except for white blood cells and skin cells, normal cells from tissues usually forgo cell 
proliferation unless signalling cascades are initiated by extracellular stimuli, i.e. glucose, 
chemokines, hormones or growth factors (Baxter, 2014; Tan et al., 2012; Wang et al., 2000). 
The PI3K/Akt/mTOR signalling pathway is an extensively studied pathway that is tightly 
controlled by tumour suppressor phosphatase and tensin homolog deleted on chromosome 10 
(PTEN). PTEN dephosphorylates phosphatidylinositol-3,4,5-trisphosphate (PIP3) to 
phosphatidylinositol-3,4-bisphosphate (PIP2), and acts as a negative regulator of 
phosphoinositide 3-kinase (PI3K) (Carracedo & Pandolfi, 2008; Chalhoub & Baker, 2009). 
Mutations or loss of PTEN expression is also frequently observed in cancer (Leslie & Downes, 
2004). Dysregulation of the PI3K/Akt/mTOR signalling pathway is critically involved in 
disease progression – especially in cancers with poor prognoses (Bellacosa et al., 2005; Testa 
& Bellacosa, 2001). Cancer cells acquire mutations that constitutively activate the 
PI3K/Akt/mTOR pathway (DeBerardinis et al., 2008). Protein kinase Akt is the central node 
of this pathway, and has a pleiotropic effect on a number of cellular processes; playing a crucial 
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role in tumourigenesis when hyper-activated (Testa & Bellacosa, 2001; Testa & Tsichlis, 
2005). 
 
 PI3K/Akt/mTOR cell signalling pathway 
Akt is a highly conserved human serine/threonine-specific protein kinase critically involved in 
the tight regulation of the PI3K/Akt/mTOR signalling pathway (Figure 1.1). Extracellular 
ligands mediate physiological effects via receptor tyrosine kinases (RTK) or G-protein-coupled 
receptors (GPCR) to activate PI3K, and subsequently phosphorylate PIP2 to PIP3. Akt is 
localised in the nucleus and cytosol until activation by PIP3 at the plasma membrane. Three 
direct downstream substrates of Akt are Forkhead box protein O1 (FoxO1), glycogen synthase 
kinase 3α/β (GSK3α/β) and the TSC1/TSC2 (hamartin-tuberin) complex; responsible for cell 
growth and proliferation (Fujita et al., 2002; Song et al., 2005), cell survival and death (Datta 
et al., 1997; Yamaguchi & Wang, 2001; Zhou et al., 2000), angiogenesis (Harada et al., 2009; 
Pore et al., 2006) and glucose and glycogen metabolism (Diehl et al., 1998; Kohn et al., 1996; 
Pap & Cooper, 1998). 
 
 Cell survival and proliferation 
The FoxO family of transcription factors is sensitive to insulin or insulin-like growth factor 
(IGF) signalling (Webb et al., 2016). Insulin-activated Akt directly phosphorylates FoxO1 at 
conserved residues; Thr24 at the N-terminus, Ser256 on the nuclear localisation sequence and 
Ser319 near the nuclear export sequence (Zhang et al., 2002). Phosphorylation of FoxO1 
generates motifs recognised by 14-3-3 proteins that assist in the exporting of FoxO1 out of the 
nucleus into the cytosol (Tzivion et al., 2011). Inhibition of FoxO1 represses transcriptional 
activity; thus inhibiting apoptosis, autophagy, cell cycle arrest and catabolism (Manning & 
Toker, 2017; Webb & Brunet, 2014; Zhang et al., 2011). 
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Figure 1.1 The PI3K/Akt/mTOR cell signalling cascade.  
This signalling pathway is stimulated by ligands (e.g. chemokines, glucose, growth factors, hormones) activating extracellularly at the plasma 
membrane. PI3K phosphorylates PIP2 to PIP3. PTEN regulates PI3K activity. Akt translocates to the plasma membrane and binds to PIP3. Akt is 
phosphorylated by PDK1 and mTORC2. Akt directly phosphorylates downstream substrates FoxO1, GSK3α/β, TSC2 responsible for cell 
proliferation and survival, angiogenesis, lipid synthesis, mRNA translation and metabolism. Akt dissociates from the plasma membrane into the 
cytosol and is dephosphorylated by PP2A and PHLPP2. 
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 Angiogenesis 
Akt upregulates the translation of hypoxia-inducible factor 1 (HIF1) in response to increased 
glucose and oxygen availability in solid cancers (Harada et al., 2009). Radiotherapy of tumours 
induces formation of free radicals; HIF1 accumulates in the nucleus to be activated in response 
to reactive oxygen species (ROS) (Moeller et al., 2004). HIF1 is a heterodimer that consists of 
the α and β-subunit. HIF1β is constitutively active and insensitive to changes in oxygenation, 
however, hydroxylation of the HIF1α at Pro564 and Pro402 is oxygen-dependent (Niecknig et 
al., 2012). Under normoxic conditions, prolyl hydroxylases tag HIF1α for ubiquitination and 
proteolysis (Lee et al., 2015). In hypoxic conditions – especially in a tumour setting, HIF1α 
escapes degradation, accumulating to dimerise with HIF1β in the nucleus; thereby activating 
vascular endothelial growth factor (VEGF) to initiate angiogenesis and inhibit apoptosis 
(Krock et al., 2011; Lee et al., 2015).  
 
 Lipid synthesis 
Cancer cells exhibit high rates of de novo lipid synthesis; used as building blocks for biological 
processes (Santos & Schulze, 2012). Akt affects the synthesis and degradation of lipids 
involved in signalling for cell growth and survival, thus aberrant changes to lipid metabolism 
contribute to oncogenesis (Santos & Schulze, 2012). The primary mechanism of Akt-mediated 
activation of mammalian target of rapamycin complex 1 (mTORC1) is through the disruption 
of the tumour suppressor TSC1/TSC2 complex. Insulin-mediated Akt directly phosphorylates 
TSC2 at Ser939 and Thr1462 residues, triggering the release and degradation of TSC2 from TSC1 
to activate mTORC1 (Huang & Manning, 2008). However, through negative feedback 
mechanisms, mTORC1 also inhibits PI3K activation (Huang & Manning, 2009). Akt-mediated 
degradation of TSC2 activates the mammalian target of rapamycin complex 1 (mTORC1) 
(Manning & Toker, 2017). In response to Akt activation, nuclear transcription factor sterol 
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regulatory element-binding protein 1 (SREBP1) activity is dependent on mTORC1 signalling 
(Porstmann et al., 2008). SREBP1 and ATP citrate lyase are activated; leading to induction of 
cholesterol synthesis, fatty acid synthase and low density lipoprotein (LDL)-receptors (Krycer 
et al., 2010; Laplante & Sabatini, 2009). 
 
 Protein synthesis 
Phosphorylation of the eIF4E-binding protein 1 (4EBP1) via the PI3K/Akt pathway also 
requires activation by mTORC1 (Gingras et al., 1998). Supplementary to the PI3K/Akt 
pathway, mitogen-activated protein kinase (MAPK) pathway also regulates eukaryotic 
translation initiation factor 4E (eIF4E). mTORC1 phosphorylates 4EBP1 to relieve its 
inhibitory binding of eIF4E (Siddiqui & Sonenberg, 2015). eIF4E (along with eIF4A, eIF4G) 
forms a subunit of the larger complex eIF4F; it binds the 5’ cap of mRNA and recruits the 40S 
ribosomal subunit, initiating mRNA translation (Lazaris-Karatzas et al., 1990; Siddiqui & 
Sonenberg, 2015; Wendel et al., 2007). Phosphorylated eIF4E at Ser209 (previously thought to 
be at Ser53) is essential for oncogenesis. Malignant transformation by overexpressing eIF4E 
was first observed in NIH/3T3 mouse fibroblast cells in vitro (Lazaris-Karatzas et al., 1990), 
followed by mouse models in vivo (Wendel et al., 2007). Overexpression of eIF4E has also 
been observed in human cancers (Siddiqui & Sonenberg, 2015). 
 
 Glucose and glycogen metabolism 
GSK3 was the first downstream substrate of Akt to be reported (Cross et al., 1995). Insulin-
mediated Akt directly phosphorylates the two isoforms, GSK3α/β, at Ser21/Ser9 residues at the 
N-terminus (Jiang et al., 2003; Pap & Cooper, 1998), GSK3 in turn, can regulate Akt activity 
by regulating PTEN expression (Maccario et al., 2007) or transporting Akt in close proximity 
to phosphatase PP2A (Beurel et al., 2015). Inhibition of GSK3 is implicated in the regulation 
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of glucose uptake and glucose transporter (GLUT) protein expression (Buller et al., 2008), 
glycogen and protein synthesis (Cross et al., 1995). In an Akt-independent setting, GSK3 is 
most notably involved in the Wnt–β-catenin pathway that regulates gene transcription (Yost et 
al., 1996). AXIN1/2, adenomatous polyposis coli and GSK3 form a destruction complex to 
trigger β-catenin destabilisation (MacDonald et al., 2009; Wu & Pan, 2010).  
 
Constitutively active Akt directly increases the rate of glucose metabolism and aerobic 
glycolysis (Elstrom et al., 2004) by activating the metabolic enzyme, hexokinase. Akt 
phosphorylates hexokinase, which thereby stimulates phosphofructokinase activity to enhance 
production of ATP (Barthel et al., 1999; Buzzai et al., 2005). Interestingly, inactive Akt inhibits 
insulin from transcribing GLUT mRNA, signifying that Akt plays a crucial role in glucose 
metabolism (Barthel et al., 1999). 
 
31 
 
1.2 Akt/Protein Kinase B 
Akt or protein kinase B (PKB), was first identified by Staal and colleagues in 1977. A 
transforming retrovirus was isolated from an AKR mouse with T-cell lymphoma and named 
AKT-8 (Staal et al., 1977). Staal showed that AKT is an oncogene in humans (Staal, 1987). 
Activation of AKT drives the switch to aerobic glycolysis; thus tumour cells require a 
continuous supply of glucose – rendering them dependent on aerobic glycolysis to survive and 
proliferate (Elstrom et al., 2004). 
 
 Isoforms of Akt/PKB 
Mammalian cells express three isoforms of Akt/PKB (Akt1/PKBα, Akt2/PKBβ, Akt3/PKBγ) 
and are members of the AGC family of protein kinases (Manning & Cantley, 2007). Akt1 is 
ubiquitously expressed in all tissues. Akt2 is expressed in metabolically active tissue, e.g. liver, 
adipose tissue and muscle. Akt3 is predominantly expressed in the brain and testes (Chan et 
al., 2014; Yang et al., 2004). Isoforms of human Akt are all similar in structure (Figure 1.2A). 
Akt consists of the N-terminus pleckstrin homology (PH) domain containing the 
phosphatidylinositol binding pocket, followed by the glycine rich linker, connected to the 
kinase domain containing the phosphorylation site threonine (Thr)30*, and the C-terminus 
regulatory domain containing the second phosphorylation site serine (Ser)47* (Alessi et al., 
1996a). The kinase domain of Akt1 shares 85% identity with Akt2 and Akt3, whilst the PH 
domain of Akt1 shares 60% identity with Akt2 and Akt3 (Masure et al., 1999) (Figure 1.2B). 
The focus of my thesis is on the isoform Akt1.  
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Figure 1.2 Structural domains and amino acid sequences of human Akt1, Akt2 and Akt3.  
A. Structure of Akt isoforms. N-terminus pleckstrin homology (PH) domain contains 
conserved cysteine (C) residues that form a disulphide bond, followed by the catalytic kinase 
domain (KD) containing the phosphorylation site threonine (T)30*, and C-terminus 
hydrophobic motif regulatory domain (RD) containing the phosphorylation site serine (S)47*. 
B. Alignment of the amino acid sequences of human Akt isoforms. Pleckstrin homology 
domain sequence is shown in the black box. Kinase domain sequence is shown in the blue box. 
Regulatory domain sequence is shown in the red box. Conserved cysteine residues are 
highlighted in yellow. Residues of interest are marked with an asterisk above the sequence. 
Conserved threonine and serine residues that are phosphorylated after activation are 
highlighted in blue. 
 
Akt1 MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQC 60
Akt2 MNEVSVIKEGWLHKRGEYIKTWRPRYFLLKSDGSFIGYKERPEAPDQTLPPLNNFSVAEC 60
Akt3 MSDVTIVKEGWVQKRGEYIKNWRPRYFLLKTDGSFIGYKEKPQDVDL-PYPLNNFSVAKC 59
Akt1 QLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQ--EEEEM 119
Akt2 QLMKTERPRPNTFVIRCLQWTTVIERTFHVDSPDEREEWMRAIQMVANSLKQRAPGEDPM 120
Akt3 QLMKTERPKPNTFIIRCLQWTTVIERTFHVDTPEEREEWTEAIQAVADRLQRQ--EEERM 117
Akt1 DFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAM 179
Akt2 DYKCGSPSDSSTTEEMEVAVSKARAKVTMNDFDYLKLLGKGTFGKVILVREKATGRYYAM 180
Akt3 NCSPTSQIDNIGEEEMDASTTH-HKRKTMNDFDYLKLLGKGTFGKVILVREKASGKYYAM 176
Akt1 KILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFH 239
Akt2 KILRKEVIIAKDEVAHTVTESRVLQNTRHPFLTALKYAFQTHDRLCFVMEYANGGELFFH 240
Akt3 KILKKEVIIAKDEVAHTLTESRVLKNTRHPFLTSLKYSFQTKDRLCFVMEYVNGGELFFH 236
Akt1 LSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKE 299
Akt2 LSRERVFTEERARFYGAEIVSALEYLHSRD-VVYRDIKLENLMLDKDGHIKITDFGLCKE 300
Akt3 LSRERVFSEDRTRFYGAEIVSALDYLHSGK-IVYRDLKLENLMLDKDGHIKITDFGLCKE 295
Akt1 GIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLF 359
Akt2 GISDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHERLF 360
Akt3 GITDAATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLF 355
Akt1 ELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYE 419
Akt2 ELILMEEIRFPRTLSPEAKSLLAGLLKKDPKQRLGGGPSDAKEVMEHRFFLSINWQDVVQ 420
Akt3 ELILMEDIKFPRTLSSDAKSLLSGLLIKDPNKRLGGGPDDAKEIMRHSFFSGVNWQDVYD 415
Akt1 KKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQ--DDSMECVDSERRPHFPQFSYSA 477
Akt2 KKLLPPFKPQVTSEVDTRYFDDEFTAQSITITPPDRYDSLGL--LELDQRTHFPQFSYSA 478
Akt3 KKLVPPFKPQVTSETDTRYFDEEFTAQTITITPPEKYDEDGMDCMDNERRPHFPQFSYSA 475
Akt1 SGTA 481
Akt2 SIRE 482
Akt3 SGRE 479
*
*
B Pleckstrin homology domain
Kinase domain
Regulatory domain
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 Akt1 membrane localisation and dissociation 
It was reported recently that Akt1 is allosterically activated by PIP3 at the plasma membrane 
by relieving autoinhibitory intramolecular interactions between the PH and kinase domains 
(Ebner et al., 2017). Upon binding of the positively charged PH domain of Akt1 to the 
negatively charged phospholipid PIP3 at the plasma membrane, Akt1 is activated and 
undergoes a conformation change. The PH domain no longer interacts with the kinase domain, 
exposing Akt1 phosphorylation sites and access for substrate binding, but not nucleotide 
binding. Phosphoinositide-dependent kinase 1 (PDK1) interacts with the activation loop and 
phosphorylates Akt1 at Thr308 in the kinase domain (Calleja et al., 2009). Akt1 activity is 
restricted to membrane sites containing PIP2 or PIP3 (Lučić et al., 2018). Upon dissociation 
from PIP3 at the plasma membrane, Akt1 briefly phosphorylates downstream nucleic and 
cytoplasmic proteins; the reported half-life of cytosolic active Akt1 is 3-5 min before 
dephosphorylation (Calleja et al., 2007). A suggested mechanism of membrane dissociation is 
the phosphorylation of Thr34, dependent on the recruitment of PKCζ (Powell et al., 2003) or 
PDK1 (concurrent phosphorylation of Thr308) (Huang et al., 2015) at the plasma membrane, 
resulting in a conformation change and inducing the detachment from the plasma membrane. 
Depending on the acquired mutation at Thr34, there are differing outcomes of Akt1 membrane 
dissociation that have been reported. Mutant Thr34Ala (T34A) has the ability to bind to PIP3 
even in the presence of PKCζ (Powell et al., 2003), although conflicting observations of the 
mutant Thr34Asp (T34D) have been reported. This mutant was either reported to mimic 
phosphorylation, thus impairing the translocation of Akt1 to the plasma membrane (Huang et 
al., 2015); or conversely, was observed to prominently localise Akt1 at the plasma membrane 
(Várnai et al., 2005). The reformation of the interaction between PH and kinase domains 
promotes Akt1 membrane dissociation and subsequent dephosphorylation (Ebner et al., 2017). 
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 Post-translational modifications of Akt1 
 Phosphorylation 
Phosphorylation and dephosphorylation of Akt1 is the most common post-translational 
modification (PTM) of the protein kinase. It is also the primary mechanism of regulating Akt1 
activation and function (Chan et al., 2014). Receptors i.e. RTK, GPCR and GLUT are 
stimulated by extracellular ligands e.g. chemokines, hormones, or epidermal (EGF), fibroblast 
(FGF), insulin-like (IGF) growth factors; thereby activating intracellular PI3K at the plasma 
membrane. PI3K phosphorylates PIP2 to PIP3; PI3K activity is regulated by tumour suppressor 
PTEN (Chalhoub & Baker, 2009). Inactive Akt1 usually resides in the cytosol until its 
recruitment to the plasma membrane. Allosteric activation of Akt1 is initiated by the binding 
of its PH domain to PIP3 (James et al., 1996), a docking phospholipid at the plasma membrane 
(Vivanco & Sawyers, 2002). Akt1 is primed for phosphorylation at the regulatory amino acid 
residues Thr308 in the kinase domain, and Ser473 in the regulatory domain, by phosphoinositide-
dependent kinase-1 and 2 (PDK1 and PDK2 (commonly known as mTORC2)), respectively 
(Garcia-Echeverria & Sellers, 2008; Vivanco & Sawyers, 2002). Thr308 phosphorylation is 
necessary for Akt1 activation; ordering the activation loop and substrate binding access, 
whereas Ser473 phosphorylation is required for maximal activity and positioning of catalytic 
residues (Testa & Bellacosa, 2001; Yang et al., 2002). The minimal consensus sequence 
required for Akt1 phosphorylation is Arg-X-Arg-X-X-Ser/Thr-h, where X represents any 
amino acid and h is a bulky hydrophobic amino acid residue (Alessi et al., 1996b). 
Constitutively active phosphorylation site Thr450 in the regulatory domain is essential for 
folding and stability of the protein (Bellacosa et al., 1998). Active Akt1 detaches from the 
plasma membrane into the cytosol and phosphorylates downstream target proteins. Cytosolic 
Akt1 is rapidly dephosphorylated by protein phosphatase 2A (PP2A) and PH domain leucine-
rich repeat-containing protein phosphatase 2 (PHLPP2), at Thr308 and Ser473, respectively. 
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 Lysine modifications 
 Acetylation 
Reversible acetylation of lysine (Lys) residues in Akt1 by histone acetyltransferases and 
deacetylases affect Akt1 membrane binding activity. Acetylation of Akt1 at Lys14 and Lys20 
inhibits the PH domain from binding to PIP3, thereby regulating its activity (Sundaresan et al., 
2011). Mutants Lys14Arg, Lys14Gln and Lys20Gln are analogous to constitutive acetylation 
of Akt1, and thus the kinase remains inactive. Interestingly, Lys20 substituted with Arg 
deacetylates Akt1; it readily binds to PIP3 to be phosphorylated (Sundaresan et al., 2011). 
 
 Ubiquitination 
Ubiquitination of Akt1 plays a significant role in its stability and activation. Akt1 with no intact 
PH domain is unable to be ubiquitinated. Proteins usually undergo Lys48-linked ubiquitination; 
resulting in protein degradation and termination of activity (Yang et al., 2010). Interestingly, 
Lys63-linked ubiquitination of Akt1 at Lys8 and Lys14 residues does not induce degradation of 
the kinase, but mediate plasma membrane binding and increase phosphorylation of Akt1 (Yang 
et al., 2009).  
 
 SUMOylation 
Covalent conjugation of the small ubiquitin-related modifier (SUMO) to an internal Lys 
residue in Akt1 is a reversible PTM that affects cell proliferation and apoptosis. SUMOylated 
Akt1 is usually localised in the nucleus (Risso et al., 2013). There are various different reports 
of SUMO-modification sites considered to be the major acceptors; Lys64 in the PH domain, 
Lys182, Lys189 (de la Cruz-Herrera et al., 2015), Lys276 (Li et al., 2013; Lin et al., 2016) and 
Lys301 (Risso et al., 2013) within the kinase domain of Akt1. When these Lys residues are 
mutated, a significant reduction of SUMOylation is observed, thus perturbing Akt1 activity (de 
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la Cruz-Herrera et al., 2015). SUMOylation of Akt1 in vivo was detected under heat-shock 
stress conditions; implying Akt1 is not constitutively modified by SUMO (de la Cruz-Herrera 
et al., 2015). 
 
 Glycosylation 
The O-linked N-acetylglucosamine modifications of serine and threonine residues in Akt1 are 
reversible PTMs that inhibit Akt1 phosphorylation (Gandy et al., 2006; Wang et al., 2012). The 
competitive relationship between glycosylation and phosphorylation of Akt1 at the same sites 
has been implicated in the progression of cancer (Costa et al., 2015). 
 
 Methylation 
DNA methylation in promoter CpG islands is an epigenetic modification that maintains gene 
silencing (Sun et al., 2012). The promoter region of Akt1 was observed to be significantly 
hypomethylated in a study of breast cancer patients (Heng et al., 2017). 
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 Akt1 mutations in cancer 
Aberrant Akt expression has been observed in over 50% of human cancers (Catalogue of 
Somatic Mutations in Cancer, COSMIC). Mutations in Akt1 occur in 3-5% of human cancers  
and are relatively conserved throughout other isoforms of Akt (Yi & Lauring, 2015) (Table 
1.1). The PH domain of Akt1 plays a regulatory role in its function; hence the disruption of the 
PH–kinase domain interaction is implicated in cancer progression (Carpten et al., 2007). 
Somatic mutations in the PH domain of Akt1 have frequently been observed to disrupt 
membrane binding and dissociation. These residues are located near the lipid binding pocket 
of Akt1, therefore aberrant structural changes are direct attributes to these mutations. 
 
The most common somatic missense mutation is Glu17 to Lys (E17K) in the PH domain of 
Akt1 near the lipid binding pocket, accounting for 36% of all Akt1 mutations (cBioPortal for 
Cancer Genomics) (Cerami et al., 2012; Gao et al., 2013; Yi & Lauring, 2015). E17K mutations 
have been observed in cancers of the breast (Carpten et al., 2007; Stephens et al., 2012; Yi et 
al., 2012), endometrium (Cohen et al., 2010), prostate (Boormans et al., 2010), bladder 
(Askham et al., 2010), non-small cell lung cancer (NSCLC) (De Marco et al., 2015; Ding et 
al., 2008), blood (Kim et al., 2008) and melanoma (Davies et al., 2008). The E17K mutation 
of Akt1 perturbs the interaction between the PH–kinase domains, inducing hyperactivation of 
Akt1; with or without insulin stimulation (Yang et al., 2009). Other missense activating 
mutations in the PH domain of Akt1 include Leu52 to Arg (L52R) and Gln79 to Lys (Q79K). 
They represent 1.2% of all Akt1 mutations (cBioPortal for Cancer Genomics) (Cerami et al., 
2012; Gao et al., 2013) in colorectal and breast cancers (Parikh et al., 2012; Stephens et al., 
2012; Yi et al., 2012).  
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Located in the PH domain of Akt1, the Cys77 mutation was also detected in cancer patients 
(COSMIC). The Cys77 to Phe (C77F) missense mutation in breast luminal carcinoma (Ellis et 
al., 2012; Yi et al., 2012), Cys77_Lys78ins10 (insertion of 10 amino acids, in breast ductal 
carcinoma (Zehir et al., 2017), and Cys77_Lys78ins12 (insertion of 12 amino acids, in frame) 
in ovarian granulosa cell tumour (Bessière et al., 2015). 
 
Inactivating mutations are also located on the PH domain of Akt1. The Arg15 to Ala (R15A) 
and Lys20 to Ala (K20A) mutations inhibit the translocation of Akt1 to the plasma membrane; 
despite the presence of insulin stimulation (Akbar et al., 2005; Huang et al., 2011). The R15Q 
mutation has also been detected in cervical cancer (COSMIC). In autoinhibited Akt1, the PH 
domain of Akt1 interacts with the C-lobe of the kinase domain near Asp323 and Asp325 residues, 
as well as the unphosphorylated activation loop, where phosphorylation site Thr308 is located 
(Lučić et al., 2018). Double mutation of Asp323 and Asp325 to Ala (D323AD325A) reportedly 
disrupts the PH domain-mediated autoinhibition by permanently exposing the kinase domain 
for phosphorylation and substrate access, thus constitutively activating Akt1 (Lučić et al., 
2018).  
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Table 1.1 Spectrum of recurrent mutations in Akt1 are relatively conserved in Akt2 and 
Akt3. 
 
Domain Akt1 Akt2 Akt3 
Pleckstrin homology 
domain 
E17K E17K E17K 
D32N/Y D32H/N D32N 
D46E D46N D46H 
P51L/S  P50L/S 
L52F/H/R  L51L/R 
Q79K/R  Q78K 
W80R W80C/L  
Glycine rich linker R121W   
Kinase domain 
D221N  D219N 
S266N/S  S264F 
D323G/H/N/Y D324G/H/N D320H 
R367C R368C/H/N  
R370C/H R371C/H/L R367Q 
 
Adapted from: Yi, K. H. & Lauring, 2015 and the Catalogue of Somatic Mutations in Cancer 
(COSMIC). 
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 Akt1 inhibitors in cancer treatment 
Akt has long been an attractive target for cancer therapeutics. So far, Akt-targeting molecules 
are limited by their lack of specificity, poor solubility and moderate potency. Current Akt 
inhibitors have shown limited success in the clinic due to toxicity or development of resistance 
(Nitulescu et al., 2016). ATP-competitive Akt inhibitors act as orthosteric ligands that occupy 
the ATP binding pocket (Chan et al., 2011); an active site that is the same throughout the 
isoforms of Akt (Yang et al., 2002). ATP-competitive Akt inhibitors lack efficacy and 
specificity against the isozymes as well as other kinases e.g. the AGC kinase family, in pre-
clinical studies and in the clinic (Nitulescu et al., 2016); unexpectedly inducing 
hyperphosphorylation (Okuzumi et al., 2009). Development of Akt isozyme-selective therapies 
that are well-tolerated in the clinic has long been a challenge due to high sequence homology 
between the isoforms of Akt (Wu et al., 2010). Known allosteric Akt1 inhibitors target the PH 
domain of Akt1 to prevent plasma membrane localisation and activation of Akt1 (Barnett et 
al., 2005; Berndt et al., 2010; Calleja et al., 2009; Jo et al., 2011; Joh et al., 2012; Nitulescu et 
al., 2016). Effectiveness however, is dependent on the PH–kinase domain interface; once 
compromised, drug sensitivity is lost and Akt1 remains active (Parikh et al., 2012). Moreover, 
the phosphatidylinositol binding pocket in the PH domain of Akt1 is an unideal target due to 
its shallow, highly charged nature (Kumar & Madison, 2005). We therefore proposed a 
different approach by targeting an allosteric disulphide bond identified in the PH domain of 
Akt1. 
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1.3 Allosteric Disulphide Bond 
Protein disulphide bonds are covalent linkages between the sulphur atoms of two cysteine (Cys) 
amino acids within or across different proteins. There are two types of disulphide bonds: 
structural and functional (Figure 1.3A). Structural disulphide bonds form during protein 
folding to stabilise protein conformation, withstanding changes in cellular environment and 
remain inert for the life of the protein (Hogg, 2003, 2013). Catalytic disulphide bonds are 
usually found in the active sites of enzymes that mediate thiol/disulphide exchange in other 
proteins. My focus is on the allosteric disulphide bond, defined as a bond that controls the 
function of the mature protein in which they reside. Conformational change of the protein is 
triggered by the formation or cleavage of the allosteric disulphide bond, altering protein 
function (Chiu & Hogg, 2019; Schmidt et al., 2006) (Figure 1.3B). 
 
 Cleavage of the allosteric disulphide bond 
Disulphide bonds can be cleaved by oxidoreductases, thiol/disulphide exchange or hydrolysis 
(Figure 1.4). Thioredoxin, protein disulphide isomerases, glutaredoxin and peroxiredoxin are 
examples of oxidoreductases in cells and blood known to catalyse the reduction of disulphide 
bonds (Arnér & Holmgren, 2000; Butera et al., 2014; Cremers & Jakob, 2013; Holmgren, 
1995). The active sites of oxidoreductases contain a reactive dithiol/disulphide that reduces or 
oxidises a protein disulphide bond (Figure 1.4A). Cleavage of disulphide bonds by 
thiol/disulphide exchange occurs within the same protein or between proteins, or between 
proteins and small molecules, however, unlike oxidoreductases, do not require additional 
electrons (Figure 1.4B). Cleavage of disulphide bonds by hydrolysis is an irreversible reaction 
resulting in a sulfenic acid/thiol pair (Figure 1.4C). Cleavage of disulphide bonds also depends 
on geometry of the atoms involved, spatial (right place) and temporal (right time) 
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considerations and energetics of the disulphide bond that is to be reduced (Chiu & Hogg, 2019; 
Cook & Hogg, 2013). 
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Figure 1.3 Types of protein disulphide bonds. 
Disulphide bonds have structural or functional roles in mature protein. A. There are two types 
of functional disulphides. Catalytic disulphide bonds, usually in oxidoreductases, alter the 
redox state of disulphide bonds in other proteins. Allosteric disulphide bonds control function 
of the protein in which they reside. B. Formation or cleavage of the allosteric disulphide bond 
induces a conformational change and alters function of the protein. 
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B
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Figure 1.4 Mechanisms of cleavage of allosteric disulphides bonds.  
A. An unpaired sulphur ion in an oxidoreductase (green) attacks one of the allosteric disulphide 
sulphur atoms in the substrate (blue). An intermediate bond between the sulphurs form 
temporarily. The allosteric disulphide bond in the substrate is reduced and the oxidoreductase 
sulphurs become oxidised. B. Conformational change brings an unpaired sulphur ion close to 
an allosteric disulphide bond in the same protein or between proteins. The sulphur ion attacks 
the allosteric disulphide and is reduced. C. Hydrolysis cleavage of the allosteric disulphide 
bond results its reduction and formation of a sulfenic acid/thiol pair. Source from: Chiu & 
Hogg, 2019. 
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 Features of the allosteric disulphide bond 
A classification system for disulphide bonds was designed when allosteric disulphides were 
first described (Schmidt et al., 2006) (Figure 1.5). Unlike protease cleavage sites, disulphide 
bonds are not readily identified from positions of cysteine residues in primary protein 
sequences. Instead, they can be identified from three-dimensional X-ray structures of the 
protein; disulphide bonds adopt certain configurations (Schmidt et al., 2006). Geometry of a 
disulphide bond is defined by two sets of three atoms linking two Cα atoms of the cystine 
residue, i.e. Cα–Cβ–Sγ–Sγ′–Cβ′–Cα′, and five dihedral (χ) angles. The signs of the central three 
χ angles define whether the bonds are spirals (–,–,– or +,+,+), hooks (+,–,– or +,+,–) or staples 
(–,+,– or +,–,+). The sulphur–sulphur (S–S) bond χ angle determines whether the conformation 
is right-handed (+) (RH) or left-handed (–) (LH). As a result, there are 20 possible 
configurations for the disulphide bond (Chiu & Hogg, 2019; Chiu et al., 2015; Wong & Hogg, 
2010) (Figure 1.5A). The –LHspiral configuration accounts for around one quarter of all 
disulphide bonds identified in the PDB and is associated with structural disulphide bonds. 
There are three emerging allosteric configurations, –RHstaple, –LHhook and –/+RHhook, 
which account for approximately 20% of all non-redundant disulphide bonds in the PDB 
(Schmidt et al., 2006), and approximately 80% of structurally defined allosteric disulphide 
bonds (Figure 1.5B). The tensile prestress in –RHstaple (-135 pN) and –/+RHhook (-221 pN) 
configurations was found to be relevant to disulphide reactivity (Schmidt et al., 2006; Zhou et 
al., 2014) (Figure 1.5C). The prestress is attributed to the stretching of the S–S bond and 
neighbouring α angles, indicative of disulphide reactivity and propensity for cleavage, and 
moreover, function of the protein (Figure 1.5D). 
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Figure 1.5 Classification of disulphide bonds and allosteric configurations.  
A. Classification system of disulphide bonds using 5 dihedral (χ) angles of the cystine residue. 
There are 20 possible disulphide configurations. B. Incidence of the three allosteric disulphide 
conformations. The –RHstaple, –LHhook, and –/+RHhook configurations constitute 
approximately 20% of all disulphide bonds in the PDB, but approximately 80% of structurally 
defined allosteric bonds (n=32, (Pijning et al., 2018)). C. Mean tensile prestress of the 20 
configurations was calculated using force distribution analysis (Zhou et al., 2014). The tensile 
prestresses on allosteric –RHstaple and –/+RHhook bonds are significantly higher than the 
other 18 configurations. D. Tensile prestress of ‒RHstaple and ‒/+RHhook disulphide bonds 
is the result of stretching of sulphur-sulphur bond length (d) and neighbouring α angles. Source 
from: Chiu & Hogg, 2019. 
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 Disulphide bonds in Akt1 
So far, about 40 allosteric disulphide bonds have been identified (Chiu & Hogg, 2019) (Table 
1.2). Crystal structures of Akt1 show two disulphide bonds in the protein: one in the PH domain 
(Cys60–Cys77) and one in the kinase domain (Cys296–Cys310). The Cys296–Cys310 disulphide 
bond is located in the kinase activation loop of Akt1, flanking the Thr308 phosphorylation site. 
Bioinformatic analyses of the Cys296–Cys310 disulphide bond revealed a –LHspiral 
configuration, typical of a structural disulphide bond (Schmidt et al., 2006). Studies have 
shown oxidation of Cys296 and Cys310 residues led to Akt1 dephosphorylation through 
increased interaction with phosphatase PP2A; however, mutations of Cys296 and Cys310 to Ser 
did not affect Akt1 phosphorylation and downstream activity (Ahmad et al., 2014). The 
phospholipid binding region in the PH domain of Akt1 revealed the presence of another 
disulphide bond between Cys60 and Cys77 residues, adopting an archetypal allosteric –RHstaple 
configuration (Schmidt et al., 2006). As previously mentioned, the tensile prestress on the –
RHstaple disulphide bond increases susceptibility to cleavage, suggesting its involvement in 
the function of Akt1 protein.  
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Table 1.2 Allosteric disulphide bonds that alter protein function in response to cleavage. 
Cleavage of allosteric disulphide bonds increases or decreases efficiency of ligand binding, 
substrate hydrolysis, proteolysis or formation of intermolecular disulphide bonds and homo- 
or hetero-oligomerisation of the protein.  
 
Change Protein Disulphide Cys Reference 
L
ig
an
d
 b
in
d
in
g
 
β2-glycoprotein I 288–326 (Ioannou et al., 2010) 
β3 integrin 177–184 (Passam et al., 2018) 
HIV gp120 
126–196 
296–331 
385–418 
(Auwerx et al., 2009; 
Azimi et al., 2010; 
Barbouche et al., 2003; 
Gallina et al., 2002; Ou & 
Silver, 2006; Reiser et al., 
2012) 
CD4 130–159 (Matthias et al., 2002) 
CD44 81–101 
(Kellett-Clarke et al., 
2015)  
Glycoprotein 1b 
4–17 
209–248 
(Li et al., 2018) 
Interleukin 4 46–99 (Plugis et al., 2018)  
Interleukin receptor subunit 
gamma 
160-209 (Metcalfe et al., 2012)  
Thrombospondin 1 974–? 
(Dieterich et al., 1997; Jin 
et al., 2011; Pinkas et al., 
2007; Plugis et al., 2017; 
Yi et al., 2018) 
Tissue Factor 186–209 
(Ahamed et al., 2006; 
Chen et al., 2006) 
Vitronectin 
137–161 
274–453 
(Bowley et al., 2017) 
von Willebrand factor 1669–1670 (Butera et al., 2018)  
S
u
b
st
ra
te
 h
y
d
ro
ly
si
s 
Adenosine-5'-phosphosulfate 
kinase 
86–119 (Ravilious et al., 2012) 
Arylsulfate sulfotransferase 418–424 
(Malojcić & 
Glockshuber, 2010) 
Botulinum neurotoxins 436–445 
(Swaminathan & 
Eswaramoorthy, 2000) 
QueF 55–99 (Mohammad et al., 2017) 
Thiolase 88–378 (Kim et al., 2015) 
hTryptaseβ 191–220 (Cook et al., 2013) 
Methionine aminopeptidase 2 228–448 (Chiu et al., 2014b) 
Prolyl cis-trans isomerase, 
AtFKBP13 
106–111 (Gopalan et al., 2004) 
Transglutaminase 2 
370–371 
230–370 
(Pinkas et al., 2007) 
Lon protease 617–691 (Nishii et al., 2015) 
CgDapF 83–221 (Sagong & Kim, 2017) 
SAMHD1 341–350 (Mauney et al., 2017) 
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P
ro
te
o
ly
si
s 
Angiotensinogen 18–138 (Zhou et al., 2010) 
Factor XI 362–482 
(Giannakopoulos et al., 
2012) 
major histocompatibility 
complex class I chain-related A 
(MICA) 
202–259 (Kaiser et al., 2007) 
Plasmin(ogen) 
512–536 
462–541 
(Butera et al., 2014) 
O
li
g
o
m
er
is
at
io
n
 
CD4 130–159 (Matthias et al., 2002)  
Vascular endothelial growth 
factor C & D 
156–165 (Chiu et al., 2014a) 
LYVE-1 201–201 (Banerji et al., 2016) 
 
Source from: Chiu & Hogg, 2019. 
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1.4 Hypothesis 
Akt plays a central role in glucose metabolism, cell survival and angiogenesis and is often 
hyper-activated in cancer cells. Akt is activated at the plasma membrane via binding to PIP3 
through its PH domain. Dissociation of Akt from the plasma membrane leads to PH domain-
mediated autoinhibition of the kinase by a mechanism that is currently unknown. This thesis 
aims to clarify the mechanism of Akt1 autoinhibition and further expand our knowledge of 
regulation of Akt1 activity. A potential allosteric Cys60–Cys77 disulphide bond was identified 
in the PH domain of Akt1. I hypothesise that the PH domain Cys60–Cys77 disulphide is an 
allosteric bond that regulates autoinhibition and functioning of the kinase. My goal was to 
characterise the role of the Cys60–Cys77 disulphide bond in Akt1 function.  
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1.5 Specific Aims 
 Characterise the features of the Akt1 Cys60–Cys77 disulphide bond in existing crystal 
structures of the protein. 
 
 Elucidate the role of the Akt1 Cys60–Cys77 disulphide bond in PIP3 and plasma membrane 
binding. 
 
 Elucidate the role of the Akt1 Cys60–Cys77 disulphide bond in Akt1 phosphorylation, Akt1 
substrate activation, and transformation of mouse fibroblasts. 
 
 Elucidate the role of the Akt1 Cys60–Cys77 disulphide bond for angiogenesis, survival and 
development in zebrafish embryos. 
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2. Materials & Methods 
2.1 Bioinformatics and Structural Biology 
 Analysis of missing labile disulphide bonds in X-ray structures  
All X-ray structures released in the PDB as of June 2017 were assembled. The list was culled 
to exclude all structures with a resolution >2.5 Å. Structures that had been prepared and 
crystallised in the presence of 1,4-dithiothreitol (DTT) or any other reducing agent were 
removed from the analysis. 
 
To identify missing disulphide bonds, each PDB chain was first mapped to a corresponding 
UniProtKB accession and protein sequence using the PDBSWS tool (Martin, 2005). 
Subsequently for each UniProtKB accession, a list of corresponding PDB chains and disulphide 
bonds present in any of these PDB chains were recorded. Disulphide bonds in structures were 
determined by the presence of an SSBOND line in the PDB file. Finally, for each disulphide 
bond that has now been associated with each UniProtKB protein, all PDB chains mapped to 
this corresponding UniProtKB accession were analysed to determine whether the disulphide 
bond is present or missing. If the disulphide bond is missing within a particular PDB chain, 
that structure was further analysed to establish whether the bond is missing due to a truncated 
or mutated PDB chain protein sequence. The annotation of each disulphide bond was 
performed as described previously (Schmidt et al., 2006). If the sequence is not truncated or 
mutated, the PDB chain was annotated as missing in the same crystal structure if the disulphide 
bond is present in another chain in the same PDB file. Otherwise, it was annotated as missing 
in a different crystal structure if the disulphide bond is only present in a different PDB file. A 
schematic diagram illustrating the analysis is shown in Figure 2.1. For the analysis of 
disulphide bond features, a list of culled disulphide bonds from all PDB structures was used. 
To define the set of culled disulphide bonds, the PISCES PDB culling server was used with a 
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cut-off of 90% homology, maximum resolution of 2.5 and R value of 1.0. Subcellular 
localisation of proteins were obtained from the UniProtKB database. Pathways enriched in 
human proteins containing labile disulphide bonds were identified using the DAVID 
Functional Annotation Tool and KEGG pathway analysis (Huang et al., 2009a, 2009b). A 
Python script was developed implementing the above analysis and can be downloaded from: 
https://github.com/jwon7011/missing_disulfide 
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Figure 2.1 Flow chart for mining of PDB X-ray structures for labile disulphide bonds. 
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2.2 Molecular Cloning 
Aerosol Barrier Tips were purchased from Interpath Services. Greiner Bio-One™ EasyLoad™ 
Refill Universal Pipette Tips were purchased from Greiner Bio-One. BD Falcon™ Conical 
Tubes were purchased from In Vitro Technologies. Microcentrifuge Tubes were purchased 
from Scientific Specialties Inc. (SSIbio). Corning® Costar® Stripette® serological pipettes and 
custom designed oligonucleotides were purchased from Sigma-Aldrich. Restriction digest 
enzymes and polymerase chain reaction (PCR) reagents were purchased from NEB. 
cOmplete™, Mini, ethylenediaminetetraacetic acid (EDTA)-free, Protease Inhibitor Cocktail 
and PhosSTOP™ Phosphatase Inhibitor tablets were purchased from Roche. Gateway™ BP and 
LR Clonase™ II Enzyme mixes and proteinase K were purchased from Thermo Fisher 
Scientific. 
 
Plasmid pcDNA-DEST53–TagRFP-T–WTAkt1 DNA construct containing the WTAkt1 insert 
was kindly provided by the James laboratory (University of Sydney). Lentiviral gene ontology 
vector LeGO-iG2 containing enhanced green fluorescent protein internal ribosome entry site 
(EGFP-IRES) expression (Weber et al., 2008; Weber et al., 2012) was kindly provided by the 
Pimanda laboratory (University of New South Wales). The C-terminal EGFP 8× His-tag vector 
pWaldo-TEV-GFPe was kindly provided by the Jormakka laboratory (Centenary Institute). 
Gateway Tol2 transposon cloning vectors (Kwan et al., 2007): pDONR™221, pDestTol2, 
p5E/ubb, p3E/p2a-tdTomato, and Tol2 transposase DNA constructs were kindly provided by 
the Oehlers laboratory (Centenary Institute). DNA plasmids were generated in One Shot™ ccdB 
Survival™ 2 T1R (Invitrogen) and Alpha-Select Gold Efficiency E. coli competent cells 
(Bioline) with the appropriate antibiotic.  
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 Construction of full-length WTAkt1 and MyrAkt1 plasmids 
Design of WTAkt1 (wild-type) and MyrAkt1 (myristoylated) oligonucleotides containing a HA-
epitope tag sequence at the 5’ end, was based off cDNA (complementary deoxyribonucleic 
acid) cloning performed previously by Liu et al., 2004 (Table 2.1). Full-length WTAkt1 was 
inserted into the empty lentiviral LeGO-iG2 vector. Each PCR reaction contained 10 pmol of 
the appropriate forward and reverse oligonucleotide, 5 ng of pcDNA-DEST53–TagRFP-T–
WTAkt1 DNA template, 1× Phusion® HF (high-fidelity) buffer containing 50 mM MgCl2, 200 
µM deoxyribose nucleoside triphosphate (dNTP) mix, amplification was started by the addition 
of 2 U/µl of Phusion® Hot Start II DNA Taq Polymerase and subjected to 15 s denaturation at 
98°C, 20 s annealing at 66°C and 1 min extension at 72°C for 25 cycles on the Mastercycler 
nexus gradient (Eppendorf). PCR products were purified with Wizard® SV Gel and PCR Clean-
Up System (Promega). Purified product of 1 µg of WTAkt1 insert and 3 µg of empty LeGO-
iG2 vector were digested at 37°C for 2 h with 10 U of high fidelity enzymes BamHI and EcoRI, 
1× bovine serum albumin (BSA), 1× CutSmart Buffer in MilliQ H2O. Digested products were 
purified with SV Gel and PCR Clean-Up System. LeGO-iG2 vector and WTAkt1 insert were 
ligated using T4 DNA ligase, 10× T4 ligase buffer in MilliQ H2O. Reaction was repeated with 
forward and reverse Lck-tag sequence oligonucleotides to construct LeGO-iG2–MyrAkt1.
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Table 2.1. Oligonucleotides designed for lentiviral full-length LeGO-iG2–Akt1 plasmids.  
BamHI and EcoRI restriction enzymes are underlined. HA-epitope tag sequence is indicated in orange. Lck-tag sequence is highlighted in yellow. 
Design adapted from Liu et al., 2004. 
 
DNA template Oligonucleotide Sequence 5’ to 3’ 
pcDNA-DEST53–TagRFP-T–WTAkt1 WTAkt1F (BamHI) 
 
MyrAkt1F (BamHI) 
 
 
Akt1R (EcoRI) 
CCGGGATCCATGGCCGCTTATCCCTATGACGTCCCGGACTATGCA
CCCATGAGCGACGTGGCTATTGTGAA 
CCGGGATCCATGGGCTGTGGCTGCAGCTCACACCCGGAAGATGAC
GCCGCTTATCCCTATGACGTCCCGGACTATGCACCCATGAGCGAC
GTGGCTATTGTGAA 
ATAAGAATGAATTCTCAGGCCGTGCTGCTGGCC 
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 Construction of full-length disulphide bond Akt1 mutant plasmids by site-directed 
ligase independent mutagenesis (SLIM) hybridisation 
Mutagenic oligonucleotides were designed to contain the point mutation of cysteine to serine 
at codon 60 (Cys60Ser), cysteine to serine at codon 77 (Cys77Ser), threonine to alanine at 
codon 308 (Thr308Ala) and serine to alanine at codon 473 (Ser473Ala) (Table 2.2). In two 
separate PCR reactions, 10 pM of each pair of tailed (T) and non-tailed (S) oligonucleotides 
hybridised to 5 ng LeGO-iG2–WTAkt1 DNA template in 5× HF buffer containing 50 mM 
MgCl2, 200 µM dNTP mix, amplification was started by the addition of 2 U/µl of DNA Taq 
Polymerase and subjected to 15 s denaturation at 98°C, 20 s annealing at 68°C and 5.5 min 
extension at 72°C for 25 cycles on the Mastercycler nexus gradient. This resulted in un-
methylated mutant plasmids. 5 U of DpnI, a type IIM restriction enzyme was incubated for 2h 
at 37°C targeting and cutting methylated parental plasmids. SLIM hybridisation reactions 
contained both PCR products, 1× H-buffer (300 mM NaCl, 50 mM Tris, pH 9.0, 20 mM EDTA, 
pH 8.0) in MilliQ H2O (Chiu et al., 2004; Chiu et al., 2008). Control group reactions contained 
only the single PCR product in H-buffer. Conditions for optimal hybridisation were 
denaturation at 99°C for 3 min, followed by two cycles of 5 min at 65°C and 15 min at 30°C. 
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Table 2.2 Oligonucleotides designed for site-directed ligase-independent mutagenesis hybridisation.  
The overhang of 18 nucleotides is underlined. Site-directed mutagenesis is bolded. LeGO-iG2 vector is highlighted in blue. 
 
DNA template Modification Oligonucleotide Sequence 5’ to 3’ 
LeGO-iG2–WTAkt1 
Point mutation of Cys60 to Ser 
Cys60SerF 
Glu66F 
Cys60SerR 
Leu52R 
AGCCAGCTGATGAAGACGGAGCG 
GAGCGGCCCCGGCCCAACA 
CGTCTTCATCAGCTGGCTCTGCGCCACAGAGAAGTTGTTG 
CTGCGCCACAGAGAAGTTGTTG 
Point mutation of Cys77 to Ser 
Cys77SerF 
Val83F 
Cys77SerR 
Pro70R 
AGCCTGCAGTGGACCACTGTCAT 
GTCATCGAACGCACCTTCCATG 
AGTGGTCCACTGCAGGCTGCGGATGATGAAGGTGTTGGG 
GCGGATGATGAAGGTGTTGGG 
Point mutation of Thr308 to Ala 
Thr308AlaF 
Tyr326F 
Thr308AlaR 
Lys307R 
GCCTTTTGCGGCACACCTGAGTA 
GAGTACCTGGCCCCCGAGGT 
AGGTGTGCCGCAAAAGGCCTTCATGGTGGCACCGTCCTTG 
CTTCATGGTGGCACCGTCCTTG 
Point mutation of Ser473 to Ala 
Ser473AlaF 
Thr479F 
Ser473AlaR 
Phe472R 
GCCTACTCGGCCAGCAGCAC 
ACGGCCTGAGAATTCCTGCAGG 
GCTGCTGGCCGAGTAGGCGAACTGGGGGAAGTGGGGCCT 
GAACTGGGGGAAGTGGGGCCT 
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 Construction of truncated Akt1-PH plasmids for protein expression 
To construct truncated PH domain of Akt1 plasmids (Akt1-PH), oligonucleotides were 
designed to contain amino acid residues 1-121 (Table 2.3). Wild-type Akt1-PH (WT-PH) was 
first to be constructed. Each PCR reaction contained 10 pM of the appropriate forward and 
reverse oligonucleotide, 5 ng of pWaldo-TEV-GFPe DNA template, 1× Phusion® HF buffer 
containing 50 mM MgCl2, 200 µM dNTP mix, amplification was started by the addition of 2 
U/µl of Phusion® Hot Start II DNA Taq Polymerase and subjected to 30 s at 98°C, followed 
by 25 cycles of 15 s denaturation at 98°C, 20 s annealing at 62°C and 1 min extension at 72°C, 
and then a further 10 min at 72°C on the Mastercycler nexus gradient (Eppendorf). PCR 
products were purified with Wizard® SV Gel and PCR Clean-Up System (Promega). Purified 
product of 1 µg of the WT-PH insert and 3 µg of empty pWaldo-TEV-GFPe vector were 
digested at 37°C for 2 h with 10 U of high fidelity enzymes EcoRI and XhoI, 1× BSA, 1× 
CutSmart Buffer in MilliQ H2O. Digested products were purified with SV Gel and PCR Clean-
Up System. pWaldo-TEV-GFPe vector and WT-PH insert were ligated using T4 DNA ligase, 
10× T4 ligase buffer in MilliQ H2O to construct pWaldo-TEV-GFPe–WT-PH. Truncated 
reduced Akt1-PH mutants pWaldo-TEV-GFPe–C60S-PH, pWaldo-TEV-GFPe–C77S-PH and 
pWaldo-TEV-GFPe–C60SC77S-PH plasmids were constructed by SLIM hybridisation as 
previously described using the pWaldo-TEV-GFPe–WT-PH DNA template (Section 2.2.2). 
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Table 2.3 Oligonucleotides designed for truncated Akt1-PH plasmids.  
EcoRI and XhoI restriction enzymes are underlined. Start and stop codons are italicised. 
 
Destination vector Oligonucleotide Sequence 5’ to 3’ 
pWaldo-TEV-GFPe 
Akt1-PHF (XhoI) CGCTCGAGCGGCTCGAGATGAGCGACGTGGCTATTGTGA 
Akt1-PHR (EcoRI) CCGGAATTCTTACCGGAAGTCCATCTCCTCCT 
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 Gateway™ BP and LR cloning 
Recombinant Gateway™ BP and LR cloning was used to generate Tol2 transposon gene transfer 
plasmids designed for zebrafish embryo microinjections. Gateway Tol2 transposon cloning 
vectors (Kwan et al., 2007) pDONR™221, pDestTol2, p5E/ubb, p3E/p2a-tdTomato, and Tol2 
transposase were generously provided by the Oehlers laboratory (Centenary Institute). DNA 
plasmids were generated in One Shot™ ccdB Survival™ 2 T1R (Invitrogen) and Alpha-Select 
Gold Efficiency E. coli competent cells (Bioline). Gateway™ BP and LR Clonase™ II Enzyme 
mixes and proteinase K were purchased from Thermo Fisher Scientific. 
 
Designed oligonucleotides of Gateway™ attB sequences flanking Akt1 to construct middle-
entry Akt1 (pME/Akt1) clones (Table 2.4). Each PCR reaction contained 10 pM of the 
appropriate forward and reverse attB oligonucleotides, 5 ng of LeGO-iG2–WTAkt1 DNA 
template, 1× HF buffer containing 50 mM MgCl2, 200 µM dNTP mix; amplification was 
started by the addition of 2 U/µl of DNA Taq Polymerase and subjected to 15 s denaturation at 
98°C, 20 s annealing at 66°C and 1 min extension at 72°C for 25 cycles on the Mastercycler 
nexus gradient. PCR product (50-150 ng) and donor vector pDONR™221 (100 ng) were 
combined with BP clonase mix in TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA) to 
generate attL recombination sites (Figure 2.2A). Reaction mix was incubated for 1 h at 25°C. 
Reaction was stopped by addition of proteinase K at 37°C for 10 min. Mix was transformed in 
Alpha-Select Gold Efficiency E. coli competent cells and selected with 50 µg/ml kanamycin. 
Plasmids were sequenced by Ramaciotti Centre for Genomics and confirmed with DNA Baser 
Sequence Assembler. Experiment was repeated to generate full-length constitutively active 
mutant pME/MyrAkt1, disulphide bond mutants pME/C60S-Akt1, pME/C77S-Akt1 and 
pME/C60SC77S-Akt1 and constitutively inactive mutant pME/T308AS473A-Akt1 middle-entry 
Akt1 clones. 
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Transfer of the WTAkt1 insert from the middle-entry pME/WTAkt1 clone into the destination 
vector required a second recombination reaction. Destination vector pDestTol2 (41 ng) 
containing attR recombinant sites, Tol2 transposon backbone and ccdB toxin gene, was mixed 
with pME/WTAkt1 (41 ng) containing attL sites from the BP clonase reaction, 5’-entry clone 
p5E/ubb (41 ng) containing attL/R recombinant sites and the ubiquitin zebrafish promoter and 
3’-entry clone p3E/p2a-tdTomato (26 ng) containing attR/L recombinant sites and fluorescent 
protein marker tandem tomato polyadenylation tailing (Figure 2.2B). Recombination of the 
transgenic DNA construct was executed with the addition of LR clonase mix in TE buffer to 
generate pDestTol2/ubb:WTAkt1-p2a-tomato. Reaction was incubated overnight at 25°C. 
Reaction was stopped by the addition of proteinase K at 37°C for 10 min. Mix was transformed 
in Alpha-Select Gold Efficiency E. coli competent cells and selected with 100 µg/ml 
ampicillin. Experiment was repeated to generate full-length constitutively active mutant 
pDestTol2/ubb:MyrAkt1-p2a-tomato, disulphide bond mutants pDestTol2/ubb;C60S-Akt1-
p2a-tomato, pDestTol2/ubb:C77S-Akt1-p2a-tomato and pDestTol2/ubb:C60SC77S-Akt1-p2a-
tomato and constitutively inactive mutant pDestTol2/ubb:T308AS473A-Akt1-p2a-tomato gene 
transfer constructs. 
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Table 2.4 Designed attB oligonucleotides for Gateway™ BP cloning.  
Lck-tag sequence is highlighted yellow. attB sequences are underlined. Start codon is italicised. Stop codon is omitted. 
 
Donor vector Oligonucleotide Sequence 5’ to 3’ 
pDONR™221 
attB1 Akt1F 
attB1 MyrAkt1F 
attB2 Akt1R 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGAGCGACGTGGCTATTGTGAA 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGGGCTGTGGCTGCAGCTCA 
GGGGACCACTTTGTACAAGAAAGCTGGGTCGGCCGTGCTGCTGGCCGAG 
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Figure 2.2 Gateway™ BP and LR recombination cloning of middle-entry pME/Akt1 and 
transgenic pDestTol2/ubb:Akt1-p2a-tomato constructs. 
A. Construction of middle-entry Akt1 (pME/Akt1) clones. attB recombination sites flanking 
Akt1 was added by PCR. Gateway™ recombination cloning of PCR product and donor vector 
pDONR™221 by BP clonase II. B. Construction of pDestTol2/ubb:Akt1-p2a-tomato transgenic 
clones for zebrafish injections. Gateway™ recombination cloning of pME/Akt1, 5’entry 
ubiquitin zebrafish promoter p5E/ubb, 3’entry tandem-Tomato polyadenylation tailing 
p3E/p2a-tdTomato and gene transfer vector backbone pDestTol2 by LR clonase II.  
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 Heat shock transformation of E. coli 
DNA plasmids were transformed into E. coli competent cells and a selective pressure as 
directed by Curr Protocols Mol Biol (Seidman et al., 2001). 1 μg of DNA plasmid was mixed 
with the appropriate E. coli competent cells and incubated on ice for 25 min. Competent cells 
were heat-shocked at 42°C in a water bath for 45 s and immediately incubated on ice for 2 min. 
Competent cells were topped-up with sterilised Luria-Burtani (LB) broth, Miller (BD Difco™) 
and resuscitated for 45 min at 37°C in the Bioline Incubator Shaker, Bench Top Style With 
Hinged Lid (Bioline) at 250 rpm. Competent cells were plated on sterile LB (BD Difco™) agar 
(Sigma-Aldrich) petri dishes (Greiner Bio-One) containing the appropriate antibiotic (100 
µg/ml ampicillin, 50 µg/ml kanamycin and/or 20 µg/ml chloramphenicol) and incubated 
overnight at 37°C. A single colony was picked with a clean pipette tip and ejected into LB 
broth containing the appropriate antibiotic and grown overnight at 37°C in the Bioline 
Incubator Shaker at 250 rpm. Plasmids were extracted and purified from the competent cells 
using the Wizard® Plus SV Minipreps DNA Purification System (Promega). DNA plasmids 
were sequenced by Ramaciotti Centre for Genomics (University of New South Wales) and 
confirmed with Align Sequence Nucleotide BLAST (National Center for Biotechnology 
Information [NCBI]) and DNA Baser Sequence Assembler. 
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 Protein expression in E. coli 
Truncated pWaldo-TEV-GFPe–Akt1-PH plasmids were transformed into Rosetta-gami™ 2 
(DE3) E. coli competent cells (Novagen) as previously described. Culture was grown in LB 
broth containing 50 µg/ml kanamycin and 20 µg/ml chloramphenicol in the Bioline Incubator 
Shaker at 37°C until OD600 reached 0.5. Protein expression was induced with 250 µM isopropyl 
β-D-1-thiogalactopyranoside (IPTG) (Sigma-Aldrich) and incubated at 20°C in the Bioline 
Incubator Shaker 250 rpm for 20 h. Induced cells were centrifuged at 2,500 × g for 10 min at 
4°C and supernatant was removed. Cells were lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 
300 mM NaCl), supplemented with 5 mM phenylmethylsulfonyl fluoride (PMSF) and 1× 
cOmplete™, Mini, EDTA-free, Protease Inhibitor Cocktail (Roche). Cell lysates were obtained 
by sonication (Branson Digital Sonifier), sonicated 3× with 1 min intervals at 4°C. Lysates 
were centrifuged to separate soluble and insoluble fractions at 13,000 × g for 10 min at 4°C. 
Supernatant was collected and adsorbed onto 0.15 ml TALON Metal Affinity Resin (GE 
Healthcare Life Sciences). The beads were washed with wash buffer (50 mM Tris, pH 7.5, 300 
mM NaCl, 100 mM imidazole), first wash 3 ml and subsequent washes (2×) 1 ml. Akt1-PH 
EGFP recombinant proteins were eluted in elution buffer (50 mM Tris, pH 7.5, 300 mM NaCl, 
250 mM imidazole) and a total of 150 µl protein fraction was collected. Fraction was analysed 
by SDS-PAGE (method below) on the 4-12% polyacrylamide gel. Protein fractions were 
pooled and transferred into Amicon Ultra-0.5 Centrifugal Filter Unit (Merck) and centrifuged 
at 14,000 × g for 20 min at 4°C. Protein was centrifuged at 1,000 × g for 2 min at 4°C in a 
clean microcentrifuge tube. Filtered elutions were dialysed with Slide-A-Lyzer Mini Dialysis 
Devices (Thermo Fisher Scientific) against 1× Dulbecco's phosphate-buffered saline (PBS) 
(Gibco) overnight. Truncated Akt1-PH recombinant proteins were stored at −80°C. 
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 RNA transcription 
Tol2 transposase DNA plasmid was linearised with restriction enzyme NotI at 37°C for 2 h. 
Digested DNA product was purified using the SV Gel and PCR Clean-Up System. Messenger 
RNA (mRNA) was transcribed from digested DNA product using the mMESSAGE 
mMACHINE SP6 Transcription Kit (Invitrogen). Capped reactions were purified using the 
NucleoSpin® RNA clean-up (Macherey-Nagel) and resuspended in RNase-free H2O. 
  
 Nucleic acid quantitation 
Purity and concentration of DNA, RNA or proteins were measured by the NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific). Ratio of absorbance was measured at 260/280 
nm; calculated ratio of >1.8 was accepted as pure DNA and calculated ratio of >2.0 was 
accepted as pure RNA. A secondary purity absorbance ratio was measured at 260/230 nm; 
calculated ratio between the range of 1.8-2.2 was accepted as pure. Absorbance of protein was 
measured at 280 nm. 
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2.3 Tissue Culture 
Corning® Cell Culture Flasks, Corning® tissue-culture treated culture microplates and dishes, 
flat bottom were purchased from Sigma-Aldrich. BD Falcon™ 12 x 75 mm Tube with Cell 
Strainer Cap were purchased from In Vitro Technologies. Nunc® CryoTubes® cryogenic vials 
were purchased from Nunc.  
 
NIH/3T3 mouse embryonic fibroblast cells, HEK293T human embryonic kidney cells and 
3T3-L1 mouse embryonic fibroblast cells were purchased from the American Type Culture 
Collection (ATCC) and cleared of any contamination or mycoplasma.  
 
Third generation lentiviral packaging and envelope plasmids pMDLg/pRRe, pRSVRev and 
pMD2.VSV-G were generously provided by the Rasko lab (Centenary Institute). 
 
 Tissue culture maintenance 
Unless otherwise specified, cells were cultured in Dulbecco's Modified Eagle Media (DMEM) 
(Gibco) with high glucose, supplemented with 1× GlutaMAX™ (Gibco) and 10% (v/v) fetal 
bovine serum (FBS) (Gibco), containing 1% (v/v) penicillin-streptomycin solution (Thermo 
Fisher Scientific) at 37°C with 95% air atmosphere and 5% CO2. Cells were washed with 1× 
PBS. Cells were passaged at 80-90% confluency and detached with 1× TrypLE Express, phenol 
red (Thermo Fisher Scientific) for 1 min at 37°C, and quenched with fresh DMEM. Cells (1.0 
× 106) were frozen down in 10% (v/v) dimethyl sulfoxide (DMSO) and 20% (v/v) FBS in 
DMEM into cryogenic vials to be stored in liquid nitrogen for later use. 
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 Lentiviral production and cell transduction 
HEK293T cells (8.0 × 105 cells/T25 cm2 flask) were co-transfected with 1.13 µg of DNA 
plasmid: LeGO-iG2 (vector control), LeGO-iG2–WTAkt1, LeGO-iG2–MyrAkt1, LeGO-iG2–
C60S-Akt1, LeGO-iG2–C77S-Akt1, LeGO-iG2–C60SC77S-Akt1 or LeGO-iG2–T308AS473A-
Akt1; with packaging and envelope plasmids pMDLg/pRRe, pRSVRev and pMD2.VSV-G in 
Opti-MEM Reduced Serum Media (Gibco), containing 30 µg polyethylenimine (PEI) for 24 h. 
Opti-MEM was removed, and cells were replenished with DMEM. Lentiviral particles 
produced in the media were collected after 72 h and purified with a 0.45 µm membrane filter 
(EMD Millipore) before infecting NIH/3T3 fibroblasts (6.0 × 105 cells/T75 cm2 flask) in the 
presence of 4 µg/ml Polybrene (hexadimethrine bromide). Viral particles were removed from 
the fibroblasts and replenished with DMEM. Cells were grown in a T175 cm2 flask up to 80% 
confluency. Transduced NIH/3T3 fibroblasts were sorted with the BD FACSAria™ II Flow 
Cytometer (Becton Dickinson Biosciences). NIH/3T3 fibroblasts expressing EGFP were 
collected and re-seeded in a T25 cm2 flask in DMEM.  
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 alamarBlue™ cell proliferation assay 
NIH/3T3 fibroblasts were seeded at 2.0 × 104 cells/96-well clear-bottom plate in DMEM. At 
72 h, alamarBlue™ reagent (1:2) was directly added to the cells and incubated for a further 2 h 
at 37°C. Fluorescence was read at Ex/Em 530/590 nm on the Infinite M1000 PRO plate reader 
(TECAN). 
 
 Soft agar colony formation 
Agar powder (Sigma-Aldrich) dissolved in MilliQ H2O was sterilised before use. Sterilised 
1.6% (w/v) agar was melted in the microwave and cooled in the 37°C water bath right before 
use. The first layer of agar was prepared by mixing 1.6% (w/v) agar and 2× DMEM (1:1), and 
deposited into a 6-well flat-bottom plate. This layer was left to solidify for 30 min at room 
temperature. Sterilised 0.6% (w/v) agar was melted in the microwave and cooled in the 37°C 
water bath right before use. The upper layer containing NIH/3T3 fibroblasts was prepared by 
mixing 0.6% agar (w/v) and 2× DMEM (1:1), and was deposited into each well (2.0 × 104 
cells/well). This layer was left to solidify for 30 min at room temperature and then incubated 
at 37°C with 90% air atmosphere and 5% CO2. DMEM was carefully added on top of the agar 
twice weekly to prevent desiccation. 21 days after seeding, cells were fixed in 4% (v/v) 
formaldehyde for 30 min at room temperature and imaged on the Axio Vert.A1 microscope 
(ZEISS). 
 
 Insulin stimulation 
NIH/3T3 fibroblasts were seeded at 2.5 × 106 cells/100 mm dishes in DMEM. At 24 h, cells 
were gently washed with 1× PBS, serum-starved with DMEM supplemented with 1× 
GlutaMAX™, no FBS for 2 h at 37°C and then stimulated with 10 nM of human recombinant 
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insulin (Sigma-Aldrich) for 20 min. DMEM and insulin was removed and cells were washed 
with 1× PBS. 
 
 Preparing Matrigel® 
Sterile dishes, plastics and reagents were pre-chilled in the fridge the night before preparation. 
Corning® Matrigel® Matrix (Sigma-Aldrich) was thawed and diluted with ice-cold 1× PBS 
(1:50). 6-well plates and 35 mm glass-bottom dishes were coated with Matrigel® and then 
incubated for 2 h at room temperature. Coated plates were washed twice with room temperature 
1× PBS prior to use. 
 
 Electroporation 
3T3-L1 fibroblasts were seeded in 100 mm dishes at 37°C with 90% air atmosphere and 10% 
CO2. Confluent dishes of fibroblasts were reseeded into Matrigel
® coated 6-well plates. At 120 
h, cells were differentiated in DMEM supplemented 0.22 µM dexamethasone, 100 ng/ml 
biotin, 2 µg/ml insulin and 500 µM 3-isobutyl-1-methylxanthine (IBMX) for 72 h. Media was 
replaced with DMEM supplemented with 2 µg/ml insulin for 72 h. Differentiated 3T3-L1 
adipocytes were replenished with fresh DMEM daily. At 7 days post-differentiation, 3T3-L1 
adipocytes were trypsinised with 5× trypsin-EDTA for 5-10 min at 37°C, and quenched with 
fresh DMEM. 3T3-L1 adipocytes were centrifuged at 150 × g for 5 min and washed twice with 
1× PBS. Cell pellets were resuspended in Electroporation Buffer (20 mM HEPES, 135 mM 
KCl, 2 mM MgCl2, 0.5% (v/v) Ficol 400, 1% (v/v) DMSO, 2 mM ATP and 5 mM glutathione, 
pH 7.6) and 5-10 µg of DNA plasmid: pcDNA-DEST53–TagRFP-T–WTAkt2, pcDNA-
DEST53–TagRFP-T–C60S-Akt2, pcDNA-DEST53–TagRFP-T–C77S-Akt2 or pcDNA-
DEST53–TagRFP-T–C60SC77S-Akt2. 3T3-L1 adipocytes were electroporated at 200 mV for 
20 ms and then plated on 35 mm glass-bottom dishes coated with Matrigel®. 
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 Total internal reflection fluorescence (TIRF) microscopy 
Live-cell imaging experiments were performed 48 h post-electroporation as described by 
Norris and colleagues (Norris et al., 2017). TIRF microscopy was performed on the Nikon Ti-
LAPP H-TIRF module (Nikon), equipped with an Okolab Cage Incubator (Okolab) and 
temperature control. 3T3-L1 adipocytes expressing pcDNA-DEST53–TagRFP-T–WTAkt2, 
pcDNA-DEST53–TagRFP-T–C60S-Akt2, pcDNA-DEST53–TagRFP-T–C77S-Akt2 and 
pcDNA-DEST53–TagRFP-T–C60SC77S-Akt2 were serum-starved in FluoroBrite DMEM 
(Gibco) supplemented with 0.2% (v/v) BSA and GlutaMAX™ for 2 h at 37°C in 10% CO2 
before stimulation with 1 nM and 100 nM insulin at 10 and 20 min time points, respectively, 
using a custom-made perfusion system. The system was standardised by testing delivery of 3 
ng/ml fluorescein isothiocyanate (FITC) (Thermo Fisher Scientific) and 100 ng/ml Alexa Fluor 
647-labelled goat anti-rabbit F(ab’)2 antibody (Thermo Fisher Scientific), to mimic the 
delivery of large proteins. Delivery to the edge and middle of the cell membrane was then 
measured by TIRF. Image and statistical analyses were performed using custom analysis 
pipelines developed in FIJI (Schindelin et al., 2012) and R programming (GNU General Public 
Licence). 
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2.4 Protein Analyses 
Bovine Serum Albumin (BSA) heat shock fraction pH 7.0, ≥ 98% and TWEEN® 20 was 
purchased from Sigma-Aldrich. Pierce™ 20× Tris-buffered saline (TBS) Buffer and Pierce™ 
ECL (enhanced chemi-luminescence) Western Blotting Substrate were purchased from 
Thermo Fisher Scientific. Total and phosphorylated (Thr308 and Ser473) Akt (60 kDa), total and 
phosphorylated (Ser256) FoxO1 (82 kDa), total and phosphorylated (Ser21/ Ser9) GSK3α/β 
(51/46 kDa) monoclonal primary antibodies were purchased from Cell Signalling Technology. 
HA-epitope tag monoclonal primary antibody was purchased from Thermo Fisher Scientific. 
β-actin (42 kDa) polyclonal primary antibody was purchased from Abcam. Mouse anti-rabbit 
and goat anti-mouse immunoglobulin/HRP (horseradish peroxidase) secondary antibodies 
were purchased from Dako.  
 
 Protein extraction and quantification 
Cells were washed with 1× PBS and lysed in lysis buffer (5 mM EDTA, 1% (v/v) Triton X-
100 in 1× PBS), supplemented with 1× Protease Inhibitor Cocktail, 1× Phosphatase Inhibitor 
and 1 mM PMSF. Whole cell lysates were incubated on ice for 30 min. Whole cell lysates were 
centrifuged at 18,000 × g for 5 min, supernatant was transferred into a new microcentrifuge 
tube. The bicinchoninic acid (BCA) method (Thermo Fisher Scientific) was performed for 
colourimetric quantitation of total proteins in collected lysates. Absorbance was read at 562 
nm on the plate reader. Lysates were diluted into appropriate concentrations (25-50 µg) and 
terminated with 1× NuPAGE™ LDS Sample Buffer (Thermo Fisher Scientific) and incubated 
for 5 min at 95°C. 
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 Immunoprecipitation 
Whole cell lysates were diluted in dilution buffer (5 mM EDTA in 1× PBS, supplemented with 
1× Protease Inhibitor Cocktail, 1× Phosphatase Inhibitor and 1 mM PMSF) to 1 mg/ml for 
immunoblotting or 3 mg/ml for mass spectrometry analyses. Dynabeads™ Protein G 
(Invitrogen) were added directly to preclear the lysate. Mixture was incubated with rotation for 
1h at 4°C. Dynabeads™ were separated with a magnet and discarded. Precleared lysate was 
transferred to a fresh microcentrifuge tube. The HA-epitope tag antibody (2 µg for 
immunoblotting, 20 µg for mass spectrometry) was directly added to the lysate. Mixture was 
incubated with rotation for 1h at 4°C. Fresh Dynabeads™ were added; mixture was incubated 
on rotation overnight at 4°C. Dynabeads™ were separated with a magnet and supernatant was 
discarded. Dynabeads™ were washed 3× with 1× PBS. Proteins on the Dynabeads™ were 
terminated with 2× LDS Sample Buffer and incubated for 5 min at 95°C. 
 
 Akt downstream activity assay 
Downstream substrate activation of immunoprecipitated Akt1 recombinant protein was 
determined by the Akt activity assay kit (Abcam). Kinase Assay Buffer and recombinant 
GSK3α substrate/ATP mixture was added to Dynabeads™ bound to Akt1 and incubated at 30°C 
for 4 hours. Dynabeads™ were separated with a magnet and supernatant was discarded. 
Dynabeads™ were 3× washed with Kinase Assay Buffer. Dynabeads™ were separated with a 
magnet and supernatant was discarded. Proteins on the Dynabeads™ were terminated with 2× 
LDS Sample Buffer and incubated for 5 min at 95°C.  
 
 Treatment of truncated Akt1-PH protein with thioredoxin protein 
Thioredoxin (Trx) protein was reduced with 10 mM DTT at room temperature for 30 min. 
Unreacted DTT was removed by Zeba™ Spin Desalting Columns, 7K MWCO, 0.5 ml (Thermo 
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Fisher Scientific) at 1,500 × g for 2 min. 3 µg of WT-PH EGFP protein was incubated with 10 
µM of reduced Trx at room temperature for 30 min. Reduced WT-PH EGFP protein was 
alkylated with 5 mM of carbon-12 ring linked to 2-iodo-N-phenylacetamide (12C-IPA) 
(Cambridge Isotopes) for 1 h at room temperature. Proteins were added to 1× LDS Sample 
Buffer and incubated for 5 min at 95°C. 
 
 Protein separation by sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Protein samples were loaded into the NuPAGE™ Novex™ 4-12% Bis-Tris Gel (Thermo Fisher 
Scientific) and separated by SDS-PAGE in 1× NuPAGE 3-(N-morpholino)propanesulfonic 
acid (MOPS) SDS Running Buffer (Thermo Fisher Scientific) using the Invitrogen™ Mini Gel 
Tank (Thermo Fisher Scientific) connected to the PowerPac™ Basic Power Supply (Bio-Rad) 
at 150 V for 1 h. 
 
 Dry protein transfer onto polyvinylidene fluoride (PVDF) membrane 
Separated proteins in the 4-12% Bis-Tris Gel was transferred onto PVDF membrane using the 
iBlot Dry Blotting System (Thermo Fisher Scientific) at 22 V for 10 min. Dried PVDF 
membrane was reactivated with methanol and washed with 1× TBS and 0.1% (v/v) TWEEN® 
20 (TBST). 
 
  Immunoblotting and densitometry analyses 
PVDF membranes were blocked with 5% (w/v) BSA in 1× TBST for 1 h at room temperature 
on a rocker. Membranes were probed with total and phospho-Akt (1:1000), total and phospho-
GSK3α/β (1:1000), and total and phospho-FoxO1 (1:1000) antibodies diluted with 5% (w/v) 
BSA in 1× TBST overnight at 4°C on a rocker. Membranes probed with β-actin (1:5000) 
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antibody were incubated for 1 h at room temperature on a rocker. Membranes were washed 3× 
with 1× TBST in 5 min intervals at room temperature on a rocker. Membranes were probed 
with appropriate HRP-conjugated secondary antibody diluted with 5% (w/v) skim milk powder 
in 1× TBST (1:2000) for 1 h at room temperature on a rocker. Membranes were washed 3× 
with 1× TBST in 5 min intervals on a rocker. Membranes were soaked in a tray of 1:1 ECL 
solution for 2 min at room temperature. Membranes were imaged on the ChemiDoc Touch 
Imaging System (Bio-Rad). Densitometry was analysed using Image Lab Software (Bio-Rad). 
 
 Differential cysteine labelling and mass spectrometry analysis 
The 4-12% Bis-Tris Gel containing protein of interest was covered in fixing solution (10% 
(v/v) methanol, 7% (v/v) acetic acid in MilliQ H2O) for 30 min at room temperature on a rocker. 
Gel was stained with SYPRO® Ruby Gel Stain (Thermo Fisher Scientific) in the dark for 30 
min at room temperature on a rocker. Gel was imaged on the ChemiDoc Touch Imaging System 
before the excision of Akt1 protein. Gel pieces were vortexed 3× using a thermomixer in wash 
buffer (25 mM ammonium bicarbonate, 50% (v/v) acetonitrile) in 10 min intervals at room 
temperature. Unpaired Cys thiols in Akt1 were alkylated with 5 mM 12C-IPA for 1 h at room 
temperature, and washed. Gel slices were incubated with 40 mM DTT for 30 min at 56C, and 
washed. Fully reduced disulphide bonded Cys thiols in Akt1 were alkylated with 5 mM of 
carbon-13 ring linked to 2-iodo-N-phenylacetamide (13C-IPA) (Cambridge Isotopes) for 1 h at 
room temperature in the dark, and washed. Samples were dried with 100% (v/v) acetonitrile 
and placed in the Speedivac for 20 min at 55C. Akt1 was digested with 12.5 ng/µl of trypsin 
(Roche) in 25 mM ammonium bicarbonate, overnight at 25C. Peptides were eluted from gel 
slices with 5% (v/v) formic acid/50% (v/v) acetonitrile, vortexed for 15 min at room 
temperature. Peptides were separated by liquid chromatography-mass spectrometry (LC-MS). 
Peptides covering both Cys60 and Cys77 residues were quantified (Table 2.5). Levels of reduced 
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and oxidised cysteines were compared by relative ion abundance of the peptides labelled with 
12C-IPA (reduced) and 13C-IPA (oxidised). Extracted ion chromatograms were analysed using 
Xcalibur™ Qual Browser Software v2.1.0 (Thermo Fisher Scientific). The area was calculated 
using automated the peak detection function. 
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Table 2.5 Peptide sequences of Cys60 and Cys77 in Akt1 generated from trypsin digest.  
Disulphide bonded and free thiols were differentially labelled and analysed by tandem mass 
spectrometry. 
 
Protein Cysteine residue Protease Peptide sequence 
Akt1 
60 
Trypsin 
EAPLNNFSVAQCQLMK 
77 CLQWTTVIER 
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 Protein–lipid binding interaction assay 
Lyophilised phospholipid PIP3 diC16 (Sapphire Bioscience) was reconstituted in 
methanol−chloroform solution (1:1) to a working concentration of 1 mM and stored at −80°C. 
PIP3 was diluted in a methanol, chloroform and MilliQ H2O solution (2:1:0.8) to various 
concentrations of 1, 5, 10, 25, 50 and 100 μM. 1 μl aliquots of selected PIP3 dilutions (1 to 100 
pM) were spotted onto Amersham Protran 0.45 μm nitrocellulose supported Western blotting 
membranes (GE Healthcare Life Sciences) and dried at room temperature for 1 h. Membranes 
were incubated in blocking buffer (20% (w/v) Bovine Serum Albumin (BSA) Fatty Acid-Free 
(Sigma-Aldrich) in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% (v/v) TWEEN® 20 (Sigma-
Aldrich) in MilliQ H2O) at room temperature for 1 h. Membrane was incubated with 10 nM 
WT-PH EGFP or reduced C60AC77A-PH EGFP protein in fresh blocking buffer overnight at 
4°C. Membranes were washed 5× in 10 min intervals with 1× TBST at room temperature. 
Membranes were probed with GFP (FL) polyclonal antibody (Santa Cruz Biotechnology) 
diluted in fresh blocking buffer (1:1000) for 1 h at room temperature. Membranes were washed 
5× in 10 min intervals with 1× TBST at room temperature. Membranes were probed with 
appropriate HRP-conjugated secondary antibody diluted with 5% (w/v) skim milk powder in 
1× TBST (1:2000) for 1 h at room temperature.  Membranes were washed 4× in 8 min intervals 
with 1× TBST at room temperature. Membranes were soaked in a tray of ECL solution (1:1) 
for 2 min at room temperature. Membranes were imaged on the ChemiDoc Touch Imaging 
System (Bio-Rad). 
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 Enzyme-linked immunosorbent assay (ELISA) 
The ELISA protocol was based off a procedure curated by Rowland et al., 2012. 96-well ELISA 
Microplates (Greiner Bio-One) were washed with Coating Buffer (20 mM Tris, pH 8.0, 0.05% 
(v/v) TWEEN® 20) for 30 min on a plate shaker at room temperature. Coating Buffer was 
removed from the wells and dried. 500 nM of 1-oleoyl-2-[12-biotinyl(aminododecanoyl)]-sn-
glycero-3-PIP3 (18:1 – 12:0 Biotin-PIP3) (Avanti) was added to each well and incubated on a 
plate shaker for 1 h at room temperature. Biotin-PIP3 was removed from the wells and washed 
with Coating Buffer 3× in 10 min intervals on a plate shaker at room temperature. Serial 
dilutions of WT-PH EGFP (untreated), reduced WT-PH EGFP (treated with 10 mM DTT for 
30 min, desalted in Zeba™ Spin Desalting Columns, 7K MWCO, 0.5 ml) and reduced C77S-
PH EGFP proteins were prepared in Protein Buffer solution (1× PBS, 0.05% (v/v) TWEEN 
20) to concentrations of 1, 5, 10, 25, 50, 100 nM. Protein solutions were added to each well 
and incubated on a plate shaker for 1 h at room temperature. Wells were washed with Protein 
Buffer solution 3× in 10 min intervals on a plate shaker at room temperature and resuspended 
in Protein Buffer solution. Bound fluorescent Akt1-PH EGFP proteins were read at 
Excitation/Emission 485/535 nm on the plate reader. 
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2.5 Zebrafish Analyses 
 Zebrafish maintenance 
Zebrafish (Danio rerio) husbandry and experimental procedures were performed adhering to 
the Australian code of animal ethics. Adult zebrafish were housed at the Garvan Institute. 
Transgenic zebrafish line Tg(fli1a:EGFP) was utilised for this project. Clutches of embryos 
were collected from natural spawning. Microinjections of pDestTol2/ubb:Akt1-p2a-tdTomato 
(Figure 2.2B) were performed at the Garvan Institute. Embryos were incubated at 28°C in E3 
media (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4, 0.1% (v/v) methylene 
blue in MilliQ H2O) at the Centenary Institute. Pigment development was prevented with the 
addition of 45 μg/ml phenylthiourea (PTU) solution (Sigma-Aldrich). In vivo imaging of 
zebrafish embryos were performed at the Centenary Institute.  
 
 Microinjection and imaging 
Tg(fli1a:EGFP) zebrafish embryos were injected with 2 nl of pDestTol2/ubb:Akt1-p2a-
tdTomato (150 ng), Tol2 transposase mRNA (20 ng) and phenol red into the animal pole at the 
one-cell stage under the SMZ1270 microscope with P-DSL32 LED Diascopic Illumination 
Stand (Nikon) at the 40× objective (Figure 2.3). Dead or unfertilised embryos were removed 
3 hours post-fertilisation (hpf). Embryos were dechorionated with 1× Pronase for 2 min at 24 
hpf. Embryos overexpressing Akt1 (tdTomato) were anesthetised with 10× Tricaine mesylate 
and mounted on 3% (w/v) methylcellulose in E3 media at 48 hpf. In vivo imaging was 
performed on the M205 FA fluorescent stereomicroscope (Leica). A new channel was applied 
to label the EGFP (green) and Cy5 (red) fluorophores. Images were processed using ImageJ 
(National Institute of Health). Completeness of intersegmental vessels (ISV) and length of 
zebrafish embryos were evaluated.  
84 
 
Figure 2.3 Timeline of Tg(fli1a:EGFP) zebrafish embryo injection and imaging. 
Vasculature (green) of Tg(fli1a:EGFP) embryos injected with mutant Akt1 (red) constructs 
imaged 48 hours post-fertilisation. 
 
 
 
Image with microscope
• Vascular patterning (EGFP) 
• Akt1 expression (tdTomato)
48 hours post-fertilisation
1-cell stage of zebrafish embryo
Incubate at 28 C in E3 media
Dead and unfertilised embryos removed
Inject mixture into animal pole
Pierce chorion and enter animal pole
pDestTol2/ubb:Akt1-p2a-tdTomato DNA 
+ Tol2 transposase mRNA 
+ phenol red
3 hours post-fertilisation
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 Protein extraction and quantification 
Embryos were centrifuged at 18,000 × g for 2 min and supernatant was discarded. Embryos 
were resuspended in Ringer’s solution (58 mM NaCl, 4 mM KCl, 4.8 mM NaHCO3, pH 7.0 in 
MilliQ H2O) and centrifuged at 18,000 × g for 2 min, supernatant was discarded. Embryos 
were washed 1× PBS and centrifuged at 18,000 × g for 2 min, supernatant was discarded. 
Embryos were harvested in RIPA buffer (1 mM EDTA, 1% (v/v) Triton X-100, 0.1% (w/v) 
sodium deoxycholate, 0.1% (w/v) SDS, 10 mM Tris-Cl, pH 8.0 in MilliQ H2O), supplemented 
with 1× Protease Inhibitor Cocktail, 1× Phosphatase Inhibitor and 1 mM PMSF. Embryo 
lysates were incubated on ice for 30 min. Lysates were centrifuged at 18,000 × g for 5 min, 
supernatant was transferred into a new microcentrifuge tube. The BCA method was performed 
for colourimetric quantitation of total proteins in collected embryo lysates. Absorbance was 
read at 562 nm on the plate reader. Method of protein separation and immunoblotting analyses 
were previously described (Section 2.4.4-2.4.7). 
 
 RNA extraction 
Zebrafish larvae were lysed with TRIzol® Reagent (Invitrogen) in E3 media (3:1) and incubated 
for 5 min at room temperature. Chloroform (Sigma-Aldrich) (2:1) was added to the mixture 
and incubated for 2 min at room temperature. Lysates were centrifuged at 12,000 × g for 15 
min at 4°C. Aqueous phase (top layer) containing total RNA was aliquoted into a fresh 
microcentrifuge tube. Isopropanol (2:1) was added and incubated for 10 min at room 
temperature to precipitate RNA. Reaction was centrifuged at 12,000 × g for 15 min at 4°C, 
supernatant was removed. RNA pellet was washed with 75% (v/v) ethanol and centrifuged at 
7,500 × g for 5 min at 4°C. Supernatant was removed and the RNA pellet was air-dried before 
resuspension in RNase-free H2O. 
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 Real-time quantitative polymerase chain reaction (RT-qPCR) 
RNA (1 µg) was mixed with 1× reverse transcriptase, 1× RT buffer, 60 µM random primers 
and 10 mM oligo(dT) primers in RNase-free H2O. Reaction mix was subjected to 10 min of 
primer extension at 25°C, synthesis of cDNA at 37°C for 2 h and termination at 85°C for 1 min 
on the Mastercycler nexus gradient. cDNA product was diluted in MilliQ H2O (1:6). Diluted 
cDNA was mixed with SYBR® Green master mix (Thermo Fisher Scientific) and the 
appropriate forward and reverse oligonucleotides of downstream Akt1 genes in zebrafish 
required for neuronal differentiation and angiogenesis (Table 2.6). Each reaction was loaded 
into a Non-skirted Flat Top Low Profile 96-well Plate, Clear (SSIbio) and read on the CFX96™ 
Real-Time PCR Detection System (Bio-Rad). Reaction mix was subjected to 3 min at 95°C, 
followed by 40 cycles of 10 s denaturation at 95°C, 30 s annealing at 55°C, data was recorded 
at each annealing step. Melt curve protocol followed by 0.5 s at 65°C to 95°C, in 0.5°C 
increments, data was recorded at each increment of the melt curve. Melt and standard curves 
were generated by the CFX Manager™ Software v2.0 (Bio-Rad). 
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Table 2.6 Oligonucleotides designed for RT-qPCR of selected genes downstream targets 
of Akt1 in the zebrafish model.  
Differentiated and progenitor neuronal markers downstream of Akt1.  
 
Oligonucleotide Sequence 5'-3' 
TbpF 
TbpR 
CGGTGGATCCTGCGAATTA 
TGACAGGTTATGAAGCAAAACAACA 
Elavl3F 
Elavl3R 
GTCAGAAAGACATGGAGCAGTTG 
GAACCGAATGAAACCTACCCC 
DeltaAF 
DeltaAR 
ACCGGGTGAAGCTTGTGAAC 
CGTCATGCYCGTCCAGAAGTT 
Her8aF 
Her8aR 
GTAACGGGGAGACGCGTCTGCAGCG 
GATTATTCCCACGATGACGGCGGCG 
Ngn1F  
Ngn1R 
CGCACACGGATGATGAAGACTCGCG 
CGGTTCTTCTTCACGACGTGCACAGTGG 
 
Tbp TATA-box binding protein is the housekeeping gene. Elavl3 ELAV-like neuron-specific 
RNA-binding protein 3; Her8a hairy-related 8a; Ngn1 neurogenin 1. 
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2.6 Statistical Analyses 
 GraphPad Prism 
Unless otherwise specified, statistical significance was assessed in GraphPad Prism 7 
(GraphPad Software) using Student’s t-tests or analysis of variance (ANOVA); comparing the 
mean of each group against the mean of every other group using Tukey’s multiple comparison 
test. Data are expressed as mean ± standard deviation (s.d.). Experiments were performed in 
duplicate or triplicate, with a minimum of n=3 independent biological experiments. *p<0.05 
was considered statistically significant. 
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3. Identification of the Cys60-Cys77 disulphide bond in the 
PH domain of Akt1 
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3.3 Abstract 
Protein disulphide bonds link pairs of cysteine sulphur atoms and are either structural or 
functional motifs. The allosteric disulphides control the function of the protein in which they 
reside when cleaved or formed. Here, we identify potential allosteric disulphides in all Protein 
Data Bank X-ray structures from bonds that are present in some molecules of a protein crystal 
but absent in others, or present in some structures of a protein but absent in others. We reasoned 
that the labile nature of these disulphides signifies a propensity for cleavage and so possible 
allosteric regulation of the protein in which the bond resides. A total of 511 labile disulphide 
bonds were identified. The labile disulphides are more stressed than the average bond, being 
characterised by high average torsional strain and stretching of the sulphur–sulphur bond and 
neighbouring bond angles. This pre-stress likely underpins their susceptibility to cleavage. The 
coagulation, complement and oxygen-sensing hypoxia inducible factor-1 pathways, which are 
known or have been suggested to be regulated by allosteric disulphides, are enriched in proteins 
containing labile disulphides. The identification of labile disulphide bonds will facilitate the 
study of this post-translational modification. 
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3.4 Introduction 
Allosteric disulphide bonds are defined by their ability to affect the functioning of the protein 
in which the bond resides. Reduction or oxidation of allosteric disulphide bonds leads to 
conformational transitions in the residing protein, that result in a change in either ligand 
binding, enzyme activity, proteolysis or oligomerisation of the protein (Cook & Hogg, 2013). 
Since the identification of this type of posttranslational control of protein function, over 30 
examples have been described. The extent to which biological processes are controlled by 
allosteric disulphides has not yet been fully elucidated. However, certain processes are highly 
regulated by this form of protein control. In humans, thrombosis and hemostasis is an example 
of a system that is regulated by allosteric disulphides (Butera et al., 2014). Disease processes 
regulated by allosteric disulphide bonds include cancer (Hogg, 2013) and viral infection 
(Wouters et al., 2004). Clinical relevance lies in the fact that these disulphide bonds can be 
targeted with inhibitors of the factors that cleave the bonds, such as protein disulphide 
isomerase (PDI). Small molecule PDI inhibitors are being developed (Bekendam et al., 2016) 
and a first generation molecule is currently being tested as an anti-thrombotic in a Phase II 
cancer clinical trial (Stopa et al., 2017). 
 
Studies of the biophysical properties of allosteric disulphides have led to the recognition of 
defining features of these bonds. Firstly, a conformational signature for allosteric disulphides 
has been identified based on the sign of the five dihedral angles which define the cystine residue 
(Schmidt et al., 2006). There are 20 different disulphide bond configurations based on this 
classification and 3 of the 20 are emerging as allosteric configurations; the –RHstaple, –
LHhook and –/+RHhook bonds. Secondly, the –RHstaple and –/+RHhook bonds are more 
stressed than the other 18 disulphide types (Zhou et al., 2014), which is primarily due to 
stretching of the sulphur-sulphur bond and neighboring bond angles. Stretching of sulphur-
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sulphur bonds is known to accelerate their cleavage (Baldus & Gräter, 2012; Li & Gräter, 2010; 
Wiita et al., 2006; Wiita et al., 2007), so the pre-stress of the –RHstaple and –/+RHhook 
configurations is very likely important for their reduction and has probably influenced their 
evolution as allosteric bonds.  
 
The three allosteric configurations constitute approximately 20% of all disulphide bonds in X-
ray structures from the PDB (Schmidt et al., 2006). While bond configuration has proven useful 
for identifying allosteric disulphides in proteins, it is likely that many, if not most, bonds with 
allosteric configurations will not have a functional role. Additional methods are needed to 
identify this post-translational modification. Here we identify 511 labile disulphide bonds in 
PDB X-ray structures from bonds that are present in some molecules of a protein crystal or in 
some structures of a protein, but absent in others. A notable feature of the labile bonds is their 
pre-stress that likely underlies their facile nature. A biological pathway enriched in proteins 
containing labile disulphides is the cytoplasmic oxygen-sensing HIF1 system. Potential 
allosteric disulphide bonds in this pathway are presented. 
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3.5 Results 
A total of 1,361 unique labile disulphide bonds were identified from the PDB as of June 2017. 
The reference dataset consisted of all 14,033 unique disulphide bonds in the PDB. To eliminate 
poorly defined or erroneous bonds, criteria of a structure resolution <2.5 Å and sulphur–sulphur 
distances <10% from the disulphide bond equilibrium length of 2.038 Å (Zhou et al., 2014) 
were applied. The datasets were refined to present each unique disulphide bond as a single 
entry. The final list contains 511 labile disulphides and 13,030 total disulphides. 
  
In X-ray crystallography, the B factor is a measure of the degree to which the electron density 
of an atom is dispersed. To ensure that the missing disulphide bonds that we detected were not 
due to uncertainty in the position of cysteines, we compared the average B factor of disulphide-
bonded cysteines with those of matched missing disulphide bonds. The B factor for each atom 
of each cysteine involved in disulphide bond formation (present or missing) was extracted from 
corresponding PDB structure. The B factor for each disulphide bond was calculated as the 
average of the 12 atoms per cysteine pair. To compare the B factor of present and missing 
disulphide bonds, the average disulphide bond B factors for all redundant structures were 
further averaged, respectively. There was no significant difference between the B factor of 
present (37.58±21.78, s.d.) and missing (36.24±21.02, s.d.) disulphide bonds (p=0.0736, paired 
t-test). 
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 Structural and functional features of the labile disulphide bonds 
By comparing the distribution of the 20 disulphide configurations between the entire PDB and 
labile disulphides, two differences were notable (Figure 3.1A). Within the labile disulphide 
bonds, an increase in the +/–RHhook and +/–LHstaple configurations was observed (χ2 test, 
p<0.0001). The –LHspiral, which is the main structural disulphide, as well as the +RHspiral 
configurations were decreased in the labile disulphides compared with the total PDB (χ2 test, 
p<0.0001). The +/–RHhook is the predominant configuration of the catalytic disulphide bonds 
of oxidoreductases (Schmidt et al., 2006), such as PDI. This reflects the conserved position of 
this bond at the end of an α-helix in a thioredoxin fold. The catalytic disulphides of 
oxidoreductases undergo cycles of reduction and oxidation and there are several examples of 
oxidised and reduced structures in the PDB, hence their prevalence in the labile disulphide 
dataset. Of the 67 proteins in the labile disulphide dataset that have a +/–RHhook configuration, 
22 are oxidoreductases. 
 
The secondary structures that a disulphide links can be informative. For instance, allosteric –
RHstaple bonds often link adjacent strands in the same antiparallel β-sheet or constrain β-loops 
(Matthias et al., 2002; Wouters et al., 2004). Also, the catalytic disulphide bonds of 
oxidoreductases link an α-helix to another or a loop structure. For the total PDB, disulphide 
bonds linking two β-strands were the most common, followed by linking of β strands and loops 
(Figure 3.1B). For labile disulphide, enrichment of bonds linking α-helices and loops was 
observed (χ2 test, p<0.0001) (Figure 3.1B), which reflects the higher relative number of 
catalytic +/–RHhook configurations. 
 
As anticipated, oxidoreductases were enriched in proteins containing labile disulphide bonds 
(Figure 3.1C). Transferases, which include kinases, methyltransferases and other enzyme that 
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transfer functional groups, were also enriched in proteins containing labile disulphide bonds 
(Figure 3.1C). Hydrolases and proteins involved in immune function were the largest category 
of disulphide-containing proteins in the PDB. Immune function proteins contain relatively 
fewer labile disulphides in this analysis. Overall, labile disulphide bonds were found in proteins 
of diverse functionalities. 
 
The subcellular localisation of proteins containing disulphide bonds was examined using the 
UniProt designation of the protein. A high proportion of cytoplasmic and nuclear proteins 
contained labile disulphide bonds (Figure 3.1D). The cytoplasm and nucleus are environments 
traditionally thought not to be conducive to disulphide bond formation. This is not the case, 
however, as 509 disulphide bonds have been structurally defined in cytoplasmic proteins. A 
high proportion of these disulphides (113 disulphides) have been characterised in oxidised and 
reduced states, indicating that they are unusually labile.  
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Figure 3.1 Structural and functional features of the labile disulphide bonds.  
A. Distribution of the 20 disulphide bond configurations in unique disulphide bonds in PDB protein X-ray structures (13,030 disulphides) and in 
labile bonds (511 disulphides). Compared with the total PDB, the labile bonds in are enriched in +/–RHhook and +/–LHstaple bonds (χ2 test, 
p<0.0001) and have relatively fewer –LHspiral and+RHspiral bonds (χ2 test, p<0.0001) (indicated by *). B. Heatmap displaying the frequency of 
the secondary structures linked by disulphide bonds in all PDB protein structures and by labile disulphide bonds. There is enrichment of disulphides 
linking α-helices and loops in labile disulphide bonds (χ2 test, p<0.0001). C. Distribution of the functional classification of all proteins containing 
disulphide bonds and proteins containing labile disulphide bonds. Compared to the total PDB, there was a significant increase in oxidoreductases, 
transferases and isomerases (indicated by *). .A significant decrease in disulphide bonds in proteins involved in signalling and immune function 
was observed (χ2 test, p<0.0001). D. Subcellular localisation of all proteins containing disulphide bonds and proteins containing labile disulphide 
bonds. Compared to the total PDB, a significant increase in cytoplasmic proteins, as well as a decrease in membrane associated and secreted 
proteins was observed (χ2 test, p<0.0001) (indicated by *). 
 
A                                                     B
C                                                     D
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 Labile disulphides are characterised by high strain 
The conformational constraints on allosteric disulphides imposed by secondary structural 
features stress the bonds. The stresses fine tune their cleavage and thus the function of the 
protein. The stresses of the labile disulphides have been compared and contrasted with the 
average disulphide. There are different measures of disulphide bond stress (Schmidt et al., 
2006; Zhou et al., 2014). 
 
DSE (dihedral strain energy) is an indicator of bond strain. The DSE is defined in terms of the 
torsion of the five dihedral or χ angles (Figure 3.2A) of the cystine residue (Katz & Kossiakoff, 
1986; Weiner et al., 1984) , and has been shown experimentally to reflect the amount of strain 
in a disulphide bond (Kuwajima et al., 1990; Pjura et al., 1990; Wells & Powers, 1986; Wetzel 
et al., 1988). The length of the sulphur-sulphur bond and magnitude of the neighbouring angles 
(Figure 3.2A) also reflect the stress in a disulphide (Zhou et al., 2014). The allosteric 
−RHstaple and−/+RHhook disulphide configurations carry tensile pre-stress in the bond due to 
direct stretching of the sulphur-sulphur bond and α angles, rather than by dihedral angle 
torsions (Zhou et al., 2014). This was shown using force distribution analysis, a technique for 
calculating atom-atom and residue-residue forces from molecular-dynamics simulations. As 
mechanical stretching of sulphur-sulphur bonds increases their redox potential (Baldus & 
Gräter, 2012; Li & Gräter, 2010; Wiita et al., 2006; Wiita et al., 2007), the pre-stressed bonds 
are more susceptible to cleavage. 
 
The mean DSE of labile disulphide bonds (different PDB) was significantly higher than that of 
all disulphide bonds in the PDB (Figure 3.2B). The mean DSE for all disulphide bonds was 
12.48 kJ mol−1, whereas that of labile disulphide bonds was 17.64 kJ mol−1. The mean sulphur-
sulphur bond length (Figure 3.2C) and α angle magnitude (Figure 3.2D) were also 
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significantly higher than those for all disulphide bonds. The mean sulphur-sulphur bond length 
of all disulphides was 2.046 Å, whereas for the labile disulphide bonds it was 2.055 Å. While 
the increased bond length is small at approximately 1 pm, the high stiffness of sulphur-sulphur 
bonds means that this change can entail substantial stress. The mean α angle of all disulphide 
bonds was 104.7°, whereas for the labile disulphide bonds it is 106.1°. Between 1 and 2° of 
stretching is also seen for the allosteric −RHstaple and −/+RHhook disulphide configurations 
(Zhou et al., 2014). Thus, the labile disulphide bonds are more stressed than the average bond 
based on three measures of strain. 
 
Correlations between the measures of strain on disulphides was examined (Figure 3.3). DSE 
positively correlated with stretching of the α-angles for both labile (p < 0.0001) and total (p < 
0.0001) disulphides. There was no correlation between DSE and sulphur-sulphur bond length, 
or between sulphur-sulphur bond length and α angles for both labile and total disulphides. This 
indicates that stretching of the α-angles is associated with high overall torsional strain, whereas 
sulphur-sulphur bond length is independent of the α-angles. 
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Figure 3.2 The labile disulphides are characterised by high dihedral strain energy, 
elongation of the sulphur-sulphur bond distance and stretching of the neighbouring bond 
angles. 
A. Angles and distances of the cystine residue. The values α1 and α2 represent the two relevant 
bending angles of the disulphide, and the five dihedral angles are χ1, χ2, χ3, χ2′, and χ1′. d is the 
sulphur-sulphur bond length. B. Relative frequency of DSE ranging from 0 to 60 kJ mol−1. The 
DSE was significantly increased for labile disulphides from different PDB compared to the 
total PDB with ****p<0.0001. C. The relative frequency of the sulphur-sulphur bond distance 
ranging from 1.96 to 2.14 Å is shown. An increase in sulphur-sulphur bond distance is observed 
for labile disulphide bonds (****p<0.0001). D. The average of both α angles was calculated 
for each disulphide bond. Shown is the relative frequency of the average angle ranging from 
95 to 120°. Angles are increased for labile disulphide bonds (****p<0.0001). T-tests were used 
to compare total PDB to labile disulphides. 
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Figure 3.3 Correlations of the measures of strain of the missing and all disulphides. 
A. Positive correlation of DSE with stretching of the α angle for both missing and all 
disulphides. B. No correlation between DSE and length of the sulphur-sulphur bond of 
disulphides for both missing and all disulphides. C. No correlation between sulphur-sulphur 
bond length and α angle for both missing and all disulphides. 
 
A
B
C
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 Labile disulphides with allosteric configurations have higher dihedral strain 
The allosteric –RHstaple, –LHhook, and –/+RHhook configurations represent 9%, 6.5%, and 
4.5% of all disulphide bonds in the PDB (Figure 3.4A). For those allosteric disulphide bonds 
where there are high resolution crystal structures (n = 29), these percentages increase to 39%, 
16%, and 16%, respectively (Figure 3.4A). The labile disulphides with allosteric 
configurations have a higher mean DSE than for all disulphide bonds (18.11 versus 12.74 kJ 
mol−1, p<0.0001, Mann-Whitney test) (Figure 3.4B), which is consistent with the known 
properties of two (−RHstaple and −/+RHhook) of the three allosteric configurations. 
 
 Labile disulphide bonds are enriched in certain biological pathways 
Five known allosteric disulphides are amongst the 511 labile bonds, which is a validation of 
this approach for identifying functional disulphides. These are the –RHstaple bonds in 
methionine aminopeptidase 2 (Chiu et al., 2014b), botulinum neurotoxins (Swaminathan & 
Eswaramoorthy, 2000) and transglutaminase 2 (Pinkas et al., 2007), the –/+RHhook 
disulphides in plasminogen (Butera et al., 2013) and Lon protease (Nishii et al., 2015), and the 
–LHhook bonds in DNA repair protein XRCC1 (Cuneo & London, 2010) and plasminogen 
(Butera et al., 2013) (Table 3.1). 
 
To determine whether specific biological processes or pathways are enriched among human 
labile disulphides, the labile dataset was analysed using the DAVID Functional Annotation 
Tool (Huang et al., 2009a, 2009b). The oxygen-sensing HIF1 pathway is significantly enriched 
in proteins containing labile disulphide bonds (Table 3.2). My focus was on protein kinase 
B/Akt involved in the PI3K/Akt/mTOR cell signalling cascade. 
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Figure 3.4 The labile disulphides with allosteric configurations have higher dihedral 
strain energy. 
A. The –RHstaple, –LHhook, and –/+RHhook configurations represent 9%, 6.5%, and 4.5% of 
all disulphide bonds in the PDB. For the structurally defined allosteric disulphide bonds (n = 
29), these percentages increase to 39%, 16%, and 16%, respectively. B. The labile disulphide 
bonds with allosteric configurations (n = 158) have an increased DSE compared to the total 
PDB (****p<0.0001, Mann-Whitney test). 
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Table 3.1 Allosteric disulphides with known configurations. 
 
Protein Species Disulphide Cys PDB Configuration 
Methionine 
aminopeptidase 2 
Homo sapiens 228–448 1B59 –RHstaple 
Tissue Factor Homo sapiens 186–209 1BOY –RHstaple 
Botulinum 
neurotoxins 
Clostridium 
botulinum 
436–445 1EPW –RHstaple 
Prolyl cis-trans 
isomerase, AtFKBP13 
Arabidopsis 
thaliana 
106–111 1Y0O –RHstaple 
HIV gp120 
Human 
immunodeficiency 
virus type 1 
126–196 
1YYM 
–RHstaple 
296–331 –RHstaple 
385–418 –RHstaple 
Transglutaminase 2 Homo sapiens 370–371 2Q3Z –RHstaple 
CD4 Homo sapiens 130–159 3CD4 –RHstaple 
Arylsulfate 
sulfotransferase 
Escherichia coli 418–424 3ELQ –RHstaple 
C-reactive protein Homo sapiens 36–97 3L2Y –RHstaple 
von Willebrand factor Homo sapiens 2451–2468 3BK3 –RHstaple 
β2-glycoprotein I Homo sapiens 288–326 1C1Z –/+RHhook 
Factor XI Homo sapiens 362–482 2F83 –/+RHhook 
Angiotensinogen Homo sapiens 18–138 2WXW –/+RHhook 
Lon protease1 Homo sapiens 617–691 3WU4 –/+RHhook 
Plasmin(ogen) Homo sapiens 462–541 4DUR –/+RHhook 
Interleukin receptor 
subunit gamma 
Homo sapiens 160–209 2ERJ –LHhook 
CD44 Mus musculus 81–101 2JCP –LHhook 
Vascular endothelial 
growth factors C & D 
Homo sapiens 156–165 2X1W –LHhook 
XRCC1 Homo sapiens 12–20 3LQC –LHhook 
Plasmin(ogen) Homo sapiens 512–536 4DUR –LHhook 
QueF Bacillus subtilis 55–99 5UDG –LHhook 
CgDapF 
Corynebacterium 
glutamicum 
83–221 5H2G –LHhook 
C-terminal Src kinase2 Homo sapiens 122–164 3EAC +LHhook 
Transglutaminase 2 Homo sapiens 230–370 3LY6 +RHstaple 
hTryptaseβ3 Homo sapiens 191–220 2FPZ –RHhook 
Thiolase 
Clostridium 
acetobutylicum 
88–378 4XL2 +/–LHspiral 
MICA Homo sapiens 202–259 1HYR –/+LHhook 
PAI-2 Homo sapiens 79–161 1BY7 Undetermined 
 
1. Also exists in a +/–LHspiral configuration (PDB 3WU4, chain A) 
2. Also exists in a +/–RHspiral configuration (PDB 3EAC, chain A) 
3. Also exists in a –RHspiral configuration (PDB 2FPZ, chain B) 
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Table 3.2 Labile disulphide bonds in the HIF1 signalling pathway.  
The first four characters are the PDB identifier followed by the strain. Underlined PDB 
identifiers of Akt1 are shown as examples in Figure 3.5. 
 
Protein Disulphide Cys PDB with bond PDB missing bond Configuration 
Akt/PKB 60–77 4EJNA, 3O96A, 
5KCVA, 2UZRA, 
1UNPA, 1UNRA 
1UNQA, 1H10A, 
2UZSA, 2UVMA 
 –RHstaple 
EGF 133–216 4KRPA 3NJPA, 3NJPB, 
1MOXA, 1MOXB, 
1NQLA, 3QWQA, 
1IVOA, 1IVOB, 
4UV7A, 4KROA, 
4UIPA, 1YY9A 
 –/+LHhook 
Egl 9 
homolog 
1 (or 
PHD2) 
201–208 4BQYA, 3OUIA, 
4BQXA, 4JZRA,  
5LATA,  4BQWA,  
3OUHA,  2Y33A,  
3HQRA,  5LBEA,  
5LBFA,  2HBTA,  
5LBBA,  5LB6A   
4UWDA, 5L9RA, 
3HQUA, 5A3UA, 
5A3UB, 5A3UC, 
4KBZA, 3OUJA, 
2HBUA, 5LBCA, 
2G19A, 2G1MA, 
5L9BA, 5L9BB, 
2Y34A 
 +/–LHspiral 
EP300 1796–1806 
1796–1801 
3P57P   3IO2A, 2MZDA, 
2MH0B, 2K8FA 
+LHspiral 
+/–RHspiral 
1177–1201 
1177–1183 
4BHWA, 4BHWB  5LKUA, 5LKTA, 
5LKZA, 5LKXA 
+/–LHstaple 
+/–RHstaple 
PI3K 357–524 4FULA   3DPDA, 2A4ZA, 
3PRZA, 3TJPA, 
4ANVA, 3ML8A, 
3ML9A, 3OAWA, 
3R7QA, 4FA6A, 
3TL5A, 5G55A, 
1HE8A 
 –LHstaple 
TEK 1040–1118 2WQBA   3L8PA, 1FVRA, 
1FVRB 
 –RHhook 
VEGFA 188–207 4DEQB   4DEQA  –LHspiral 
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 Identification of the Cys60–Cys77 disulphide bond in crystal structures of the PH domain 
of Akt1 
The PH domain of Akt1 (Akt1-PH) contains a labile disulphide bond that links Cys60 and Cys77 
residues near the lipid binding pocket. The Cys60–Cys77 disulphide bond is formed in all apo 
structures of truncated Akt1-PH (Figure 3.5A), but is absent in all Akt1-PH structures bound 
to inositol 1,3,4,5-tetrakis-phosphate (IP4); the head group of phospholipid PIP3 (Figure 3.5B). 
In addition, the Cys60–Cys77 disulphide bond has the archetypal –RHstaple allosteric 
configuration (Schmidt et al., 2006). Reduction of the Cys60–Cys77 disulphide bond results in 
movement of variable loop (VL) 3 adjacent to the disulphide bond and VL1 that lines the 
phosphatidylinositol binding pocket, suggesting it may be involved in PIP3 membrane binding. 
Additionally, a short acidic α-helix in VL2 is present when the disulphide is intact but not when 
the bond is cleaved. Structurally, alignment of the oxidised and reduced crystal structures show 
that there is a distinct conformational change of Akt1-PH depending on the redox state of the 
labile disulphide bond (Figure 3.5C); suggesting it may be an allosteric disulphide. 
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Figure 3.5 Conformational change in the PH domain of Akt1 from cleavage of a labile 
disulphide bond. 
Crystal structures of oxidised (PDB identifier 1UNPA) and reduced (PDB identifier 1UNQA) 
PH domains of Akt1 (Akt1-PH) adapted from Milburn et al., 2013. A. The apo structure (cyan) 
contains an oxidised Cys60–Cys77 disulphide bond that has an archetypal allosteric –RHstaple 
configuration. B. The Cys60–Cys77 disulphide bond is reduced (blue) in structures of the Akt1-
PH bound to inositol 1,3,4,5-tetrakisphosphate (IP4). C. Conformational differences in oxidised 
versus reduced Akt1-PH structures. The oxidised (A) and reduced (B) structures have been 
overlayed. Positions of variable loops (VL) 1, 2 and 3 differ depending on the redox state of 
the disulphide bond. 
 IP4
Cys60
Cys77
VL1
VL2
Cys60–Cys77
VL3
VL1
VL2
VL3
VL1
VL2
IP4
A                       B                      C
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3.6 Discussion 
External mechanical forces regulate cleavage of protein disulphide bonds (Ainavarapu et al., 
2008; Baldus & Gräter, 2012; Garcia-Manyes et al., 2009; Keten et al., 2012; Li & Gräter, 
2010; Liang & Fernandez, 2009; Ribas-Arino & Marx, 2012; Wiita et al., 2006; Wiita et al., 
2007). Rates of thiol/disulphide bond exchange are subject to mechano-chemical coupling. 
That is, the reactivity of a disulphide bond can be increased or decreased by mechanical forces 
that stretch, bend and twist the sulphur-sulphur and neighbouring bonds. For example, 
stretching of the sulphur-sulphur bond enhances cleavage of the disulphide. 
 
Internal mechanical forces also control cleavage of protein disulphide bonds in an analogous 
fashion (Zhou et al., 2014). Two of the twenty disulphide bond configurations; –RHstaple and 
–/+RHhook bonds, are particularly subject to topological stresses and allosteric function has 
been reported for seventeen of these bonds thus far. The –LHhook configuration is also being 
associated with allosteric function with seven examples thus far, although these bonds are no 
more stressed than the other eighteen configurations and it remains to be determined the reason 
for this functional association. 
 
While these biophysical properties are informative and have proven useful for identifying new 
allosteric bonds, it is likely that the majority of the approximately 2,800 disulphide bonds with 
allosteric configurations in known protein structures will not be redox active. To facilitate 
identification of this post-translational control of protein function, we mined X-ray structures 
for labile disulphide bonds that exist in some structures of a protein but are reduced in others. 
Our hypothesis is that the facile nature indicates a propensity for cleavage and so possible 
allosteric regulation of the protein in which the disulphide resides.  
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The limitations of this analysis are the availability of crystal structures, potential differences in 
the qualities of the structures themselves, and the non-native conditions that may have been 
employed to obtain the crystals and structures. For example, purifying and crystallising 
cytosolic proteins in oxidising conditions. It is also possible that some of the identified labile 
bonds are the result of cleavage by X-rays during data collection (Sutton et al., 2013), or 
inefficient formation during maturation of the protein. This does not exclude an allosteric 
function for these particular bonds, although they may have no functional role in the protein. 
 
Five hundred and eleven labile disulphide bonds were identified and we suggest that these 
bonds are enriched in allosteric disulphides. This conclusion is supported by the finding that 
the labile bonds are stressed based on high average dihedral strain coupled with an average 
elongated sulphur-sulphur bond length and extended bond angles. As stretching of the sulphur-
sulphur bond makes disulphides easier to cleave (Baldus & Gräter, 2012), this feature is likely 
a major reason why the identified bonds are labile. Five known allosteric disulphides are 
captured in the labile bonds and visual inspection of some of the labile bonds suggest an 
allosteric function, which further supports the conclusion that the labile bonds are enriched in 
allosteric disulphides. 
   
A high proportion of labile disulphide bonds occur in proteins that reside in the cytoplasm or 
nucleus. This finding implies that these intracellular compartments are conducive to this post-
translational protein control. Cleavage and/or formation of the labile disulphides are 
presumably enabled by the precise redox buffering mechanisms of the cytoplasm/nucleus.  
Pathway analysis showed that proteins involved in the HIF1 oxygen homeostasis system were 
enriched among human proteins containing labile disulphides. Notably, reversible disulphide 
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bond formation has been speculated to be a common regulatory mechanism of oxygen sensors 
(Cremers & Jakob, 2013).  
 
Among the list of human proteins involved in the HIF1 signalling pathway, the Cys60–Cys77 
disulphide bond in the PH domain of Akt1 was of interest due its –RHstaple allosteric 
configuration (Schmidt et al., 2006). Cleavage of the Cys60–Cys77 disulphide bond induced a 
significant conformational change of the lipid-bound Akt1 PH domain. In this thesis, I 
investigate whether the redox state of the Cys60–Cys77 disulphide bond has a functional role in 
Akt1 function. 
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4. The Cys60–Cys77 disulphide bond is involved in plasma 
membrane localisation of Akt1 
4.1 Introduction 
Akt is a highly conserved human serine/threonine protein kinase. Mammalian cells express 
three isoforms; Akt1/PKBα, Akt2/PKBβ and Akt3/PKBγ. Isoforms of human Akt are similar 
in structure, consisting of an N-terminus PH domain, followed by the catalytic kinase domain 
and the C-terminus regulatory domain. The focus of this study is primarily on the Akt1 isoform. 
 
Growth factor stimulation recruits PI3K to the plasma membrane catalysing the 
phosphorylation of PIP2 to generate PIP3. Allosteric activation of Akt1 is initiated by its PH 
domain binding to PIP3 (Ebner et al., 2017), resulting in a significant conformational change in 
Akt1 to expose its activation loop (Milburn et al., 2003). Akt1 is subsequently phosphorylated 
at Thr308 and Ser473 residues by PDK1 and mTORC2, respectively. Upon Akt1 membrane 
dissociation, allosteric communication between the PH and kinase domains promotes 
autoinhibition; the rate limiting step for Akt1 dephosphorylation (Ebner et al., 2017). 
 
Akt1 is often overexpressed and hyperactivated in cancers to promote tumour growth and 
survival (Bellacosa et al., 2005; Hers et al., 2011; Manning & Cantley, 2007; Staal et al., 1977; 
Sun et al., 2001). The autoinhibitory role of the membrane binding PH domain is to maintain 
the inactive conformation of Akt1. The common somatic mutation of Glu17 to Lys (E17K-
Akt1) in the PH domain of Akt1 weakens the PH–kinase domain interaction, leading to 
oncogenic activation of Akt1 (Carpten et al., 2007; Parikh et al., 2012). Exposure of the PH 
and kinase domains constitutively activates Akt1 by promoting PIP3 membrane localisation 
and phosphorylation of the kinase. The somatic mutation of Cys77 to Phe (C77F-Akt1) in the 
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PH domain of Akt1 was identified in clinical samples (Cerami et al., 2012; Ellis et al., 2012; 
Gao et al., 2013; Yi et al., 2012). This suggested that the Cys77 mutation may similarly perturb 
Akt1–PIP3 membrane localisation by interfering with the PH–kinase domain interface. 
 
In chapter 3, bioinformatic analyses revealed crystal structures of the PH domain of Akt1 
contain a labile Cys60–Cys77 disulphide bond with a distinct –RHstaple allosteric configuration 
(Figure 3.5A). The Cys60–Cys77 disulphide bond is formed in all apo structures of PH domain, 
but is notably reduced in PH domain structures with IP4 (Milburn et al., 2003). In this chapter, 
I investigate the effect of the Cys60–Cys77 disulphide bond on Akt1 membrane localisation. I 
also examine the redox state of the Cys60–Cys77 disulphide bond in truncated wild-type Akt1 
PH domain and full-length WTAkt1 recombinant proteins. 
 
The PH domain of Akt1 plays a critical role in the translocation and localisation of Akt1 at the 
plasma membrane (Andjelkovic et al., 1997). Moreover, mutations near the lipid binding site 
of the PH domain have been linked to cancer progression and may indicate a functional role, 
therefore justifying my investigation of the Cys60–Cys77 disulphide bond. I hypothesise that the 
Cys60–Cys77 disulphide bond in the PH domain of Akt1 is an allosteric disulphide bond that 
regulates Akt1 membrane localisation. 
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4.2 Results 
To examine the effect of the redox state of the Cys60–Cys77 disulphide bond in the PH domain 
of Akt1 on plasma membrane localisation, I designed truncated Akt1-PH DNA constructs to 
investigate the functional relevance of the Cys60–Cys77 disulphide bond. Truncated Akt1-PH 
clones (Akt1 amino acid residues 1-121) constructed by PCR (Figure 4.1A) were based on 
constructs previously reported by Milburn and colleagues (Milburn et al., 2003). Disulphide 
bond Akt1-PH mutants were constructed by SLIM hybridisation (Chiu et al., 2004; Chiu et al., 
2008). Cys60 and/or Cys77 residues in the PH domain were mutated to serine (Ser) (C60S-PH, 
C77S-PH, C60SC77S-PH), ablating formation of the Cys60–Cys77 disulphide bond. Truncated 
wild-type (WT-PH) and reduced-PH DNA constructs (C60S-PH, C77S-PH and C60SC77S-
PH) transformed in Rosetta-gami™ 2 (DE3) E. coli competent cells expressed recombinant 
Akt1-PH proteins. Crystal structures of WT-PH protein contain a mix of oxidised and reduced 
Cys thiols (Milburn et al., 2003), whilst the single or double cysteine mutant-PH protein is 
permanently in the reduced state and is lipid bound to IP4 (Figure 4.1B).  
 
In this chapter, disulphide bond Akt1 mutants (single or double Cys mutations) are denoted as 
reduced Akt1-PH (truncated) or reduced Akt1 (full-length) recombinant proteins. An EGFP 
tag was introduced at the C-terminus of designed truncated Akt1-PH DNA constructs to 
facilitate immunoblotting of truncated Akt1-PH protein.  
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Figure 4.1 Schematic DNA and protein structures of designed truncated Akt1-PH.  
A. Schematic structure of truncated oxidised and reduced Akt1-PH DNA constructs. Positions 
of functional or mutated amino acid residues in the pleckstrin homology (PH) domain of Akt1 
are noted. EGFP tag is at the C-terminus of each construct. Reduced Akt1-PH constructs where 
cysteine (C) was replaced by serine (S) were generated by the PCR-based, SLIM hybridisation 
method (Chiu et al., 2004; Chiu et al., 2008). All Akt1-PH constructs were sub-cloned into the 
pWaldo-TEV-GFPe vector. B. Crystal structures of truncated wild-type (WT-PH) (PDB 
identifier 1UNPA) and reduced-PH (PDB identifier 1UNQA) recombinant proteins were 
adapted from Milburn et al., 2013. WT-PH contains both disulphide bonded and reduced Cys60 
and Cys77 thiols. Single and double cysteine mutant-PH are permanently reduced. Oxidised-
PH protein, defined by the Cys60–Cys77 disulphide bond, is formed in all apo structures. 
Reduced-PH protein, defined by the cleavage of the disulphide bond, is lipid bound to inositol 
1,3,4,5-tetrakisphosphate (IP4) at the plasma membrane. 
 C77S-PH       C60SC77S-PH
Cys77  Ser77
Cys60  Ser60
Cys77  Ser77
Cys60  Ser60
C77
WT-PH
C60S-PH
C77S-PH
C60SC77S-PH 
C60
PH
S60
S77
S77
S60
Cys60–Cys77
WT-PH                                                  C60S-PH 
Cys60
Cys77
A                       
B
IP4
Cys60
Cys77
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 The Cys60–Cys77 disulphide bond is oxidised in truncated WT-PH protein 
The native state of the Cys60–Cys77 disulphide bond in purified, truncated Akt1 wild-type PH 
domain (WT-PH) recombinant protein was investigated by differential cysteine alkylation and 
mass spectrometry analyses (Bekendam et al., 2016; Butera et al., 2018; Pasquarello et al., 
2004; Passam et al., 2018). Protein expression of WT-PH detected by SDS-PAGE and SYPRO 
Ruby Gel staining (Figure 4.2A) was further verified by LC-MS. Reduced unpaired cysteine 
thiols in WT-PH were alkylated with 12C-IPA; whilst the remaining oxidised disulphide bonded 
cysteines were reduced with 40 mM DTT and alkylated with 13C-IPA (Figure 4.2B). Peptide 
sequences encompassing the disulphide Cys60 (EAPLNNFSVAQCQLMK) and Cys77 
(CLQWTTVIER) in the PH domain of Akt1, generated from trypsin digest, were resolved and 
analysed. Peptides were validated by their relative retention time (RT) (Figure 4.3) and 
fragmentation spectra (Figure 4.4A-D). Quantification of Cys60 and Cys77 residues in WT-PH, 
in the presence or absence of the cellular oxidoreductase Trx, were calculated from the relative 
ion abundance of peptides alkylated with 12C-IPA and/or 13C-IPA molecules. The ratio of 
reduced (12C-IPA) to oxidised (13C-IPA) Cys60 and Cys77 residues represents the fraction of the 
disulphide bond in the population that is in the reduced state (Figure 4.4E). In untreated WT-
PH, 20% of Cys60 and 15% of Cys77 residues were in the reduced state, indicating 75-80% of 
cysteines were oxidised and formed the Cys60–Cys77 disulphide bond. Incubation of WT-PH 
with Trx resulted in a significant change in the redox state of the disulphide bond to an increase 
of 50% reduced, 50% oxidised of both Cys60 and Cys77 residues. This suggested Trx may 
potentially be involved in the reduction of the Cys60–Cys77 disulphide bond of Akt1 in the 
cellular environment.  
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Figure 4.2 Redox state of the Cys60–Cys77 disulphide bond in truncated Akt1 WT-PH 
recombinant protein determined by differential cysteine alkylation and mass 
spectrometry. 
A. Eluates of WT-PH protein expressed in Rosetta-gami™ 2 (DE3) E. coli competent cells 
yielded 0.3 mg per 100 ml of culture. WT-PH protein was purified. B. Differential cysteine 
alkylation and mass spectrometry method of measuring the redox state of Cys60 and Cys77 in 
WT-PH protein. Unpaired Cys60 and Cys77 thiols are alkylated with carbon-12 isotope linked 
2-iodo-N-phenylacetamide (12C-IPA), whilst disulphide bonded thiols are alkylated with 
carbon-13 isotope linked 2-iodo-N-phenylacetamide (13C-IPA) following reduction with 
dithiothreitol (DTT). 
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Figure 4.3 Retention time and area of Cys60 and Cys77 peptides in truncated Akt1 WT-
PH recombinant protein following differential cysteine alkylation. 
Relative elution times and peak areas of EAPLNNFSVAQCQLMK (Cys60) and 
CLQWTTVIER (Cys77) peptides labelled with carbon-12 isotope linked 2-iodo-N-
phenylacetamide (12C-IPA) and carbon-13 isotope linked 2-iodo-N-phenylacetamide (13C-IPA) 
in WT-PH protein, either untreated or treated with thioredoxin (Trx). 
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12C-IPA alkylation of WT-PH + Trx Cys77
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Figure 4.4 The Cys60–Cys77 disulphide bond in truncated Akt1 WT-PH recombinant 
protein is oxidised. 
Tandem mass spectra of the EAPLNNFSVAQCQLMK (Cys60) and CLQWTTVIER (Cys77) 
peptide sequence alkylated with labelling molecules carbon-12 isotope linked 2-iodo-N-
phenylacetamide (12C-IPA) and carbon-13 isotope linked 2-iodo-N-phenylacetamide (13C-IPA) 
in WT-PH untreated or treated with thioredoxin (Trx). The EEWTTAIQTVADGLK peptide 
sequence (predicted: [M + 2H]2+ = 831.4227 m/z) was not a peptide of interest. A. Accurate 
mass spectra of the Cys60 peptide labelled with 12C-IPA (predicted: [M + 2H]2+ = 963.4660 
m/z, detected [M + 2H]2+= 963.4635 m/z) and 13C-IPA (predicted: [M + 2H]2+ = 966.4761 m/z, 
detected [M + 2H]2+= 966.4721 m/z) are displayed in the inset. B. Accurate mass spectra of the 
Cys77 peptide labelled with 12C-IPA (predicted: [M + 2H]2+ 691.3503 = m/z, detected [M + 
2H]2+ 691.3484 = m/z) and 13C-IPA (predicted: [M + 2H]2+ = 694.3603 m/z, detected [M + 
2H]2+= 694.3577 m/z). C. Accurate mass spectra of the Cys60 peptide labelled with 12C-IPA 
(predicted: [M + 2H]2+ = 963.4660 m/z, detected [M + 2H]2+ 963.4618 = m/z) and 13C-IPA 
(predicted: [M + 2H]2+ = 966.4761 m/z, detected [M + 2H]2+ 966.4713 = m/z). D. Accurate 
mass spectra of the Cys77 peptide labelled with 12C-IPA (predicted: [M + 2H]2+ 691.3503 = 
m/z, detected [M + 2H]2+ 691.3477 = m/z) and 13C-IPA (predicted: 694.3603 = m/z, detected 
[M + 2H]2+ 694.3575 = m/z). E. Redox state of the Cys60 and Cys77 residues in WT-PH protein; 
in the presence or absence of Trx. Data are expressed as the mean ± s.d. 
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 Ablation of the Akt1 Cys60–Cys77 disulphide bond increases affinity of Akt1-PH domain 
for PIP3 
Allosteric activation of Akt1 is fundamentally dependent on the conformation of its membrane 
binding PH domain (Andjelkovic et al., 1997; Lučić et al., 2018). At the plasma membrane, 
phospholipid PIP3 binds to the PH domain of Akt1 at its lipid binding site, thereby disrupting 
the PH domain-mediated autoinhibitory mechanism on the kinase domain (Ebner et al., 2017). 
Crystal structures show the Cys60–Cys77 disulphide bond is located near the lipid binding 
pocket of the PH domain (Figure 3.5A). I therefore examined the effect of the Cys60–Cys77 
disulphide bond in truncated Akt1-PH recombinant protein on binding affinity for PIP3 
phospholipid by two independent methods.  
 
The protein–lipid interaction assay was based on a method designed by Cho and colleagues 
(Cho et al., 2017). Previous reports have shown truncated Akt1-PH recombinant protein readily 
binds to pmol levels of PIP3 (Frech et al., 1997; James et al., 1996). PIP3 phospholipid was 
blotted onto nitrocellulose membrane and incubated with truncated WT-PH, transforming 
mutant E17K-PH and double cysteine mutant C60AC77A-PH recombinant proteins; followed 
by immunoblotting with an EGFP antibody (Figure 4.5A-B). Transforming mutant E17K-PH 
was utilised as a PIP3 membrane binding positive control (Figure 4.5A). Reduced C60AC77A-
PH prominently bound to PIP3 from 5 to 100 pmol, while WT-PH lost its binding capacity at 
10 pmol (Figure 4.5B). Lipid binding capacity of Akt1-PH was measured by densitometry 
analyses of EGFP (Figure 4.5C-D). Apparent Kd values of WT-PH indicated a lower affinity 
for PIP3 than mutant C60AC77A-PH; but interestingly, a higher affinity for PIP3 than 
transforming mutant E17K-PH (Table 4.1). 
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The ELISA Biotin-PIP3 assay method was based on a procedure by Rowland and colleagues 
(Rowland et al., 2012). Similar to my protein–lipid overlay assays, transforming mutant E17K-
PH was utilised as the positive control for Biotin-PIP3 binding. Biotin-PIP3 was incubated with 
untreated WT-PH, WT-PH treated with reducing agent DTT, single cysteine mutant C77S-PH 
and transforming mutant E17K-PH. Binding capacity of Akt1-PH to Biotin-PIP3 was measured 
by EGFP fluorescent levels (Figure 4.5E). Apparent Kd values of E17K-PH indicated a higher 
binding affinity to Biotin-PIP3 than all other Akt1-PH mutants (Table 4.1). Kd values of WT-
PH showed lower affinity to Biotin-PIP3 compared to that of DTT-treated WT-PH, suggesting 
reduction of the Cys60–Cys77 disulphide bond influences Akt1 membrane binding. This was 
further supported by apparent Kd values of single cysteine mutant C77S-PH displaying higher 
affinity for PIP3 than both untreated and DTT-treated WT-PH, possibly attributed to the mutant 
Ser77 residue causing a change in polarity at this position (the Ser hydroxyl is more polar than 
the Cys thiol) and altering the molecular conformation of the PH domain. 
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Figure 4.5 The Cys60–Cys77 disulphide bond in truncated Akt1-PH recombinant protein 
affects phospholipid PIP3 binding. 
Binding affinity of truncated Akt1-PH proteins to phospholipid PIP3 was measured by EGFP 
fluorescence. A-D. Protein–lipid overlay assays. Immunoblots (IB) detecting EGFP displayed 
in A. is of an individual experiment, and B. is representative of two independent experiments. 
C-D. Nonlinear regression in relative intensity (%) of blots displayed in A-B. Data are 
expressed as the mean ± s.d. E. Biotin-PIP3 ELISA assay is representative of three independent 
experiments. Nonlinear regression of Akt1-PH protein fluorescence in relative fluorescent 
units (RFU). Data are expressed as the mean ± s.d.  
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Table 4.1 Apparent equilibrium binding constant measurements between truncated 
Akt1-PH recombinant proteins and phospholipid PIP3.  
Apparent Kd values of Akt1-PH–PIP3 protein–lipid overlay assay and Akt1-PH–Biotin-PIP3 
ELISA assay displayed in Figure 4.5.  
 
Method of detection Akt1-PH  Apparent Kd, µM Reference 
Protein–lipid overlay assay 
WT-PH 11.7 ± 0.14 
Figure 4.5A,C 
E17K-PH 18.7 ± 0.47 
WT-PH 8.15 ± 0.26 
Figure 4.5B,D 
C60AC77A-PH 0.02 ± 0.11 
ELISA assay 
WT-PH 193 ± 2.98 
Figure 4.5E 
WT-PH + DTT 140 ± 13.1 
C77S-PH 63.0 ± 14.2 
E17K-PH 19.0 ± 34.9 
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 The Cys60–Cys77 disulphide bond is reduced in full-length WTAkt1 protein 
The redox state of the Cys60–Cys77 disulphide bond in immunoprecipitated full-length WTAkt1 
recombinant protein was investigated in NIH/3T3 fibroblasts stably transfected with WTAkt1, 
in the absence or presence of insulin. WTAkt1 protein was immunoprecipitated from cell 
lysates by the HA-epitope tag engineered in the N-terminus of all full-length Akt1 DNA 
constructs (Figure 5.1). Subsequently, I investigated the redox state of the Cys60–Cys77 
disulphide bond in response to insulin stimulation. Reduced unpaired Cys thiols in full-length 
WTAkt1 were alkylated with 12C-IPA, whilst oxidised disulphide bonded Cys were reduced 
with DTT and alkylated with 13C-IPA. Firstly, I confirmed that the full-length WTAkt1 DNA 
constructs were effectively transfected into wild-type NIH/3T3 fibroblasts. 
Immunoprecipitated full-length WTAkt1 protein was verified by SDS-PAGE, followed by 
immunoblot detection of total Akt (Figure 4.6A) and SYPRO Ruby Gel staining (Figure 
4.6B). Cysteine residues are sensitive targets of ROS generated by insulin stimulation 
(Goldstein et al., 2005). I therefore investigated whether oxidation of the Cys60–Cys77 
disulphide bond could be induced by insulin-stimulated ROS in the cell. NIH/3T3 fibroblasts 
expressing WTAkt1 were stimulated with insulin (10 nM) for 20 min. Immunoprecipitated 
untreated or insulin-stimulated full-length WTAkt1 recombinant protein was verified by SDS-
PAGE, followed by SYPRO Ruby Gel staining (Figure 4.6C). Reduced unpaired cysteine 
thiols in WTAkt1 were alkylated with 12C-IPA; whilst the remaining oxidised disulphide 
bonded thiols were reduced with 40 mM DTT and alkylated with 13C-IPA  (Figure 4.6D). 
Peptide sequences encompassing the disulphide Cys60 (EAPLNNFSVAQCQLMK) and Cys77 
(CLQWTTVIER) in the PH domain of Akt1, generated from trypsin digest, were resolved and 
analysed. Peptides were validated by their relative RT (Figure 4.7) and fragmentation spectra 
(Figure 4.8A-D). Quantification of Cys60 and Cys77 residues in untreated or insulin-stimulated 
WTAkt1 were calculated from the relative ion abundance of peptides alkylated with 12C-IPA 
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and/or 13C-IPA molecules. The ratio of reduced (12C-IPA) to oxidised (13C-IPA) Cys60 and 
Cys77 residues represent the fraction of the disulphide bond in the population that is in the 
reduced state (Figure 4.8E). Insulin stimulation was unable to induce Cys60–Cys77 disulphide 
formation in immunoprecipitated full-length WTAkt1 protein; with >95% of both Cys60 and 
Cys77 residues reduced. 
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Figure 4.6 Redox state of the Cys60–Cys77 disulphide bond in full-length WTAkt1 
recombinant protein determined by differential cysteine alkylation and mass 
spectrometry. 
Whole cell lysates were subjected to immunoprecipitation (IP) with a HA-epitope tag 
immunoglobulin G (IgG) antibody. Immunoprecipitated WTAkt1 was detected by A. 
immunoblotting (IB) for total Akt and B. SYPRO Ruby Gel staining. C. Immunoprecipitated 
untreated and insulin-stimulated WTAkt1 protein was subjected to differential cysteine (Cys) 
labelling. D. Differential cysteine alkylation and mass spectrometry method of measuring the 
redox state of Cys60 and Cys77 in WTAkt1. Unpaired Cys60 and Cys77 thiols are alkylated with 
carbon-12 isotope linked 2-iodo-N-phenylacetamide (12C-IPA), whilst disulphide bonded 
thiols are alkylated with carbon-13 isotope linked 2-iodo-N-phenylacetamide (13C-IPA) 
following reduction with dithiothreitol (DTT). 
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Figure 4.7 Retention time and area of Cys60 and Cys77 peptides in full-length WTAkt1 
recombinant protein following differential cysteine alkylation. 
Relative elution times and peak areas of EAPLNNFSVAQCQLMK (Cys60) and 
CLQWTTVIER (Cys77) peptides labelled with carbon-12 isotope linked 2-iodo-N-
phenylacetamide (12C-IPA) and carbon-13 isotope linked 2-iodo-N-phenylacetamide (13C-IPA) 
in untreated or insulin-stimulated WTAkt1 protein. 
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Figure 4.8 The Cys60–Cys77 disulphide bond in full-length WTAkt1 recombinant protein 
is reduced. 
Tandem mass spectra of the EAPLNNFSVAQCQLMK (Cys60) and CLQWTTVIER (Cys77) 
peptide sequence alkylated with labelling molecules carbon-12 isotope linked 2-iodo-N-
phenylacetamide (12C-IPA) and carbon-13 isotope linked 2-iodo-N-phenylacetamide (13C-IPA) 
in insulin-stimulated WTAkt1. A. Accurate mass spectra of the Cys60 peptide labelled with 
12C-IPA (predicted: [M + 2H]2+ = 963.4660 m/z, detected [M + 2H]2+= 963.4616 m/z) and 13C-
IPA (predicted: [M + 2H]2+ = 966.4761 m/z, detected [M + 2H]2+= 966.4694 m/z) are displayed 
in the inset. B. Accurate mass spectra of the Cys77 peptide labelled with 12C-IPA (predicted: 
[M + 2H]2+ 691.3503 = m/z, detected [M + 2H]2+ 691.3468 = m/z) and 13C-IPA (predicted: [M 
+ 2H]2+ = 694.3603 m/z, detected [M + 2H]2+= 694.3555 m/z).C. Accurate mass spectra of the 
Cys60 peptide labelled with 12C-IPA (predicted: [M + 2H]2+ = 963.4660 m/z, detected [M + 
2H]2+= 963.4622 m/z) and 13C-IPA (predicted: [M + 2H]2+ = 966.4761 m/z, detected [M + 
2H]2+= 966.4699 m/z) are displayed in the inset. D. Accurate mass spectra of the Cys77 peptide 
labelled with 12C-IPA (predicted: [M + 2H]2+ 691.3503 = m/z, detected [M + 2H]2+ 691.3480 
= m/z) and 13C-IPA (predicted: [M + 2H]2+ = 694.3603 m/z, detected [M + 2H]2+= 694.3566 
m/z). E. Redox state of the Cys60 and Cys77 residues in untreated or insulin-stimulated WTAkt1 
protein. Data are expressed as the mean ± s.d. 
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 Ablation of the Akt2 Cys60–Cys77 disulphide bond impairs full-length Akt2 plasma 
membrane localisation in 3T3-L1 adipocytes 
The Cys60 and Cys77 residues in the PH domain of Akt1 of interest are well-conserved 
functionally and structurally in the PH domain of Akt2 (Masure et al., 1999). Akt1 and Akt2 
share a high degree of structural homology; amino acid sequence is 81% identical (Laine et al., 
2002). Total internal reflection fluorescence (TIRF) microscopy analyses of protein membrane 
binding was previously well-established with Akt2 protein (Norris et al., 2017), therefore, data 
presented here are of isoform Akt2.  
 
Conformational changes of the PH–kinase domains primarily govern Akt activation and 
inactivation by phosphorylation and dephosphorylation, respectively (Lučić et al., 2018). 
Inactive Akt is maintained by the autoinhibitory interaction between the membrane binding PH 
domain, and the catalytic kinase domain. Phospholipid PIP3 drives the disruption of the PH–
kinase domain interface to initiate Akt activation (Ebner et al., 2017). Once the PH domain 
binds to the lipid head group of PIP3 at the plasma membrane and relieves the kinase domain 
from its hold, it exposes the substrate binding cleft of the kinase domain for phosphorylation 
(Milburn et al., 2003). We therefore examined whether the redox state of the Cys60–Cys77 
disulphide bond in full-length Akt affects plasma membrane recruitment. 
 
Membrane translocation kinetics of full-length wild-type and reduced TagRFP-T–Akt2 
recombinant proteins in response to insulin stimulation were examined by TIRF microscopy 
detecting the red fluorescent protein (RFP) fluorophore (Figure 4.9). Previous reports of Akt2 
membrane recruitment in live-cell experiments have presented inconsistent observations 
(Calleja et al., 2007; Gonzalez & McGraw, 2009; Parikh et al., 2012), possibly due to EGFP 
as the chosen fluorescent protein marker and its affinity for nucleus localisation (Seibel et al., 
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2007). An improved fluorescent Akt2 reporter was developed to emulate endogenous Akt2 
plasma membrane localisation. EGFP-tagged Akt2 displayed impaired recruitment to the 
plasma membrane when compared to endogenous Akt2, however, TagRFP-T–Akt2 plasma 
membrane recruitment was observed to be comparable to endogenous Akt2 (Norris et al., 
2017). 
 
TIRF microscopy has allowed for the detection of full-length Akt2 localisation at the plasma 
membrane of 3T3-L1 adipocytes in response to insulin stimulation. Untreated wild-type and 
reduced TagRFP-T–Akt2 proteins were not detectable at the plasma membrane. Insulin 
stimulation rapidly altered TIRF signalling for TagRFP-T–Akt2 at the plasma membrane, 
which displayed a graded intracellular dose response to insulin (Figure 4.10). Insulin 
stimulation prominently increased TIRF fluorescent signalling of WTAkt2 protein when 
compared to disulphide bond Akt2 proteins, with a 2.8-fold and 3.7-fold increase at the plasma 
membrane in response to insulin at 1 and 100 nM, respectively. TIRF signalling for reduced 
C60S-Akt2 protein saw a moderate reduction of plasma membrane recruitment compared to 
WTAkt2 protein, with a 1.7-fold and 2.2-fold increase at the plasma membrane in response to 
insulin at 1 and 100 nM, respectively. Interestingly, TIRF signalling for reduced C77S-Akt2 
and C60SC77S-Akt2 proteins were similar to untreated baseline measurements, suggesting the 
mutation of Cys77 to Ser in the PH domain significantly impaired Akt2 plasma membrane 
recruitment. 
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Figure 4.9 TIRF microscopy detecting full-length Akt2 recombinant proteins in 3T3-L1 
adipocytes in response to insulin stimulation. 
Translocation kinetics of full-length Akt2 proteins were examined by total internal reflection 
fluorescence (TIRF) microscopy. Laser light produces the evanescent wave that penetrates 
through the objective lens of the microscope, immersion oil and cover slip interface; reaching 
the plasma membrane but not the cytosol of the cell. Red fluorescent protein (RFP) 
fluorophores excited by the evanescent field at the plasma membrane were recorded. Insulin 
stimulation resulted in the translocation of Akt2 protein from the cytosol to the plasma 
membrane. 
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Figure 4.10 Ablation of the Akt2 Cys60–Cys77 disulphide bond impairs full-length Akt2 
plasma membrane localisation.  
Quantification of time-lapse total internal reflection fluorescence (TIRF) signalling in response 
to 1 nM and 100 nM of insulin stimulation of 3T3-L1 adipocytes expressing TagRFP-T–Akt2 
mutants at 10 and 20 min, respectively. Data are expressed as the mean ± s.d. (Su et al., 
unpublished data). 
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4.3 Discussion 
In the inactive state of Akt1, the PH domain occludes the phosphorylation of the Thr308 residue 
on the activation loop of the kinase domain (Lučić et al., 2018). Akt1 usually resides in the 
cytosol and nuclei and stimulation with insulin rapidly induces transient accumulation of 
cytosolic Akt1 at the plasma membrane (Ebner et al., 2017). Once recruited to the plasma 
membrane, the PH domain of Akt1 has strong affinity for phospholipid PIP3. Engagement of 
the PH domain with PIP3 stabilises Akt1 phosphorylation, attributed to relief of the PH domain-
mediated autoinhibitory interaction with the kinase domain (Ebner et al., 2017). Upon 
membrane dissociation, reformation of the autoinhibitory PH–kinase domain interface 
promotes Akt1 dephosphorylation at Thr308 and Ser473 residues (Ebner et al., 2017). 
 
The most common somatic mutation E17K-Akt1 is located near the lipid binding pocket of the 
PH domain of Akt1 and has been observed in cancers of the breast (Carpten et al., 2007; 
Stephens et al., 2012; Yi et al., 2012), endometrium (Cohen et al., 2010), prostate (Boormans 
et al., 2010), bladder (Askham et al., 2010), NSCLC (De Marco et al., 2015; Ding et al., 2008), 
blood (Kim et al., 2008) and melanoma (Davies et al., 2008). Through the disruption of the 
PH–kinase domain interface, this transforming mutation was noted to activate Akt1 (Parikh et 
al., 2012). Given that PIP3 membrane attachment is facilitated by the configuration of the PH 
domain of Akt1, I postulated that the Cys60–Cys77 labile disulphide bond in the PH domain of 
Akt1 is functional in nature. In the previous chapter, crystal structures of Akt1 PH domain 
show the different redox states of the Cys60–Cys77 disulphide bond led to significant structural 
alterations of the lipid-binding pocket (Figure 3.5). Here I propose the Cys60–Cys77 disulphide 
bond is a regulatory mechanism of Akt1 membrane recruitment. 
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The comparison in PIP3 membrane binding behaviour between truncated Akt1-PH and full-
length Akt1 recombinant proteins revealed notable differences. In two independent assays, 
truncated WT-PH was shown to have weaker binding affinity for PIP3 when compared to 
truncated reduced-PH protein. This suggested that the reduction of the Cys60–Cys77 disulphide 
bond promotes Akt1-PH domain binding affinity to PIP3; consistent with the finding that 
crystal structures of IP4 phospholipid were in complex with reduced-PH proteins (Figure 
4.1B). However, my observations of the membrane binding behaviour of full-length reduced 
Akt2 revealed that Cys60 and/or Cys77 to Ser mutations profoundly impaired plasma membrane 
localisation when compared to full-length WTAkt2.  
 
In this chapter, I show that the majority of Cys60 and Cys77 residues naturally form disulphide 
bonds in truncated WT-PH recombinant protein. The disulphide bonds in turn, are readily 
reduced by cellular oxidoreductase thioredoxin. Contrastingly, Cys60 and Cys77 residues in 
insulin-stimulated, full-length WTAkt1 recombinant protein were predominantly reduced. 
Akt1 is known to be sensitive toward insulin-stimulated reactive oxygen species i.e. H2O2 
(Okoh et al., 2013; Ushio-Fukai et al., 1999; Zhang et al., 2016); despite minimal detection of 
Cys60–Cys77 disulphide bonds in the protein. Cysteines residues are sensitive targets of H2O2, 
inducing disulphide bond formation (Goldstein et al., 2005; Paulsen & Carroll, 2013). Bursts 
of H2O2 generated from growth factor stimulation lasts for 10 min (Lee et al., 1998). To capture 
maximal oxidative effects, differential cysteine alkylators 12C-IPA and 13C-IPA would require 
a longer timeframe for internalisation and equilibration in NIH/3T3 fibroblasts post-stimulation 
(Abo & Weerapana, 2015). 
 
I have shown that the redox state of the Cys60–Cys77 disulphide bond in full-length Akt2 has a 
critical role in plasma membrane localisation. The ability of Akt2 membrane recruitment was 
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slightly decreased by the mutation of Cys60 to Ser compared to the wild-type, whereas the 
mutation of Cys77 to Ser completely impaired Akt2 membrane recruitment. Lack of Akt2 
recruitment to the plasma membrane suggested that the Cys60–Cys77 disulphide bond possibly 
causes a structure change at the lipid-binding pocket in the PH domain.  
 
In this study, the redox state of the Cys60–Cys77 disulphide bond was observed to have a 
functional role in Akt plasma membrane binding affinity. Activated cellular full-length Akt2 
is predominantly membrane bound, and my research has indicated that the redox state of the 
Cys60–Cys77 disulphide bond plays an influential role in membrane localisation. Differing 
results in PIP3 membrane binding between the reduced forms of truncated Akt1-PH and full-
length Akt2 recombinant proteins may possibly be attributed to the cysteine mutation affecting 
the configuration of the kinase domain; subsequently inhibiting the Akt phosphorylation loop. 
My data therefore suggests the Cys77 residue is especially critical for Akt membrane binding 
affinity. To investigate my findings in an in vitro model, I next examined the role of the Cys60–
Cys77 disulphide bond in Akt function in the NIH/3T3 mouse fibroblast cell line. 
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5. The Cys60–Cys77 disulphide bond is involved in 
phosphorylation of Akt1 in vitro 
5.1 Introduction 
The PI3K/Akt/mTOR pathway is a critical signalling pathway that regulates various cellular 
processes; namely cell proliferation, survival and metabolism (Yu & Cui, 2016). Akt is often 
hyper-activated in cancer cells that facilitates catabolism and anabolism of nutrients to meet 
their increased demands of growth and survival (Ward & Thompson, 2012).  
 
Inactive Akt resides in the cytoplasm and adopts an autoinhibitory conformation with its PH 
domain inhibiting the kinase domain, thereby preventing phosphorylation of the activation loop 
(Calleja et al., 2007). In response to extracellular stimulation, i.e. insulin, PI3K is activated and 
catalyses the phosphorylation of PIP2 to PIP3 at the plasma membrane. Akt subsequently 
translocates and localises at the plasma membrane through the interaction between the PH 
domain of Akt and PIP3, therefore relieving the autoinhibitory function of the PH domain on 
the kinase domain (Ebner et al., 2017). Maximal activation of Akt requires phosphorylation of 
Ser473 in the hydrophobic motif by PDK1, which in turn stabilises phosphorylation of Thr308 
by mTORC2 (Testa & Bellacosa, 2001; Yang et al., 2002). 
 
A previously established model of Akt activation was that membrane recruitment and Akt 
phosphorylation of Thr308 and Ser473 impacts the protein–lipid binding interaction between the 
PH domain of Akt and PIP3 at the plasma membrane. General consensus is that activated Akt 
dissociates from the plasma membrane in the cytosol; phosphorylating downstream substrates 
until its rapid dephosphorylation by PP2A and PHLPP2 at Thr308 and Ser473, respectively 
(Calleja et al., 2007). A recent study however, shows mutating Thr308 and Ser473 residues to 
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either abolishing (T308AS473A) or mimicking (T308DS473D) phosphorylation had no effect 
on PIP3 binding or plasma membrane localisation (Arauz et al., 2016). This suggests Akt 
binding affinity to PIP3 is not dependent on the phosphorylation status of Akt, and thus Akt 
membrane dissociation is regulated by a different mechanism of action. 
 
Ebner and colleagues recently proposed an alternative model of Akt activation. Active Akt is 
restricted to PIP3-containing membranes to govern substrate selectivity (Ebner et al., 2017). 
Upon dissociation from PIP3 at the plasma membrane, reformation of the PH–kinase domain 
interface is the rate-limiting step for Akt dephosphorylation (Ebner et al., 2017), with a short 
active half-life of 3-5 min in the cytosol (Calleja et al., 2007; Kunkel et al., 2005). Moreover, 
growth factor stimulation can prolong Akt activity in the cytosol to at least 1-2 h post-
stimulation (Kubota et al., 2012; Kunkel et al., 2005). 
 
In chapter 4, I showed the Cys60–Cys77 disulphide bond in the PH domain of Akt is an important 
regulator of Akt membrane binding. My data showed the mutation of Cys60 to Ser decreases 
Akt2 localisation at the plasma membrane by 50%, whilst mutation of Cys77 to Ser abolishes 
all ability of Akt2 translocation to the plasma membrane. This suggests that the Cys60 and Cys77 
residues are involved in Akt2 membrane localisation, which potentially impacts on Akt 
activity. In this chapter, the immortalised NIH/3T3 mouse embryonic fibroblast cell line was 
chosen to assess proliferative activity and oncogenic transformation (Liu et al., 2004; Parikh et 
al., 2012); the Akt1 gene is catalytic inactive in serum-starved immortalised fibroblasts (The 
Human Protein Atlas). Here I show the effect of the Cys60–Cys77 disulphide bond on the 
phosphorylation of Akt1 at Thr308 and Ser473 residues, in response to growth factor stimulation. 
Growth factor stimulation of Akt1 directly attenuates signalling of well-studied downstream 
targets; FoxO1 inhibits apoptosis and autophagy (Zhang et al., 2002; Zhang et al., 2011) and 
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GSK3α represses glycogen synthesis and glucose uptake (Buller et al., 2008; Pap & Cooper, 
1998). And so, I further demonstrate its effect on the activation of Akt1 downstream substrates. 
 
Further supporting our data, the somatic mutation Cys77 to Phe (C77F-Akt1) on the PH domain 
of Akt1 has previously been identified in clinical samples (Cerami et al., 2012; Ellis et al., 
2012; Gao et al., 2013; Yi et al., 2012), suggesting the Cys77 mutation may induce malignancy. 
I propose that the Cys60–Cys77 disulphide bond in the PH domain of Akt1 is the mechanism by 
which Akt1 is activated and autoinhibited in vitro. 
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5.2 Results 
To investigate whether the Cys60–Cys77 disulphide bond is an allosteric disulphide involved in 
Akt1 activation, I designed full-length Akt1 DNA constructs to examine the functional 
relevance of the Cys60–Cys77 disulphide bond on Akt1 activity in vitro (Figure 5.1). Cys60 
and/or Cys77 residues in the PH domain of Akt1 were mutated to Ser (C60S, C77S and 
C60SC77S), ablating formation of the disulphide bond. A constitutively active form of Akt1 
(Myr) was constructed by inserting an N-terminus Lck tag sequence (MGCGCSSHPEDD) 
(Patwardhan & Resh, 2010). Myristoylation signalling promotes the permanent docking of 
Akt1 at the plasma membrane and was used as the positive control for oncogenic growth 
(Aicart-Ramos et al., 2011). Constitutively inactive Akt1 mutant, with both phosphorylation 
residues Thr308 and Ser473 mutated to Ala (T308AS473A) was constructed to abolish Akt kinase 
activity (Kitamura et al., 1998; Kotani et al., 1999). Wild-type (LeGO-iG2–WTAkt1), 
constitutively active mutant (LeGO-iG2–MyrAkt1), disulphide bond mutants (LeGO-iG2–
C60S-Akt1, LeGO-iG2–C77S-Akt1, LeGO-iG2–C60SC77S-Akt1), constitutively inactive 
mutant (LeGO-iG2–T308AS473A-Akt1) and vector control (LeGO-iG2) were stably transfected 
into NIH/3T3 fibroblasts by the lentiviral transduction system. NIH/3T3 fibroblasts positively 
expressing Akt1 constructs were sorted using flow cytometry by green fluorescence arising 
from IRES–EGFP expression on the LeGO-iG2 vector.  
 
In this chapter, NIH/3T3 fibroblasts expressing LeGO-iG2 served as the vector control, while 
NIH/3T3 fibroblasts expressing constitutively active MyrAkt1 and constitutively inactive 
T308AS473A-Akt1 were the positive oncogenic control and negative kinase-dead control, 
respectively. Disulphide bond Akt1 mutants (single or double Cys mutations) are denoted as 
reduced Akt1. A HA-epitope tag in the N-terminus of designed constructs facilitated 
immunoprecipitation of Akt1 protein from NIH/3T3 fibroblasts. 
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Figure 5.1 Schematic representation of designed full-length LeGO-iG2–Akt1 constructs 
stably transfected into NIH/3T3 mouse fibroblasts. 
The pleckstrin homology (PH), kinase (KD) and regulatory (RD) domains of Akt1 are 
indicated. Positions of functional or mutated amino acid residues in the domains are noted. 
HA-epitope tag is at the N-terminus of each construct. Lck tag encoding the myristoylation 
signal is indicated as a black box. Reduced Akt1 mutant constructs where cysteine (C) was 
replaced by serine (S), and constitutively inactive Akt1 where threonine (T) and serine (S) were 
replaced by alanine (A); were generated by the PCR-based, SLIM hybridisation method (Chiu 
et al., 2004; Chiu et al., 2008). All Akt1 constructs were sub-cloned into the LeGO-iG2 vector 
(Weber et al., 2008). 
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 Ablation of the Akt1 Cys60–Cys77 disulphide bond increases proliferation of mouse 
fibroblasts 
The alamarBlue™ (resazurin) cell viability assay is an established, sensitive method of 
quantifying proliferation of animal cell lines that involves no cell lysis (O'Brien et al., 2000; 
Rampersad, 2012). We determined the effect of the Cys60–Cys77 disulphide bond on the 
proliferative rate of stably transfected NIH/3T3 fibroblasts by measuring metabolic activity of 
viable cells (Figure 5.2). Viable cells metabolised resazurin into the red fluorescent resorufin, 
whilst non-viable cells do not metabolise the dye, and thus cannot generate fluorescence. 
Fluorescence exhibited from NIH/3T3 fibroblasts expressing Akt1 constructs were normalised 
against the LeGO-iG2 vector control. NIH/3T3 fibroblasts expressing disulphide bond mutant 
constructs C60S-Akt1 (*p=0.02), C77S-Akt1 (**p=0.007) and C60SC77S-Akt1 (*p=0.01) 
showed significant proliferative activity compared to WTAkt1. Interestingly, NIH/3T3 
fibroblasts expressing constitutively active MyrAkt1 showed only moderate increase in cell 
proliferation, which was not statistically significant compared to WTAkt1. 
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Figure 5.2 Ablation of the Akt1 Cys60–Cys77 disulphide bond increases rate of cell 
proliferation. 
Cell proliferation of NIH/3T3 fibroblasts were quantified by the alamarBlue™ assay after 72h 
of incubation. Fluorescence generated from viable cells were normalised to the LeGO-iG2 
vector control. Graph is representative of four independent experiments performed in triplicate. 
Data are expressed as the mean ± s.d (One-way ANOVA, *p<0.05; **p<0.01). 
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 Ablation of the Akt1 Cys60–Cys77 disulphide bond impairs transformation of mouse 
fibroblasts 
We assessed transformation of NIH/3T3 fibroblasts expressing reduced Akt1 mutants by the 
soft agar colony formation assay to test anchorage-independent oncogenic growth. It was 
previously shown that the somatic mutant E17K-Akt1, leads to oncogenic transformation of 
fibroblast cells (Carpten et al., 2007; Parikh et al., 2012). Colony measurements were based on 
previous reports of NIH/3T3 fibroblast (mouse), Rat1 fibroblast (rat) and CEF fibroblast 
(chicken) cell lines stably transfected with Akt1, capable of transforming cells in vitro and 
inducing tumour growth in in vivo models (Aoki et al., 1998; Carpten et al., 2007; Liu et al., 
2004; Parikh et al., 2012). Measurements of <19 µm was an individual cell incapable of colony 
formation, 20-40 µm was considered a mid-range sized colony, and >41 µm was considered a 
high-range sized colony.  
 
Unstimulated stably transfected NIH/3T3 fibroblasts were incubated in soft agar for 21 days 
and imaged (Figure 5.3). Measurements of 300 individual NIH/3T3 fibroblasts or colonies 
were analysed in each cell population (Table 5.1). As expected, NIH/3T3 fibroblasts 
expressing the LeGO-iG2 vector control did not form colonies; indicating no transformation of 
cells (<19 μm). NIH/3T3 fibroblasts expressing constitutively inactive T308AS473A-Akt1 
mutant similarly formed very few mid-range (20-40 μm) or high-range sized colonies (>41 
μm). Notably, NIH/3T3 fibroblasts expressing disulphide bond mutants C60S-Akt1 
(****p<0.0001; ****p<0.0001), C77S-Akt1 (****p<0.0001; ****p<0.0001) and C60SC77S-
Akt1 (***p<0.001; ****p<0.0001) were found to be incapable of forming mid-range or high-
range sized colonies when compared to WTAkt1. NIH/3T3 fibroblasts expressing MyrAkt1 
significantly formed high-range sized colonies not only compared to WTAkt1, but across the 
cohort (****p<0.0001); demonstrating its highly malignant transforming ability.
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Figure 5.3 Expression of the Akt1 Cys60–Cys77 disulphide bond impairs transformation of NIH/3T3 mouse fibroblasts. 
NIH/3T3 fibroblasts were grown in 0.6% (w/v) soft agar and 2× DMEM (1:1) in a 6-well plate. Images were taken after 21 days of incubation at 
the 4× objective. A. Images displayed are representative of three independent experiments in duplicate. B. Column graph of colony measurements 
in each fibroblast population (%) expressing Akt1 constructs. Data are expressed as the mean ± s.d (One-way ANOVA, *p<0.05; ***p<0.001; 
****p<0.0001). 
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Table 5.1 Cell and colony measurements of NIH/3T3 mouse fibroblasts expressing Akt1 
mutants. 
Mean percentage of each fibroblast population in 3 independent soft agar colony formation 
assays displayed in Figure 5.3. Data are expressed as the mean ± s.d. 
 
NIH/3T3 fibroblasts <19 µm (%) 20-40 µm (%) >41 µm (%) 
LeGO-iG2 99.2±1.1 0.8±1.1 0.0±0.0 
WTAkt1 50.2±10.3 44.1±13.8 5.7±3.7 
MyrAkt1 30.4±7.8 27.8±10.9 41.8±13.3 
C60S-Akt1 95.5±4.4 3.3±4.2 1.2±0.6 
C77S-Akt1 98.5±2.4 1.5±2.4 0.0±0.0 
C60SC77S-Akt1 92.5±10.8 6.7±10.3 0.8±0.8 
T308AS473A-Akt1 95.0±7.1 4.3±6.0 0.8±1.1 
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 Ablation of the Akt1 Cys60–Cys77 disulphide bond impairs Akt1 phosphorylation in 
mouse fibroblasts 
Phosphorylation of Akt1 is the primary mechanism of regulating Akt1 activation and function 
(Chan et al., 2014). The transforming mutant E17K-Akt1 increased levels of Akt1 
phosphorylation at both Thr308 and Ser473 residues when compared to WTAkt1, independent of 
growth factor stimulation (Carpten et al., 2007). Although no transformative capabilities were 
observed in NIH/3T3 fibroblasts expressing reduced Akt1 mutants, we further examined 
phosphorylation and activation of Akt in response to insulin in vitro. NIH/3T3 fibroblasts were 
serum-starved for 2 h and activated with insulin for 30 min. Akt1 is catalytically inactive in 
serum-starved cells (Franke et al., 1995), growth factor stimulation, i.e. insulin, induces kinase 
activity of Akt1 in cells (Alessi et al., 1996a; Gonzalez & McGraw, 2009).  
 
Protein expression levels of Akt and downstream substrates in whole cell lysates were 
determined by immunoblotting (IB) (Figure 5.4A). Expression levels of pan-Akt (total Akt) 
protein detected in NIH/3T3 fibroblasts expressing LeGO-iG2 vector control represent the 
endogenous Akt protein expression in NIH/3T3 fibroblasts. In NIH/3T3 fibroblasts expressing 
WTAkt1 or C60S-Akt1, total Akt protein levels were found to be higher due to heterologous 
Akt1 expression. Nonetheless, in fibroblasts expressing MyrAkt1 or C60SC77S-Akt1, 
heterologous expression of Akt1 did not lead to an increase in total Akt protein. In NIH/3T3 
fibroblasts expressing C77S-Akt1 and T308AS473A-Akt1, total Akt protein levels were 
moderately increased when compared to NIH/3T3 fibroblasts expressing LeGO-iG2, but not to 
the same extent as NIH/3T3 fibroblasts expressing WTAkt1 or C60S-Akt1. 
 
In response to insulin stimulation, NIH/3T3 fibroblasts expressing LeGO-iG2 and WTAkt1 
exhibited phosphorylation of Akt at Thr308 (****p<0.0001) and Ser473 (*p=0.01) (Figure 5.4B) 
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in response to insulin. In insulin-stimulated NIH/3T3 fibroblasts expressing C60S-Akt1, 
comparable levels of phosphorylation of Thr308 and Ser473 were detected, indicating that the 
mutation of Cys60 to Ser does not appreciably perturb phosphorylation of Akt. However, 
insulin-stimulated NIH/3T3 fibroblasts expressing C77S-Akt1 and C60SC77S-Akt1, 
phosphorylation of Thr308 and Ser473 was only slightly increased to a level similar to that of 
NIH/3T3 fibroblasts expressing constitutively inactive T308AS473A-Akt1. This suggested the 
mutation of Cys77 to Ser in Akt1 impairs phosphorylation of Akt. Despite low levels of total 
Akt expression in NIH/3T3 fibroblasts transfected with MyrAkt1, Thr308 and Ser473 were highly 
phosphorylated independent of insulin stimulation, indicating MyrAkt1 protein is 
constitutively activated. 
 
Phosphorylation of Akt downstream substrates of GSK3α/β at Ser21/Ser9, and FoxO1 at Ser256 
corresponded with insulin-mediated Akt phosphorylation (Figure 5.4). Upon insulin 
stimulation, GSK3α/β and FoxO1 were phosphorylated in NIH/3T3 fibroblasts expressing 
LeGO-iG2 vector control, WTAkt1 and C60S-Akt1. In NIH/3T3 fibroblasts expressing 
constitutively active MyrAkt1, GSK3α/β and FoxO1 were phosphorylated independent of 
insulin stimulation. Low expression of phosphorylated GSK3α/β and FoxO1 were observed in 
insulin-stimulated NIH/3T3 fibroblasts expressing constitutively inactive T308AS473A-Akt1. 
Interestingly, phosphorylation of GSK3α/β and FoxO1 was not affected by the mutation of 
Cys77 to Ser. NIH/3T3 fibroblasts expressing C77S-Akt1 and C60SC77S-Akt1 showed 
comparable phosphorylation of GSK3α/β and FoxO1 to NIH/3T3 fibroblasts expressing 
WTAkt1.  
 
 
 
 
 
.
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Figure 5.4 Ablation of the Akt1 Cys60–Cys77 disulphide bond impairs Akt1 phosphorylation in whole cell lysates. 
NIH/3T3 fibroblasts were untreated or stimulated with insulin (100 nM) for 30 min. NIH/3T3 fibroblasts were harvested in lysis buffer (5 mM 
EDTA, 1% (v/v) Triton X-100 in 1× PBS). Immunoblots (IB) are representative of three independent experiments. A. IB of whole cell lysates (50 
µg) detecting total and phospho-GSK3α/β (S21/S9) (51/46 kDa), FoxO1 (S256) (82 kDa) and Akt (T308/S473) (60 kDa). β-actin is the loading 
control. B. Densitometry analyses in arbitrary units (A.U.) of blots displayed in A. Data are expressed as the mea ± s.d (One-way ANOVA, 
*p=0.01; **p<0. 01; ****p<0.0001). 
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 Ablation of the Akt1 Cys60–Cys77 disulphide bond impairs Akt1 downstream activity in 
mouse fibroblasts 
To measure the activity of heterologous protein expression in stably transfected NIH/3T3 
fibroblasts, wild-type and mutant Akt1 recombinant proteins were immunoprecipitated from 
whole cell lysate by the HA-epitope tag engineered in the N-terminus of all full-length Akt1 
DNA constructs (Figure 5.1). Subsequently, immunoprecipitated Akt1 activity was assessed 
by its ability to phosphorylate recombinant GSK3α substrate to confirm my previous 
observations of Akt phosphorylation in whole cell lysate (Figure 5.4). Immunoprecipitation 
analyses enabled the discrimination of exogenous Akt1 from endogenous Akt1 protein in 
NIH/3T3 fibroblasts and was a test of the veracity of the results in whole cell lysates.  
 
As expected, there was no immunoprecipitation of Akt1 protein in LeGO-iG2 vector control 
NIH/3T3 fibroblasts, which also indicates that the endogenous protein was not captured in the 
pull-down. Phosphorylation (Figure 5.5A) and activity (Figure 5.6A) of the 
immunoprecipitated Akt1 protein was measured. Activity was indicated by Akt1 
phosphorylation of recombinant GSK3α substrate. Consistent with our whole cell lysate 
immunoblots, immunoprecipitated WTAkt1 protein was phosphorylated in an insulin-
dependent manner and activated Akt phosphorylated recombinant GSK3α substrate.  
 
NIH/3T3 fibroblasts expressed lower levels of constitutively active MyrAkt1 than WTAkt1 
protein. Low amounts of MyrAkt1 protein were also immunoprecipitated from NIH/3T3 
fibroblasts. Nonetheless, MyrAkt1 protein was significantly phosphorylated at Thr308 
(p**<0.01; p***<0.001) and Ser473 (****p<0.0001) independent of insulin stimulation 
(Figure 5.5B), and exhibited activity towards recombinant GSK3α substrate similar to 
WTAkt1 protein, when protein level is taken into account (Figure 5.6B). The single mutation 
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of Cys60 to Ser in Akt1 slightly reduced phosphorylation of Akt1 at Thr308 and Ser473, 
furthermore, impaired its ability to phosphorylate GSK3α when compared to WTAkt1 protein 
(*p<0.05). The mutation of Cys77 to Ser in Akt1 reduced phosphorylation of Akt1 at Thr308 and 
Ser473 to an almost undetectable level. Moreover, its ability to phosphorylate GSK3α was 
moderately decreased when compared to WTAkt1 protein (*p<0.05). Double Cys mutant 
(C60SC77S-Akt1) similarly reduced phosphorylation of Akt1 at Thr308 and Ser473 to an almost 
undetectable level, and displayed no downstream activity toward GSK3α (**p<0.01). As 
expected, immunoprecipitated constitutively inactive T308AS473A-Akt1 protein displayed no 
phosphorylation of Akt1 and little activity toward GSK3α s (**p<0.01).  
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Figure 5.5 Ablation of the Akt1 Cys60–Cys77 disulphide bond impairs Akt1 
phosphorylation. 
NIH/3T3 fibroblasts were untreated or stimulated with insulin (100 nM) for 30 min. NIH/3T3 
fibroblasts were harvested in lysis buffer (5 mM EDTA, 1% (v/v) Triton X-100 in 1× PBS). 
Immunoprecipitation (IP) of Akt1 with a HA-epitope tag antibody. Immunoblots (IB) are 
representative of three independent experiments. A. IB detecting total and phospho-Akt 
(T308/S473) (60 kDa). B. Densitometry analyses of blots displayed in A. Data are expressed 
as the mean ± s.d (One-way ANOVA, p**<0.01, p***<0.001; ****p<0.0001). 
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Figure 5.6 Ablation of the Akt1 Cys60–Cys77 disulphide bond impairs Akt1 downstream 
activation. 
Downstream activity of immunoprecipitated Akt1 protein was measured by the addition of 
recombinant GSK3α substrate. Immunoblots (IB) are representative of two independent 
experiments. A. IB detecting total and phospho-GSK3α (S21) (51 kDa). B. Densitometry 
analyses of blots displayed in A. Data are expressed as the mean ± s.d. (One-way ANOVA, 
p*<0.05, p**<0.01). 
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5.3 Discussion 
The mechanism of Akt1 activation is heavily dependent on the role of its PH domain (Bellacosa 
et al., 1998). Perturbations of the PH–kinase domain interaction is associated with tumour 
progression. The most common transforming somatic mutation in Akt1 is located at the lipid 
binding site of the PH domain (Carpten et al., 2007; Parikh et al., 2012). E17K-Akt1 is an 
activating mutation identified in cancer patients that alters lipid binding specificity by relieving 
the PH domain-mediated autoinhibition of Akt1 (Askham et al., 2010; Boormans et al., 2010; 
Carpten et al., 2007; Cohen et al., 2010; Davies et al., 2008; De Marco et al., 2015; Ding et al., 
2008; Kim et al., 2008; Parikh et al., 2012; Stephens et al., 2012). The somatic mutant C77F-
Akt1, also located near the lipid binding pocket of the PH domain, was previously identified in 
a breast cancer patient (Cerami et al., 2012; Ellis et al., 2012; Gao et al., 2013; Yi et al., 2012). 
Crystal structures of truncated PH domain of Akt1 showed that the absence of the Cys60–Cys77 
disulphide bond enabled co-crystallisation with phospholipid IP4, suggesting the reduced form 
of PH domain promotes PIP3 lipid binding interaction (Figure 3.5B), however, my membrane 
binding data and in vitro studies of full-length Akt1 has shown otherwise. 
 
In this chapter, I showed that the redox state of the Cys60–Cys77 disulphide bond plays a vital 
role in Akt1 activity, in response to growth factor stimulation. Mutation of Cys60 or Cys77 to 
Ser in the PH domain of Akt1 led to differential effects on Akt1 function in NIH/3T3 
fibroblasts. Mutation of Cys60 to Ser in Akt1 resulted in moderately reduced levels of Akt 
phosphorylation in NIH/3T3 fibroblasts when compared to WTAkt1. Interestingly, the 
mutation of Cys77 to Ser in Akt1 resulted in the near ablation of Akt phosphorylation.  
 
Non-transformative capabilities of NIH/3T3 fibroblasts expressing disulphide bond mutants 
(C60S-Akt1, C77S-Akt1 or C60SC77S-Akt1) suggest that oxidation to form the Cys60–Cys77 
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disulphide bond may be required to induce oncogenic transformative effects. Moreover, 
decreased levels of Akt phosphorylation in these NIH/3T3 fibroblasts may be explained by 
their altered ability to localise at the plasma membrane (Figure 4.5). The ability to recruit Akt 
to the membrane was somewhat decreased by the mutation of Cys60 to Ser compared to the 
wild-type. Moreover, a complete loss of recruitment was prompted by the mutation of Cys77 to 
Ser. This correlated with levels of Akt phosphorylation in NIH/3T3 fibroblasts expressing 
C60S-Akt1 and C77S-Akt1, respectively.  
 
My results suggest that the mutation of Cys77 to Ser heavily impairs full-length Akt1 membrane 
recruitment and subsequently cannot be activated by PIP3. I postulate that the mutation of Cys
77 
to Ser induces the intramolecular interaction between the PH and kinase domains of Akt1 to 
promote its autoinhibition. To test this hypothesis, I aimed to assess the effect of the Cys60–
Cys77 disulphide bond on the binding interaction between the PH–kinase domains by co-
immunoprecipitation in vitro. A previous study has shown co-transfected truncated E17K-
PH/WT-KD weakens the PH–kinase domain interaction when compared to truncated WT-
PH/WT-KD, increasing phosphorylation of the kinase (Parikh et al., 2012). I therefore 
transiently co-transfected truncated wild-type and reduced Akt1 PH domain constructs (WT-
PH, C60S-PH, C77S-PH and C60SC77S-PH) with the truncated wild-type kinase domain (WT-
KD) construct in HEK293T cells, however, co-expression of both constructs was unsuccessful 
and after several attempts this experiment was not pursued further.  
 
My investigations have shown the relevance of the Cys77 to Ser mutation in full-length Akt1 
for Akt function in vitro. My data suggested the formation of the Cys60–Cys77 disulphide bond 
is required in membrane recruitment and subsequent Akt1 activation. I propose that the Cys60–
Cys77 disulphide bond is an allosteric disulphide bond that controls the autoinhibition of Akt1 
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by controlling the conformation of the PH–kinase domain interface. To test my findings in an 
in vivo model, I next examined the role of the Akt1 Cys60–Cys77 disulphide bond in zebrafish 
embryos. 
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6. The Cys60–Cys77 disulphide bond is involved in 
physiological function of Akt1 in vivo 
6.1 Introduction 
New blood vessel formation, or angiogenesis, in tumours enables the supply of excess nutrients 
and oxygen to meet their increased demands of cell metabolism (Hanahan & Weinberg, 2011). 
The vasculature of an organism undergoes constant growth and remodelling during 
embryogenesis but enters quiescence and retains morphogenetic plasticity once it has reached 
adulthood. To form new sprouting vessels, signal transduction via VEGF receptors regulate 
angiogenesis (Ellertsdottir et al., 2010). Perturbation of the PI3K/Akt/mTOR signalling 
pathway is often implicated in the increase of VEGF-induced angiogenesis (Zhong et al., 
2000). Akt upregulates the translation of HIF1α in response to increased glucose and oxygen 
availability in solid cancers (Harada et al., 2009). HIF1α subsequently activates VEGF, which 
plays a vital role in the branching, sprouting and remodelling of new blood vessels through the 
activation of endothelial cells (Hoeben et al., 2004; Kitamura et al., 2008). Endothelial cells 
predominantly express the Akt1 isoform (Chen et al., 2005), which is a key mediator for 
survival and migration of endothelial cells; essential for vascular development (Lee et al., 2014; 
Yu et al., 2015).  
 
The PI3K/Akt/mTOR signalling pathway is also known to interact with the Delta-Notch 
signalling pathway, which is essential for normal vascular remodelling through negative 
regulation of endothelial cell formation (Leslie et al., 2007; Thurston & Kitajewski, 2008). 
Perturbation of the Delta-Notch signalling pathway is not only implicated in tumour 
angiogenesis (Siekmann & Lawson, 2007; Thurston & Kitajewski, 2008) but is also linked to 
human neurodevelopmental diseases (Cornell & Eisen, 2002; Jeffery et al., 2015). Ablation of 
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Akt and mTOR in the brain results in the disruption of cell cycle progression of neural 
progenitor cells during development (Ka et al., 2014; Wang et al., 2016). Although Akt3 is the 
predominant isoform found in the brain, Akt1 and Akt2 are also moderately expressed (Chan et 
al., 2014). Hemimegalencephaly – malformation of the brain characterised by an enlarged 
cerebral hemisphere, contains the somatic transforming mutation E17K in Akt3 (Poduri et al., 
2012). This activating mutation is homologous to the E17K mutation in Akt1 and Akt2 and is 
linked to somatic overgrowth disorders (Keppler-Noreuil et al., 2016). Decreased levels of 
Akt1 protein have also being associated with schizophrenia (Emamian, 2012). Akt1 has also 
been found to play a role in supporting cardiac development (Cohen, 2013). 
 
To understand physiological functions of Akt1 in vertebrate systems, Akt1 knockout organisms 
have previously been generated. Akt1-null mice (Mus musculus) displayed growth retardation 
and impaired vascular maturation; resulting in developmental and heart defects, significantly 
increasing perinatal mortality (Ackah et al., 2005; Chang et al., 2010; Chen et al., 2005). 
Abnormalities in neuronal morphology were also observed in Akt1 deficient mice (Lai et al., 
2006). In zebrafish (Danio rerio), loss of Akt1 resulted in defective arterial development (Ren 
et al., 2010) and precocious neuronal differentiation (Cheng et al., 2013); indicating an 
evolutionary conserved role of Akt1 as a key regulator in zebrafish embryonic development. 
 
Zebrafish embryos rapidly form a complete primary organ system within 48 hours post-
fertilisation (hpf). Transparency of their embryos is advantageous for live imaging of early-
stage vasculature development and cellular patterning in whole vertebrae without invasive 
methods (Chávez et al., 2016). The zebrafish model is a useful organism for studying the 
biological functions of the Cys60–Cys77 disulphide bond in the PH domain of Akt1. The 
Tg(fli1a:EGFP) zebrafish line expressing fluorescence in blood vessels (Lawson & Weinstein, 
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2002) was chosen to assess phenotype of zebrafish embryos injected with wild-type and mutant 
Akt1 constructs. 
 
In previous chapters, I revealed the Cys60–Cys77 disulphide bond in the PH domain of Akt1 as 
an important regulator of Akt1 function in vitro. Mutation of Cys60 to Ser slightly reduced Akt1 
lipid binding and somewhat impacted Akt1 phosphorylation, whilst mutation of Cys77 to Ser 
heavily impaired all aspects of Akt1 function. In this chapter, we performed microinjections of 
nucleic acids into zebrafish embryos to report the function of the Cys60–Cys77 disulphide bond 
in Akt1 on angiogenesis, growth and survival during zebrafish development. We further 
analysed the effect of the Cys60–Cys77 disulphide bond on the activation of downstream Akt1 
genes responsible for neural differentiation in zebrafish (Chung et al., 2011; Cornell & Eisen, 
2002; Park et al., 2000; Riley et al., 1999). Although additional studies of disulphide bond Akt1 
mutants in in vivo models are required, I postulate that the Cys60–Cys77 disulphide bond in the 
PH domain of Akt1 is an allosteric disulphide bond required for normal physiological functions 
of Akt1. 
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6.2 Results 
To examine the functional relevance of the Cys60–Cys77 disulphide bond in the PH domain of 
Akt1 in the zebrafish in vivo model, I designed transgenic constructs encoding the sequence of 
full-length human Akt1 inserted in the pDESTTol2 transposon vector. Previously described in 
the in vitro studies, Cys60 and/or Cys77 residues in the PH domain of Akt1 were mutated to Ser 
(C60S, C77S and C60SC77S). Constitutively active Akt1 (Myr) contains an N-terminus Lck 
tag sequence (MGCGCSSHPEDD). The constitutively inactive Akt1 mutant cannot be 
phosphorylated as Thr308 and Ser473 residues are mutated to Ala (T308AS473A).  
 
Transgenic Akt1 clones were constructed by the Tol2kit cloning system as described by Kwan 
and colleagues; based on att site-specific Gateway™ BP and LR recombination cloning 
(Hartley et al., 2000; Kwan et al., 2007). Middle-entry clones of full-length wild-type 
(pME/WTAkt1), constitutively active mutant (pME/MyrAkt1), disulphide bond mutants 
(pME/C60S-Akt1, pME/C77S-Akt1 and pME/C60SC77S-Akt1) and constitutively inactive 
mutant (pME/T308AS473A-Akt1) were constructed by Gateway™ BP recombination cloning 
(Figure 6.1A). 
 
To facilitate fluorescence-based phenotypic visualisation, transgenic DNA of full-length wild-
type (pDestTol2/ubb:WTAkt1-p2a-tomato), constitutively active mutant (pDestTol2/ubb; 
MyrAkt1-p2a-tomato), disulphide bond mutants (pDestTol2/ubb:C60S-Akt1-p2a-tomato, 
pDestTol2/ubb:C77S-Akt1-p2a-tomato and pDestTol2/ubb:C60SC77S-Akt1-p2a-tomato) and 
constitutively inactive mutant (pDestTol2/ubb:T308AS473A-Akt1-p2a-tomato) Akt1 were 
constructed by Gateway™ LR recombination cloning (Figure 6.1B). The pDestTol2 vector 
contains Tol2 transposable elements flanked the DNA cassette at both ends to enable germline 
transgenesis (Kawakami, 2007). Zebrafish endogenous ubiquitin (ubb) promoter at the 5’ end 
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drives transgenic expression of mutant Akt1 constructs of interest and the polyadenylated 
tandem-tomato fluorescent cassette (p2a-tdTomato) at the 3’ end as a single mRNA transcript. 
Picornavirus p2a sequence is a ribosome skipping site (Kim et al., 2011) that enables co-
expression of mutant Akt1 and red fluorescent protein tdTomato for tracking ectopic Akt1 
expression. Transgenic Akt1 mutants were subsequently co-injected with Tol2 transposase 
mRNA in Tg(fli1a:EGFP) embryos at the one-cell stage.  
 
In this chapter, uninjected embryos were the control with no injection of Akt1 mutant 
constructs. Embryos injected with WTAkt1 is the wild-type control. Embryos injected with 
constitutively active MyrAkt1 and constitutively inactive T308AS473A-Akt1 were positive 
oncogenic and negative kinase-dead controls, respectively. Disulphide bond Akt1 mutants 
(single or double Cys mutations) were denoted as reduced Akt1 mutants. All Akt1 constructs 
were designed without the stop codon to allow translation of the p2a-tdTomato section of each 
construct. This fluorescent tandem Tomato tag facilitated the screening of embryos with 
ectopic Akt1 expression by fluorescence microscopy prior to analyses. Injected embryos were 
raised to adults for breeding; however, expression of constructed Akt1 mutants were not passed 
onto F1 progeny. 
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Figure 6.1 Schematic representation of designed pME/Akt1 and pDestTol2/ubb:Akt1-p2a-tdTomato constructs. 
The pleckstrin homology (PH), kinase (KD) and regulatory (RD) domains of Akt1 are indicated. Positions of functional or mutated amino acid 
residues in the domains are noted. Lck tag encoding the myristoylation signal is indicated as a black box. Mutant human Akt1 constructs where 
cysteine (C) is replaced by serine (S); threonine (T) and S are replaced by alanine (A), are generated by the PCR-based, SLIM hybridisation method 
(Chiu et al., 2004; Chiu et al., 2008). A. Middle-entry pME/Akt1 clones constructed by Gateway™ BP recombination cloning of pDONR™221 
donor vector and Akt1 PCR product. B. Transgenic pDestTol2/ubb:Akt1-p2a-tdTomato clones constructed by Gateway™ LR recombination cloning 
of pDestTol2 destination vector, middle-entry pME/Akt1 as shown in A, p5E/ubb 5’-entry zebrafish ubiquitin promoter, and p3E/p2a-tdTomato 
3’-entry polyadenylated tandem Tomato. 
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 Ablation of the Akt1 Cys60–Cys77 disulphide bond induces angiogenesis in zebrafish 
In the trunk of the zebrafish, homologous mesodermal segments derived from somites give rise 
to skeletal muscles during embryogenesis (Stickney et al., 2000). Between pairs of somites are 
sprouting intersegmental vessels (ISV); the recognised paradigm used to study angiogenesis in 
the zebrafish model (Blum et al., 2008). The process of ISV formation via angiogenesis is 
accompanied by endothelial cell migration and differentiation (Blum et al., 2008). Endothelial 
cells sprout from the dorsal aorta and posterior cardinal vein to form to the intersegmental 
artery and vein (Ellertsdottir et al., 2010), together, they are termed as intersegmental vessels 
(ISV) that run along the vertical myotomal boundaries of the zebrafish trunk and into the dorsal 
longitudinal anastomotic vessel (Isogai et al., 2001). ISV growth in zebrafish embryo is also 
similar to that of mouse embryo (Ellertsdottir et al., 2010). Within 48 hours post-fertilisation 
(hpf), zebrafish embryos form a complete primary organ system. ISVs in the trunk and tail are 
lumenised and active in circulation (Childs et al., 2002; Isogai et al., 2001; Kimmel et al., 
1995). We examined the redox state of the Cys60–Cys77 disulphide bond in the PH domain of 
Akt1, on the process of angiogenesis during zebrafish development. We determined whether 
overexpression of Akt1 mutants perturbed vasculature formation during zebrafish 
embryogenesis. Wild-type Tg(fli1a:EGFP) zebrafish embryos were injected at the one-cell 
stage with transgenic Akt1 DNA constructs. ISV formation was termed ‘complete’ if they 
branched from the dorsal aorta or posterior cardinal vein, fully extending into the dorsal 
longitudinal anastomotic vessel. 
 
Zebrafish embryos were imaged at 48 hpf to capture optimal Akt1 expression and ISV 
formation due to the transient expression of Akt1 (Figure 6.2A). Akt1 was not ubiquitously 
expressed throughout the entire organism, and only observed in a few muscle striations in the 
trunk extending across somite. ISV in 200 individual embryos were analysed in each injected 
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population (Table 6.1). Complete ISVs formation in uninjected embryos was the reference 
point (Figure 6.2B). Tg(fli1a:EGFP) embryos injected with constitutively active MyrAkt1 and 
double cysteine mutant C60SC77S-Akt1 modestly increased complete formation of ISVs, but 
was not statistically significant compared to Tg(fli1a:EGFP) embryos injected with WTAkt1. 
Tg(fli1a:EGFP) embryos injected with single cysteine mutant C60S-Akt1 (One-way ANOVA, 
**p<0.01) and C77S-Akt1 (One-way ANOVA, *p<0.05) significantly increased complete 
formation of ISVs when compared to Tg(fli1a:EGFP) embryos injected with WTAkt1. 
Tg(fli1a:EGFP) embryos injected with constitutively inactive mutant T308AS473A-Akt1 
moderately decreased complete formation of ISVs, however, was not statistically significant 
when compared to Tg(fli1a:EGFP) embryos injected with WTAkt1. 
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Figure 6.2 Ablation of the Akt1 Cys60–Cys77 disulphide bond increases intersegmental 
vessel formation in the zebrafish model.  
Tg(fli1a:EGFP) zebrafish embryos were injected with human Akt1 constructs at the one-cell 
stage. A. Representative images of vascular growth in an individual embryo at 48 hpf are 
displayed under the 40× objective. Blue box indicates the trunk. Injected Akt1 mutants are 
expressed in muscle striations labelled red (tdTomato). Intersegmental vessels (ISV) branching 
from the dorsal aorta (DA) or posterior cardinal vein (PCV) into the dorsal longitudinal 
anastomotic vessel (DLAV) are labelled green (EGFP). White scale bar indicates 500 µm. B. 
Complete formation of ISVs were analysed. Data are expressed as the mean ± s.d (One-way 
ANOVA, *p<0.05). 
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Table 6.1 Completeness of intersegmental vessel formation in Tg(fli1a:EGFP) zebrafish 
embryos injected with Akt1 mutants. 
Mean percentage of each injected Tg(fli1a:EGFP) embryo population in ten independent 
experiments displayed in Figure 6.2.  
 
Tg(fli1a:EGFP) zebrafish embryos Complete ISV formation (%) 
Uninjected 86.7 ± 11.3 
WTAkt1 84.9 ± 12.0 
MyrAkt1 89.3 ± 9.3 
C60S-Akt1 93.9 ± 7.4 
C77S-Akt1 90.9 ± 7.2 
C60SC77S-Akt1 89.6 ± 6.5 
T308AS473A-Akt1 82.9 ± 10.9 
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 Ablation of the Akt1 Cys60–Cys77 disulphide bond perturbs development of zebrafish 
A single clutch of zebrafish embryos will develop at variable rates, therefore the measurement 
of time post-fertilisation is not considered an adequate indicator for developmental progress 
(Kimmel et al., 1995). During the early stages of embryonic development, genetic changes can 
perturb zebrafish growth (Parichy et al., 2009). We therefore determined the effect of the 
Cys60–Cys77 disulphide bond in Tg(fli1a:EGFP) embryos injected with reduced Akt1 
constructs on zebrafish development by measuring their growth (mm) (Figure 6.3). Standard 
length of the snout to the vent is the preferred indicator for developmental staging of zebrafish 
embryos due to the high correlation between fish size and physiological rates (Fuiman et al., 
1998). Growth measurements of 200 individual Tg(fli1a:EGFP) embryos were examined in 
each injected population (Table 6.2). Uninjected Tg(fli1a:EGFP) embryo measurements were 
the normal reference point. As expected, Tg(fli1a:EGFP) embryos injected with constitutively 
active MyrAkt1 were significantly larger in size when compared to Tg(fli1a:EGFP) embryos 
injected with WTAkt1 (One-way ANOVA, ****p<0.0001); whereas Tg(fli1a:EGFP) embryos 
injected with constitutively inactive T308AS473A-Akt1 were significantly stunted compared to 
Tg(fli1a:EGFP) embryos injected with WTAkt1 (One-way ANOVA, ***p<0.001). Injection of 
single cysteine mutants C60S-Akt1 and C77S-Akt1 did not affect growth of Tg(fli1a:EGFP) 
embryos when compared to Tg(fli1a:EGFP) embryos injected with WTAkt1. Interestingly, 
Tg(fli1a:EGFP) embryos injected with double cysteine mutant C60SC77S-Akt1 significantly 
increased growth when compared to Tg(fli1a:EGFP) embryos injected with WTAkt1 (One-way 
ANOVA, ****p<0.0001).  
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Figure 6.3 Ablation of the Akt1 Cys60–Cys77 disulphide bond increases growth in the 
zebrafish model. 
Developmental stage was measured by snout to vent length of individual Tg(fli1a:EGFP) 
zebrafish embryos at 48 hpf. Data are expressed as the mean ± s.d (One-way ANOVA, 
***p<0.001; ****p<0.0001).  
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Table 6.2 Growth measurements of Tg(fli1a:EGFP) zebrafish embryos injected with 
Akt1 mutants. 
Mean measurements of each injected Tg(fli1a:EGFP) embryo displayed in Figure 6.3. 
 
Tg(fli1a:EGFP) zebrafish embryos Length from snout to vent (mm) 
Uninjected 2.8 ± 0.3 
WTAkt1 2.6 ± 0.2 
MyrAkt1 3.0 ± 0.4 
C60S-Akt1 2.8 ± 0.2  
C77S-Akt1 2.7 ± 0.3 
C60SC77S-Akt1 3.0 ± 0.2 
T308AS473A-Akt1 2.3 ± 0.2  
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 Ablation of the Akt1 Cys60–Cys77 disulphide bond does not affect survival of zebrafish 
It was previously observed that Akt1 deletion in a mouse model hindered heart development, 
resulting in high rates of perinatal mortality (Chang et al., 2010), whereas Akt2 deletion by 
CRISPR/Cas9 technology in the zebrafish model exhibited only partial lethality (Zhang et al., 
2017). We determined the role of the Cys60–Cys77 disulphide bond in Akt1 on zebrafish embryo 
survival. Survival rates of zebrafish embryos injected with human Akt1 mutant constructs were 
normalised to survival rates of uninjected embryos (Figure 6.4). Survival rates of 
Tg(fli1a:EGFP) embryos injected with MyrAkt1, reduced Akt1 and T308AS473A-Akt1 mutants 
were not statistically significant when compared to Tg(fli1a:EGFP) embryos injected with 
WTAkt1. Although Akt1 injections proved to be slightly more lethal when comparing survival 
rates of uninjected embryos, however, this is possibly attributed to genetic changes induced by 
the expression of Akt1 constructs or physical injury from the injector needle. Constitutively 
active MyrAkt1 injections slightly rescued Tg(fli1a:EGFP) embryo survival when compared to 
Tg(fli1a:EGFP) embryos injected with WTAkt1 at 24 hpf, but was somewhat lethal at 48 hpf. 
Embryos injected with reduced Akt1 did not cause lethality when compared to Tg(fli1a:EGFP) 
embryos injected with WTAkt1 at 24 hpf. However, Tg(fli1a:EGFP) embryos injected with 
single cysteine mutant C60S-Akt1 slightly rescued zebrafish survival, whilst single and double 
Cys77 mutant injections were shown to be somewhat lethal when compared to Tg(fli1a:EGFP) 
embryos injected with WTAkt1 at 48 hpf. Tg(fli1a:EGFP) embryos injected with constitutively 
inactive T308AS473A-Akt1 slightly reduced survival rates when compared to Tg(fli1a:EGFP) 
embryos injected with WTAkt1 at both time points.  
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Figure 6.4 Ablation of the Akt1 Cys60–Cys77 disulphide bond does not increase mortality 
in the zebrafish model. 
Survival rates of Tg(fli1a:EGFP) embryos at 24 and 48 hpf. Embryos injected with human 
Akt1 constructs were normalised to uninjected Tg(fli1a:EGFP) embryos. Data are expressed as 
the mean ± s.d.  
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 Ablation of the Akt1 Cys60–Cys77 disulphide bond does not affect Akt activity in 
zebrafish 
Human Akt1 has a high degree of similarity compared to zebrafish Akt1; with 89% sequence 
identity and 94% conserved amino acids (Cheng et al., 2013). Moreover, Cys60 and Cys77 
residues of interest are also evolutionarily conserved in zebrafish. Akt1 is primarily transcribed 
during the early stages of development in the zebrafish model, and is essential in the regulation 
of angiogenesis (Liu et al., 2008) and proliferation of neural progenitor cells (Sinor & Lillien, 
2004). Loss of Akt1 causes precocious neuronal differentiation in the zebrafish model (Cheng 
et al., 2013; Jeffery et al., 2015); observed as an increase of the differentiated neuronal marker, 
ELAV like neuron-specific RNA binding protein 3 (Elavl3/HuC) (Park et al., 2000); and 
concurrent decrease of the neural progenitor markers from the Delta-Notch signalling pathway, 
also responsible for angiogenic endothelial cell formation (Siekmann & Lawson, 2007): DeltaA 
(Riley et al., 1999), hairy-related 8a (Her8a) (Chung et al., 2011) and neurogenin 1 (Ngn1) 
(Cheng et al., 2013; Cornell & Eisen, 2002). To investigate the redox state of the Cys60–Cys77 
disulphide bond in Akt1 on the expression of downstream Akt1 genes in zebrafish embryos 
injected with reduced Akt1 constructs were analysed by RT-qPCR (Figure 6.5).  
 
Elavl3 expression in Tg(fli1a:EGFP) embryos injected with constitutively active MyrAkt1 and 
reduced Akt1 and was around half that of Tg(fli1a:EGFP) embryos injected with WTAkt1; 
connoting an increase in differentiated neurons. Unexpectedly, levels of Elavl3 expression 
were also decreased in Tg(fli1a:EGFP) embryos injected with constitutively inactive 
T308AS473A-Akt1 by 50% when compared to Tg(fli1a:EGFP) embryos injected with WTAkt1. 
 
DeltaA expression in Tg(fli1a:EGFP) embryos injected with constitutively active MyrAkt1 and 
C77S-Akt1 were moderately increased by around 33% when compared to Tg(fli1a:EGFP) 
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embryos injected with WTAkt1. Levels of DeltaA expression in Tg(fli1a:EGFP) embryos 
injected with C60S-Akt1 and C60SC77S-Akt1 were 2.5-fold higher than Tg(fli1a:EGFP) 
embryos injected with WTAkt1. This implied that the Cys60 mutation decreased the number of 
neuronal progenitor cells. Interestingly, levels of DeltaA expression were also moderately 
increased in Tg(fli1a:EGFP) embryos injected with constitutively inactive T308AS473A-Akt1 
by 50% more than Tg(fli1a:EGFP) embryos injected with WTAkt1. 
 
Her8a expression in Tg(fli1a:EGFP) embryos injected with constitutively active MyrAkt1 were 
increased by 50%, whereas Tg(fli1a:EGFP) embryos injected with constitutively inactive 
T308AS473A-Akt1 decreased by 50% when compared to Tg(fli1a:EGFP) embryos injected 
with WTAkt1 as expected. Levels of Her8a expression in Tg(fli1a:EGFP) embryos injected 
with reduced Akt1 were around half that of Tg(fli1a:EGFP) embryos injected with WTAkt1; 
implicating defects of neuronal differentiation during embryo development. 
 
Ngn1 expression in Tg(fli1a:EGFP) embryos injected with constitutively active MyrAkt1, 
single cysteine mutant C60S-Akt1 and constitutively inactive T308AS473A-Akt1 were 
comparable to Tg(fli1a:EGFP) embryos injected with WTAkt1. Expression in Tg(fli1a:EGFP) 
embryos injected with double cysteine mutant C60SC77S-Akt1 were increased by 2-fold when 
compared to Tg(fli1a:EGFP) embryos injected with WTAkt1; denoting an increase in 
differentiated neurons. Contrastingly, levels of Ngn1 expression in Tg(fli1a:EGFP) embryos 
injected with single cysteine mutant C77S-Akt1 were half that of Tg(fli1a:EGFP) embryos 
injected with WTAkt1; implying neuronal developmental defects. 
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Figure 6.5 Ablation of the Akt1 Cys60–Cys77 disulphide bond does not affect expression 
of selected Akt1 downstream genes in the zebrafish model.  
Tg(fli1a:EGFP) embryo cDNA was isolated by RT-qPCR. Gene transcripts of ELAV like 
neuron-specific RNA binding protein 3 (Elavl3), DeltaA, Hairy-related 8a (Her8a) and 
neurogenin 1 (Ngn1) were normalised to housekeeper TATA-binding protein (Tbp) expression. 
Gene expression of target genes were normalised relative to Tg(fli1a:EGFP) embryos injected 
with WTAkt1. Results are expressed in numbers of fold. Data are expressed as the mean ± s.d. 
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6.3 Discussion 
A range of physiological processes are regulated by Akt; a highly conserved human 
serine/threonine protein kinase critically involved in the tight regulation of the 
PI3K/Akt/mTOR signalling pathway (Kitamura et al., 1998). Akt plays an essential role in the 
development of organisms. Akt phosphorylates to activate or inhibit various downstream 
substrates responsible for cell growth and survival, angiogenesis and neuronal differentiation 
(Vasudevan & Garraway, 2010). 
 
The role of Akt in survival and phenotype were previously studied in vivo; in zebrafish injected 
with mRNA morpholinos against Akt1 (Cheng et al., 2013) and zebrafish engineered to lack 
the Akt2 gene via CRISPR/Cas9 technology (Zhang et al., 2017). The Akt1 morphants showed 
neuronal and developmental abnormalities during embryonic development, whilst Akt2-null 
zebrafish exhibited growth deficiencies and partial lethality. My in vivo data of Tg(fli1a:EGFP) 
zebrafish embryos injected with full-length human Akt1 constructs were relatively comparable. 
 
In this chapter, I showed that the redox state of the Cys60–Cys77 disulphide bond in human full-
length Akt1 is involved in the induction of angiogenesis in Tg(fli1a:EGFP) zebrafish embryos. 
The completeness of ISV formation in the zebrafish organism is a recognised paradigm of 
studying angiogenesis (Blum et al., 2008); vascular malformations of the embryos were 
deemed as a developmental abnormality. Mutations of Cys60 to Ser and/or Cys77 to Ser were 
observed to affect the induction of angiogenesis during zebrafish embryonic development. 
Tg(fli1a:EGFP) embryos injected with single cysteine mutants C60S-Akt1 and C77S-Akt1 
increased the rate of ISV completion when compared to Tg(fli1a:EGFP) embryos injected with 
WTAkt1. Moreover, Tg(fli1a:EGFP) embryos injected with double mutant C60SC77S-Akt1 
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moderately increased completeness of ISV formation but was not statistically significant when 
compared to Tg(fli1a:EGFP) embryos injected with WTAkt1. 
  
Interestingly, Tg(fli1a:EGFP) embryos injected with single cysteine mutants C60S-Akt1 and 
C77S-Akt1, did not stunt the growth of zebrafish embryos when compared to Tg(fli1a:EGFP) 
embryos injected with WTAkt1. Although, Tg(fli1a:EGFP) embryos injected with double 
cysteine mutant C60SC77S-Akt1 significantly increased growth. 
 
Akt1 also plays an essential role in neural differentiation in zebrafish by phosphorylating 
downstream targets of Akt1 (Cheng et al., 2013; Jeffery et al., 2015). As determined by RT-
qPCR, expression of disulphide bond Akt1 mutants in zebrafish embryos did not significantly 
alter gene expression of neural progenitor and differentiated neuronal markers downstream of 
Akt1.  
 
To further examine the phosphorylation state of Akt in zebrafish embryos injected with human 
disulphide bond Akt1 mutants, expression levels of both human and zebrafish Akt proteins 
were discernable as different sized bands by immunoblotting. Protein expression levels of 
zebrafish and human pan-Akt (total Akt) were detected, however, phosphorylated Akt at Thr308 
and Ser473 were not detected and this experiment was not pursued further. 
 
Limitations of this study were that Akt1 was transiently expressed in Tg(fli1a:EGFP) zebrafish 
model. Despite the use of the pDestTol2 gene transfer vector, new zebrafish lines expressing 
human Akt1 constructs were unable to be generated. The ramifications were that human Akt1 
constructs were not ubiquitously expressed throughout the zebrafish organism; and thus, 
complete ISV formation, growth and development, and expression of downstream Akt1 targets 
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may be attributed to endogenous zebrafish Akt1. To fully elucidate the function of disulphide 
bond Akt1 mutants in vivo, a zebrafish line lacking the Akt1 gene via CRISPR/Cas9 technology 
is preferred; as seen in a previous study of Akt2 function in a zebrafish model (Zhang et al., 
2017). 
 
I have so far shown the redox state of the Cys60–Cys77 disulphide bond in the PH domain of 
Akt1 potentially plays a role in physiological functions of Akt1 in the zebrafish model. 
Reduced human Akt1 was observed to increase the induction of angiogenesis and development 
of zebrafish embryos, however, was unable to activate downstream targets of Akt1. Additional 
in vivo studies investigating the role of the Cys60–Cys77 disulphide bond in physiological 
function of Akt1 are required. 
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7.  Conclusions & Future Directions 
This thesis focuses on the role of a potential allosteric disulphide bond identified in the PH 
domain of Akt and its impact in Akt function. Cleavage of allosteric disulphide bonds has been 
shown to alter function of various proteins involved in various biological systems i.e. 
thrombosis and haemostasis (Butera et al., 2018; Passam et al., 2018); as well as a growing 
number found in cancer-related proteins (Hogg, 2013). From an analysis of labile disulphide 
bonds in all X-ray structures from the PDB, my colleagues and I identified a potential allosteric 
disulphide bond, Cys60–Cys77, in the PH domain of the serine/threonine protein kinase, Akt1. It 
was only recently discovered that Akt is allosterically activated by phospholipid PIP3 at the 
plasma membrane via its N-terminal PH domain (Ebner et al., 2017). The mechanism by which 
Akt dissociates from the plasma membrane, and therefore its inactivation, is unknown. I 
hypothesised that the Cys60–Cys77 disulphide bond, located near the lipid binding pocket in the 
PH domain of Akt, is an allosteric disulphide that regulates Akt autoinhibition. I explored the 
role of the Akt Cys60–Cys77 disulphide bond in in vitro and in vivo systems. In the in vitro 
setting, I determined that the Cys60–Cys77 disulphide bond is involved in Akt plasma membrane 
binding, and consequently, is essential for Akt activation and autoinhibition in mouse 
fibroblasts. In the in vivo model, the Cys60–Cys77 disulphide bond was observed to play a role 
in the biological function of Akt in angiogenesis and growth development of zebrafish 
embryos. Together, my findings suggest that the Cys60–Cys77 disulphide bond is an allosteric bond 
that is involved in PH domain-mediated autoinhibition of Akt. The Cys60–Cys77 disulphide bond is 
therefore a potential cancer drug target. 
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7.1 Identification of the Cys60–Cys77 disulphide bond in the PH domain of 
Akt1 
Using a bioinformatic approach, my colleagues and I identified labile disulphide bonds in all 
protein structures from the PDB (Chapter 3). The labile nature of some of these disulphide 
bonds implied their cleavability; and visual inspection of some of these labile disulphides 
suggested an allosteric function. At the time of writing this thesis, five known allosteric 
disulphide bonds were among the 511 labile disulphide bonds identified in all PDB X-ray 
structures; validating this approach to uncover more potential allosteric disulphide bonds. By 
comparing the distribution of the 20 disulphide configurations between the entire PDB and 
labile disulphides, two differences were notable. Labile disulphide bonds were observed to be 
enriched with catalytic +/–RHhook disulphide bonds; and on the other hand, contained fewer 
structural –LHspiral disulphide bonds (Schmidt et al., 2006). Of the 67 proteins in the labile 
disulphide dataset that have a +/–RHhook configuration, 22 of them are oxidoreductases. 
Labile disulphide bonds are enriched in bonds linking α-helices and loops. Catalytic disulphide 
bonds of oxidoreductases link an α-helix to another or a loop structure, and undergo cycles of 
reduction and oxidation and there are several examples of oxidised and reduced structures in 
the PDB; hence their prevalence in the labile disulphide dataset. 
 
Secondary structures of labile disulphide bonds were also investigated. Allosteric –RHstaple 
disulphide bonds often link adjacent strands in the same antiparallel β-sheet or constrain β-
loops (Matthias et al., 2002; Wouters et al., 2004). In the labile disulphide bonds dataset, the 
Cys60–Cys77 disulphide bond was identified in truncated Akt1-PH. Crystal structures show 
Akt1-PH has seven β-strands forming two orthogonal anti-parallel β-sheets, closed at one end 
by the C-terminal α-helix (Milburn et al., 2003). In all apo structures of Akt1-PH, the Cys60–
Cys77 disulphide bond is oxidised and has an archetypical –RHstaple allosteric disulphide 
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configuration. The Cys60–Cys77 disulphide bond is cleaved in all structures of Akt1-PH bound 
to IP4, the head group of phospholipid PIP3; resulting in a significant conformational change. 
This discovery warranted further investigations on the potential functional role of the Cys60–
Cys77 disulphide bond in Akt1 plasma membrane binding. 
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7.2 The role of the Cys60–Cys77 disulphide bond in Akt1 plasma 
membrane localisation 
Crystal structures and membrane binding data of truncated reduced Akt-PH bound to 
phospholipid suggested that full-length reduced Akt was the membrane-bound, active form of 
the protein. My data of full-length Akt2 plasma membrane binding capabilities has shown 
otherwise. Truncated reduced Akt1-PH domain had slightly stronger binding affinity for PIP3 
than the wild-type, whereas ablation of the disulphide bond in full-length Akt2 profoundly 
impaired Akt plasma membrane binding (Chapter 4). The differing results in membrane 
binding between the truncated Akt1-PH domain and full-length Akt2 proteins is possibly due 
to the cysteine mutations affecting the configuration of PH domain binding to the kinase 
domain and thus autoinhibition of Akt.  
 
A critical aspect that was not explored in the membrane binding study is the redox state of 
Cys60 and Cys77 in membrane-bound versus cytosolic Akt protein, in response to insulin 
stimulation in the cell. Cysteines residues are particularly susceptible to oxidative stress, 
inducing the formation of disulphide bonds (Goldstein et al., 2005; Paulsen & Carroll, 2013). 
As a product of growth factor stimulation, cellular ROS i.e. H2O2, a weak oxidant, increase the 
activation of Akt; implying that Akt is indeed redox-sensitive (Koundouros & Poulogiannis, 
2018; Okoh et al., 2013; Ushio-Fukai et al., 1999). Bursts of H2O2 generated from growth factor 
stimulation last for 10 min in the cell (Lee et al., 1998). My mass spectrometry data has shown 
the Cys60–Cys77 disulphide bond in total cellular WTAkt1 protein is >95% reduced in insulin-
stimulated mouse fibroblasts. An aim for future studies is to capture and measure the redox 
state of the small fraction of total cellular Akt1 bound to the plasma membrane. My prediction 
is that this pool of membrane bound Akt1 will be oxidised, possibly induced by the burst of 
H2O2 as a product of insulin stimulation. The cysteine alkylators I have used are iodoacetamide-
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based chemical probes that are poorly membrane permeable and cytotoxic at high 
concentrations (Abo & Weerapana, 2015). To capture the redox state of membrane-bound 
Akt1, the cysteine alkylators would require a longer timeframe for internalisation and 
equilibration in cells post-stimulation, which may not be technically feasible. Future work will 
instead utilise a caged electrophilic probe (Abo et al., 2017) to label cysteines in WTAkt1 
protein subject to oxidation upon insulin stimulation of mouse fibroblasts. This approach has 
been used to quantify oxidative modifications of cysteines in live cells upon epidermal growth 
factor-stimulated ROS production (Abo & Weerapana, 2015). H2O2-induced oxidation of the 
other disulphide bond in Akt1 (Cys296–Cys310) was observed to dephosphorylate Akt1 through 
increased interaction with phosphatase PP2A, deactivating the kinase. However, mutations of 
Cys296 and Cys310 residues did not affect Akt1 phosphorylation or kinase activity (Ahmad et 
al., 2014). 
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7.3 The role of the Cys60–Cys77 disulphide bond for Akt1 activity in mouse 
fibroblasts and zebrafish embryos 
Akt1 activity is restricted to PIP3-containing membranes (Ebner et al., 2017), signifying the 
importance of a functional PH domain. The PH domain of Akt1 binds to PIP3 at the plasma 
membrane, exposing the activation loop and phosphorylation sites on the kinase and regulatory 
domains of Akt1 (Lučić et al., 2018). I explored the mechanism of PH domain-mediated Akt1 
autoinhibition in this thesis. I have shown that the Cys60–Cys77 disulphide bond impairs Akt1 
phosphorylation and downstream substrate activation in mouse fibroblasts, suggesting it is 
involved in Akt1 autoinhibition (Chapter 5). Despite insulin stimulation, mutation of Cys60 to 
Ser in full-length Akt1 resulted in moderate impairment of Akt1 phosphorylation and activation 
in mouse fibroblasts, whereas mutation of Cys77 to Ser in full-length Akt1 led to the near 
ablation of phosphorylation of Akt1 and significant impairment of downstream activity. 
Studies in mouse fibroblasts suggested that oxidation of the Cys60–Cys77 disulphide bond is 
required to induce oncogenic transformation of the cells. This result suggested that the Cys60–
Cys77 disulphide bond is critical for full-length Akt1 plasma membrane recruitment and 
subsequent activation by PIP3. 
 
Allosteric disulphide bonds are cleaved by oxidoreductases or thiol–disulphide exchange; 
altering the function of the protein in which they reside (Cook & Hogg, 2013). An important 
question that will be explored in a future study is how the Cys60–Cys77 disulphide bond is 
cleaved in the cytosol. Thioredoxin is a small cytosolic oxidoreductase that maintains protein 
thiol homeostasis in the cell (Leveillard & Ait-Ali, 2017), and I postulate that it reduces the 
Cys60–Cys77 disulphide bond of Akt1 to induce the PH domain-mediated autoinhibition. Future 
experiments will correlate thioredoxin activity in the cytosol with the redox state of the Akt1 
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Cys60–Cys77 disulphide bond (Holmgren, 1995; Holmgren & Bjӧrnstedt, 1995; Montano et al., 
2014).  
 
I have shown the Cys60–Cys77 disulphide bond affects the physiological function of Akt1 in a 
biological system (Chapter 6). Mutations of Cys60 and Cys77 to Ser in full-length Akt1 
increased the induction of angiogenesis and growth of zebrafish embryos, suggesting the 
Cys60–Cys77 disulphide bond in Akt1 is involved in zebrafish development. However, to better 
distinguish injected human Akt1 from endogenous zebrafish Akt1, this study will require 
further validation in a zebrafish model that ubiquitously expresses human Akt1. Multiple 
attempts were also made to examine the phosphorylation state of Akt1 in zebrafish embryos 
injected with human Akt1 constructs. Protein expression levels of zebrafish and human pan-
Akt (total Akt) were semi-quantitatively examined; however, phosphorylated Akt at Thr308 or 
Ser473 residues were not detected and this experiment was not pursued further. 
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7.4 The Cys60–Cys77 disulphide bond in Akt1 is an allosteric disulphide 
involved in Akt1 function 
A working model of the mechanistic role of the Cys60–Cys77 disulphide bond in Akt1 function 
is presented in Figure 7.1. In the model, reduced Akt1 is the inactive form; it is unable to be 
phosphorylated and does not activate substrates due to the PH and kinase domains adopting an 
autoinhibitory conformation (Figure 7.1A). As a product of growth factor stimulation, bursts 
of ROS oxidise Akt1 to form the Cys60–Cys77 disulphide bond. Oxidised Akt1 translocates to 
the plasma membrane and is allosterically activated by PIP3 (Ebner et al., 2017), disrupting the 
autoinhibitory interaction between the PH–kinase domains of Akt1 (Figure 7.1B). Oxidised 
Akt1 is docked at the plasma membrane; PDK1 and mTORC2 have access to the activation 
loop in the kinase domain and phosphorylate Akt1 at Thr308 at Ser473 residues, respectively. 
Active Akt1 phosphorylates downstream substrates, namely FoxO1, GSK3 and TSC2 (Figure 
7.1C). I propose that dissociation of active Akt1 from the plasma membrane; the rate-limiting 
step for Akt1 dephosphorylation and autoinhibition (Ebner et al., 2017; Lučić et al., 2018), is 
prompted by thioredoxin cleavage of the Cys60–Cys77 disulphide bond, triggering PH domain-
mediated autoinhibition. Reduced Akt1 is rapidly dephosphorylated by PP2A and PHLPP2 at 
Thr308 and Ser473 residues, respectively (Figure 7.1D). 
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Figure 7.1 Working model for the role of Cys60–Cys77 disulphide bond in Akt1 activation and autoinhibition in the cell. 
The pleckstrin homology (PH), kinase (KD) and regulatory (RD) domains of Akt1 are indicated. A. Reduced Akt1, defined by unpaired Cys60 and 
Cys77 thiols in the PH domain, is inactive and adopts an autoinhibitory conformation. B. Growth factor stimulation of receptor tyrosine kinase 
(RTK) phosphorylates phosphoinositide 3-kinase (PI3K) to further phosphorylate phosphatidylinositol-4,5-bisphosphate (PIP2) to 
phosphatidylinositol-3,4,5-trisphosphate (PIP3). Growth factor stimulation also produce bursts of reactive oxygen species (ROS) that triggers 
formation of the Cys60–Cys77 disulphide bond in the PH domain. Oxidised Akt1, defined by an intact Cys60–Cys77 disulphide bond in the PH 
domain, translocates to the plasma membrane and is allosterically activated by PIP3. Akt1 undergoes a conformational change; relieving PH 
domain-mediated autoinhibition of the kinase domain and allowing substrate access. C. Oxidised Akt1 at the plasma membrane is phosphorylated 
by phosphoinositide-dependent kinase 1 (PDK1) and mammalian target of rapamycin complex 2 (mTORC2) at Thr308 and Ser473, respectively. 
Active Akt1 subsequently phosphorylates downstream substrates. D. Cytosolic oxidoreductase thioredoxin (Trx) is reduced by thioredoxin 
reductase (TrxR) by an NADPH-dependent mechanism, cleaving the Cys60–Cys77 disulphide bond in the PH domain of Akt1. Reduced Akt1 
dissociates from the plasma membrane and regains its autoinhibitory conformation. Reduced Akt1 is rapidly dephosphorylated by protein 
phosphatase 2 (PP2A) and PH domain and leucine rich repeat protein phosphatase (PHLPP2) at Thr308 and Ser473, respectively. 
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7.5 Targeting the Akt1 Cys60–Cys77 disulphide bond in cancer 
Another interesting aspect of this study is the relevance of the Cys60–Cys77 disulphide bond in 
other isoforms of Akt. Akt1 is ubiquitously expressed in all tissues. Akt2 is expressed in 
metabolically active tissue e.g. liver, adipose tissue and muscle. Akt3 is predominantly 
expressed in the brain and testes (Chan et al., 2014; Yang et al., 2004). When overexpressed, 
Akt1 is known to be involved in the progression of the breast (Carpten et al., 2007; Stephens 
et al., 2012; Yi et al., 2012), endometrial (Cohen et al., 2010), prostate (Boormans et al., 2010), 
bladder (Askham et al., 2010), NSCLC (De Marco et al., 2015; Ding et al., 2008), blood (Kim 
et al., 2008) and melanoma (Davies et al., 2008) cancers. Akt2 is often linked to diabetes 
mellitus type 2 (Cohen, 2013) and Akt3 is associated with neurological disorders (Poduri et al., 
2012). The development of Akt isozyme-selective therapies has long been a challenge due to 
the high degree of amino acid sequence homology of the kinase domains but diverge in the PH 
and regulatory domains (Nitulescu et al., 2016). The amino acid sequence of the PH domain of 
Akt1 is more similar to Akt2 than Akt3; therefore the role of the Cys60–Cys77 disulphide bond 
in Akt2 is presumably similar to Akt1. The amino acid sequence of the linker region that 
connects the PH and kinase domains of Akt is also poorly conserved between the isoforms. 
This sequence variation has led to the development of allosteric Akt inhibitors that have 
isozyme specificity and lower toxicity (Nitulescu et al., 2016).  
 
For example, the isoform-specific Cys124 residue in the linker region of Akt2 is sensitive to 
endogenous H2O2 (Wani et al., 2014; Wani et al., 2011). Oxidation of Akt2 promotes cell 
migration and cell cycle distribution (G1-S transition), a possible factor in the development of 
diabetes mellitus type 2 (Wani et al., 2014; Wani et al., 2011). Another study has shown the 
isoform-specific Cys119 residue in the linker region of Akt3 is sensitive to the electrophilic lipid 
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4-hydroxynonenal, inhibiting Akt3 activity in mammalian cells and the zebrafish model (Long 
& Aye, 2017; Long et al., 2017).  
 
Targeting allosteric disulphide bonds in proteins is still a relatively new approach for the 
treatment of cancer. Future research will include the development of an inhibitor that impairs 
the function and formation of the Cys60–Cys77 allosteric disulphide bond in the PH domain of 
Akt1 (Figure 7.2). Cysteine-directed electrophiles can be designed to target poorly reactive 
cysteines in an activity-based manner (Shannon & Weerapana, 2015). Thiol alkylators 
containing a weak electrophilic moiety will be designed to modify only the functionally 
relevant Cys60 and Cys77 residues in activated Akt1. 
 
Current examples of anti-angiogenic and anti-cancer thiol alkylating drug compounds include 
4-(N-(S-glutathionylacetyl)amino)phenylarsonous acid (GSAO) and its derivative 4-(N-(S-
penicillaminylacetyl)amino)phenylarsonous acid (PENAO). GSAO and PENAO are trivalent 
arsenical compounds that cross-link Cys57 and Cys257 in human adenine nucleotide translocase 
(ANT) of the inner-mitochondrial membrane. Cys160 and Cys257 residues in ANT are usually 
disulphide bonded in quiescent cells and so these compounds selectively target proliferating 
tumour cells (Park et al., 2012). Inhibition of ANT leads to the partial uncoupling of oxidative 
phosphorylation, resulting in mitochondrial membrane permeability transition, superoxide 
production and tumour cell death (Decollogne et al., 2015; Dilda et al., 2009; Dilda & Hogg, 
2007; Dilda et al., 2008; Don et al., 2003; Elliott et al., 2012; Park et al., 2012; Ramsay et al., 
2011; Shen et al., 2015). GSAO and PENAO recently completed Phase I clinical trials and was 
well tolerated in patients with solid tumours refractory to standard treatment. No significant 
organ toxicity was observed (trial identifiers CTA-21106-0222-001 and 
ANCTRN12612000908831) (Elliott et al., 2012; Horsley et al., 2013). GSAO has a short t½ 
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of 10.1 min (Horsley et al., 2013), but its efficacy is limited by the expression of multidrug 
resistance proteins 1 and 2 (MRP1/2). PENAO accumulates in tumour cells 85-fold faster than 
GSAO due to the decreased rate of export via MRP1/2 (Dilda et al., 2009) however, has an 
unexpectedly long t½ in human circulation of 5-9 days. These pharmacokinetic findings 
warrant further investigations of an appropriate dosage schedule and to identify combination 
therapies with other known metabolic inhibitors. 
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Figure 7.2 Blocking the formation of the Cys60–Cys77 disulphide bond in the PH domain 
of Akt1 with a targeted thiol alkylator. 
A targeted thiol alkylator can be designed to disrupt the formation of the Cys60–Cys77 
disulphide bond in the PH domain of Akt1. The reactive electrophilic group of the compound 
(chloroacetyl moiety is pictured) is brought into close proximity to an unpaired Cys77 residue 
in the PH domain of reduced Akt1, thereby blocking thiol–disulphide exchange and 
inactivating the kinase. The hexagon cartoon represents a non-defined structure that interacts 
with the binding pocket of the PH domain. The wavy line in the compound represents a non-
defined structure. 
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